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Summary 
Cyclic di-adenosine monophosphate (c-di-AMP) is a second messenger involved in 
diverse metabolic processes such as cell wall homeostasis, biofilm formation, antibiotics and 
heat resistance, among others. In Lactococcus lactis and Enterococcus faecalis, Lactic Acid 
Bacteria used not only as research models but also as a cell factory in biotechnological 
processes, the only reported interaction partner of c-di-AMP is the pyruvate carboxylase 
enzyme, PyrCarb. Nevertheless, in the last year investigations directed its main role towards 
potassium metabolism.  
In this thesis, KupA and KupB, two potassium transporters encoded in L. lactis IL1403 
genome, are described for the first time. According to an in silico analysis, these proteins, which 
belong to the Kup/HAK/KT family, are highly conserved in this species, being therefore a strain 
independent potassium uptake system. In addition, evidence shows that both proteins are able 
to uptake this cation with high affinity, and we demonstrate that KupA as well as KupB bind to 
and are down-regulated by c-di-AMP. 
On the other hand, different strains derived from L. lactis IL1403 were developed aiming 
to modify intracellular pools of c-di-AMP in a stable system. One strategy for the reduction of 
c-di-AMP levels was the obtaining of ∆gdpP mutants via homologous recombination. 
Maintenance of this second messenger levels close to wild type ones, suggested the presence 
of another c-di-AMP degrading enzyme. A first description of a putative enzyme with this 
activity, encoded by yheB gene was done by BNPP assay. In addition, by use of a pH inducible 
vector, construction of strain L. lactis LL03 with concentrations of this second messenger above 
15 times basal levels was possible. This system was therefore selected for further investigations 
on the development of a vaccine prototype against Chagas disease.  
On the other hand, L. lactis is a promising candidate for the development of mucosal 
vaccines with more than 20 years of experimental research. Moreover, c-di-AMP has been 
reported as a strong mucosal adjuvant promoting both humoral and cellular immune responses. 
Altogether, in this thesis the development of a recombinant L. lactis strain is reported, able to 
produce both an antigen as well as an adjuvant in order to develop a novel vaccine prototype 
against the Trypanosoma cruzi parasite, the causal agent of Chagas disease. This is a tropical 
disease originated in a specific area of South America but currently spreading in four continents. 
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Finally, an initial approach was done on c-di-AMP metabolism in E. faecalis. The 
presence of a Kup transporter was also corroborated in this species, and some basic 
characteristics of the c-di-AMP degradative pathway were explored via a ∆gdpP mutant 
construction. Finally, the impact of GdpP on the virulence of E. faecalis was analyzed by use 
of the infection model Galleria mellonella. 
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1. Introduction 
“Remember to look up at the stars and not down at your feet. Try to 
make sense of what you see and wonder about what makes the 
universe exist” Stephen Hawking 
 
Introduction 
1.1. Lactic Acid Bacteria 
Along the course of history, human beings always sought for efficient ways of 
improving quality of everyday life. When food supplies were not round the corner, one of these 
ways concerned food preservation. In this sense, a wide variety of products including meat, 
cheese, vegetables and dairies to name a few, were well conserved thanks to the process of 
fermentation. Successful results were not investigated, there was a lot of variation from one 
fermented product to the next one and optimization of these procedures was obtained after trial 
and error. A widely practiced technique consisted on separating a small portion of a successful 
batch of a fermented product and using it to start the process in fresh food. This “back-slopping” 
method allowed people to maintain food in good conditions, by transferring the microorganisms 
which made fermentation possible. In lactic fermentation, the most represented amount of 
bacteria conforming the inocula were Lactic Acid Bacteria (LAB) (1) .  
Nowadays, mechanisms of preservation are thoroughly understood and different 
combinations of LAB are used to inoculate a culture, expecting specific features in the final 
fermented product. In the cheese making industry, for instance, certain strains are used as starter 
or adjunct cultures to contribute to flavor and aroma development, or to other specific 
organoleptic features such as the formation of eyes via CO2 release (2) . Also, proteolysis and 
lipolysis are key pathways for texture and flavor improvement and so is the formation of C4 
aroma compounds like acetoin and diacetyl, both derivatives of lactic acid (3). 
The group of LAB cannot be addressed as microorganisms falling in one simple 
definition. Instead, they are referred to as a group of bacteria with certain key characteristics in 
common. Principally, the high amounts of lactic acid they produce when grown in the presence 
of a suitable carbon source, as result of homofermentation or heterofermentation, in which case 
they produce acetic acid and ethanol as well. These acidic compounds and the concomitant 
decrease in pH are one of the main reasons for the growth inhibition of undesired 
microorganisms. Moreover, LAB have less than 50% of G+C content in their genomes and they 
are non-sporulating Gram-positive bacteria. They are strictly fermentative, anaerobic or 
aerotolerant and morphologically they can be cocci or rod shape bacteria. Phylogenetically, 
LAB genera are all included in the firmicutes phylum, except for the Bifidobacterium genus, 
belonging to Actinobacteria. Genera within Firmicutes comprise: Aerococcus, Aloiococcus, 
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Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, 
Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weisella, among others (4). 
Due to its historical utilization in food industry, they have been classified as “Generally 
Regarded as Safe” (GRAS) by the Food and Drug Administration of the United States of 
America (FDA) and they have also been designated with the “Qualified Presumption of Safety” 
(QPS) according to the European Food Safety Authority (EFSA). Consequently, in the last 
decades increasing interest and lines of investigations have been opened concerning other fields 
and applications of LAB, which is how from food preservation and starter cultures they 
expanded into probiotics development, enzymes production, drugs delivery, vaccines 
formulation, among others. 
Nevertheless, within the LAB group there are also some controversial species, which 
are pathogens or opportunistic pathogens, like members of the Streptococcus and Enterococcus 
group (Fig. 1). Even though some strains of Enterococcus are able to produce bactericidal 
compounds and therefore their biotechnological applications are encouraged, special care need 
to be taken when working with microorganisms prone to acquire antibiotic resistances and turn 
into nosocomial pathogens (see below). 
Members of LAB, apart from the acidifying effect on growth media as previously 
mentioned, are also efficient inhibitors of undesired microorganisms due to the synthesis of 
bacteriocins. These are peptidic compounds with bactericidal effects on closely related bacteria 
from the same ecological niche, which provides an evolutionary advantage to the producer 
strain (5). Its effects have also been proven in more distant species, mainly when environmental 
conditions can be adjusted to favor the bacteriocin mode of action. The first recognized 
bacteriocin synthesized by L. lactis was nisin, which has been employed for decades in food 
industry for its antimicrobial action against members of Gram-positive bacteria. Noteworthy, it 
also inhibits growth of Clostridium and Bacillus spores, and different combinations of nisins, 
nisin producer starter strains and other preservation mechanisms have been applied in food 
industry and fermentation processes without health risks for consumers (6, 7). 
9 
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Fig. 1 Schematic phylogenetic tree of LAB based on 16 rRNA gene sequence 
homology. Representative LAB species related to the food industry are included. 
Species that do not represent a risk for human health are depicted in green, 
opportunistic pathogens in red. 
Other bacteriocins active against pathogenic bacteria in human infections have prompt 
the development of probiotics. Probiotics are live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host (8). The intestinal lumen is an elaborated 
matrix with complex microbiota that varies for each host and is influenced by different direct 
and indirect agents. Examples of indirect agents are the use of antibiotics and also the diet, 
which has been referred to as the most efficient way of modulating gut microbiota (9) . Diets 
complemented with probiotics and symbiotics have a beneficial impact on the immune system 
of individuals with infectious bacterial diseases and even a connection was established between 
the increase of Lactobacillus levels and the vitamin A supplementation for Norovirus treatment 
(10). Interesting results have been obtained as well for Helicobacter pylori inhibition by use of 
LAB isolated from fermented noodle (11), and bacteriocins synthesized by LAB have also been 
reported to be active against pathogenic bacteria like Listeria monocytogenes, Staphylococcus 
aureus and Streptococcus mutans (12, 13). 
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1.1.1. Lactococcus lactis 
Lactoccus lactis is one of the most used starter culture in the cheese making industry as 
well as the best characterized LAB (14). Several strains have been thoroughly studied for their 
impact on the fermented final product, and they fall mainly into two subspecies, L. lactis subsp. 
cremoris (preferentially used as starter since they cause less bitterness), and L. lactis subsp. 
lactis (known as a fast acidifier). A biovariety can also be found within L. lactis species, i. e. L. 
lactis subsp. lactis biovar. diacetylactis, capable of citrate fermentation and therefore affecting 
flavor development via acetoin and diacetyl synthesis (15). 
From an evolutionary point of view, L. lactis has been able to colonize different 
ecological niche, like plant surfaces, the urogenital and gastrointestinal tract of mammals as 
well as other animal tissue surfaces. It can also be found in different types of foods including 
dairies, meats and fermented products. Strains from diverse sources have evolve loosing or 
gaining specific sets of genes which made possible their adaptation to the defined media 
employed in industries, the rich media of dairy matrices and the most demanding natural 
environments of non-dairy sources such as plants. Consistent with this, a recent study 
performed on 30 sequenced genomes available on the NCBI database belonging to L. lactis 
taxon, reported that 16% of the unique gene families of each genome correspond to phage 
proteins acquired through the integration of a particular pro-phage element (16). Moreover, 
about 19% of these gene families showed to be involved in mobilization and conjugation, 
transposases and IS elements, or genes encoding systems providing a beneficial niche specific 
advantage related to bacteriocin production, sugar metabolism and restriction-modification 
systems. This study also showed a clear division between lactis and cremoris subspecies, and 
allowed the determination of the core genome sizes being of 1406 and 1413 genes, respectively 
(plasmids were excluded from the study) (16). For industrially relevant L. lactis strains, the 
most important set of genes are those coding for proteins that enable lactose fermentation, the 
prevalent carbon source in dairy products. These genes are encoded in the lacABCDEFGX 
operon, which is found in plasmids of all cremoris subspecies, except for the plasmid free strain 
MG1363 and its derivative NZ9000. On the other hand, within lactis subspecies the non-
degrading lactose strains are more represented, being IL1403 one of these. Altogether, L. lactis 
is a very versatile species with a wide research history and range of options for industrial 
applications, which are currently under investigation. 
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L. lactis subsp. lactis IL1403 (from now on L. lactis IL1403) was the first sequenced 
lactis strain, and it is the plasmid free version of strain IL594 isolated from a cheese starter 
culture  (17). Together with strain NZ9000 and MG1363, it is the most used genetic and 
physiological L. lactis model in the laboratory (14) (for a summary of L. lactis strains used for 
research and industrial applications see Fig. 2 and Table I). L. lactis IL1403 has been employed 
in research for decades and its consequent adaptation and domestication led to a small genome 
of approximately 2500 open reading frames (ORF), nearly the half of other well-known 
bacterial models such as Bacillus subtilis. As a member of LAB, this strain is expected to be 
strictly fermentative, but genes related to aerobic respiration have been found in L. lactis IL1403 
genome (18). Namely, men and cytABCD operons are present, involved in menaquinone 
synthesis and cytochrome d biogenesis respectively, and even hemH, hemK and hemN for late 
steps of heme biosynthesis (oxidation of porphyrinogen and attachment of iron to heme), 
although no genes for the early steps were identified. 
L. lactis ssp. cremoris MG1363 was initially obtained as the plasmid cured progeny of 
the dairy origin NCD0712 strain (19) and it is today the model laboratory strain for genetic 
engineering and biotechnology of L. lactis (Fig. 2). From this strain also derives one 
fundamental tool for the nisin-controlled gene expression system (NICE), which was obtained 
via replacement of pepN gene (coding for an aminopeptidase) for the nisK and nisR genes (20), 
encoding a histidine-kinase and a cytoplasmic response regulator, respectively. The strain thus 
created, named NZ9000, is able to sense nisin in the medium upon which NisK 
autophosphorylates and transfers the phosphate to the counterpart of the two-component 
system, NisR, being thus activated. The active version of NisR induces in turn the PnisA 
promoter, present in the pNICE series of vectors, for which expression of a gene of interest 
cloned under it is successfully induced (21). It is important to mention that L. lactis NZ9000 
lacks 1821 nucleotides in the pepN-napC locus and when compared to the original strain 
MG1363, it has 6 point mutations independently acquired, being otherwise genetically 
equivalent (22). 
Another tool developed for L. lactis engineering and biotechnology, of special relevance 
for this work, is strain clpP-htrA, which shows reduced proteolytic activity, due to the lack of 
both major proteases Clp and HtrA (Fig. 2). Consequently it is a good strategy for the stable 
production of a heterologous protein of interest (23). 
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Fig. 2 Representative diagram of the development of L. lactis strains commonly used for genetic engineering 
and gene expression. L. lactis IL594 contains seven plasmids (pIL1 to 7), and is the parental strain of the plasmid 
free IL1403 strain. On the other hand, L. lactis MG1363 is the free plasmid version of strain NCDO712. It is also 
the parental strain of NZ9000, which carries the nisKR insertion, for nisin sensing and activation of the NICE 
system vector series. Strain clpP-htrA lacks the proteolytic enzymes HtrA and ClpP due to a deletion in the former 
case, and an erythromycin gene replacement, in the latter. 
1.1.2. Enterococcus faecalis 
Enterococcus faecalis is a natural commensal member of the human gut flora, and a 
very versatile bacterium for diverse niches colonization. As a member of the Enterococcus 
genus, it can grow in temperatures ranging from 10º C to 45º C, it can survive acidic and alkaline 
conditions (from pH 4.0 to 9.6), and can resist high salt concentrations (up to 6.5% NaCl) (24). 
E. faecalis can be found in plant materials and foods, especially in fermented products of animal 
origin, although in water and non-fermented meat articles its presence is not desired and 
normally it is used as an indicator of sanitary quality (25).  
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E. faecalis is as well one of the most controversial LAB, since it can participate in DNA 
exchange, being able to acquire antibiotic resistances, genes related to haemolysin-cytolysin 
production, proteins involved in adhesion to host tissue, or other virulence factors (26). The 
most complicated strains are the vancomycin resistant, which normally enter the host via 
wounds and catheters, causing endocarditis, bacteraemia and urinary tract infections (27). 
Nevertheless, due to E. faecalis wide genetic variability, strains isolated from clinical samples 
are significantly different from those isolated from food. Abriouel et al. showed that species 
most frequently involved in human diseases are also most frequently associated with clinical 
samples and in the same study enterococcal isolates from fruits and vegetables showed a much 
lower incidence of antibiotic resistance compared to clinical samples (28). 
Notwithstanding its controversial profile, it is a reality that Enterococcus (mainly E. 
faecalis, E. faecium and E. durans) are part of food products, either due to contamination along 
the manufacturing process or as part of dairy starter, adjunct and/or non-starter cultures (29). 
Moreover, E. faecalis is the species with the most acidifying, proteolytic and lipolytic activities, 
which as previously mentioned, exerts a strong contribution to flavor development. It is well 
known nowadays that its presence in food products like cheese and fermented meats contributes 
to the ripening process in the development of favorable organoleptic features (30). 
Some strains of E. faecalis have even been reported as probiotics and others are known 
for its bacteriocin production (31). E. faecalis synthesizes enterocin AS-48, which has a broad 
inhibitory spectrum, and offers interesting possibilities for food preservation. It has been shown 
to be active against Gram-positive bacteria like L. monocytogenes, S. aureus, Mycobacterium, 
Bacillus cereus and even some Gram-negative bacteria (32-34). 
1.2. Potassium homeostasis 
Ion homeostasis is a key factor for life in the three kingdoms. Particularly, potassium 
(K+) is the most abundant cation in the cytosol, and its uptake is essential and tightly regulated 
in all living cells. It intervenes in important cellular processes like translation, being essential 
for prokaryotic 50S and 30S ribosomal subunits activity, in charge of the peptidyl transferase 
reaction and the binding of phenylalanine-transfer RNA in vitro, respectively (35, 36). 
Potassium concentration is a limiting factor for protein synthesis, and it has been reported that 
the rate of protein synthesis slows down fourfold when K+ concentrations are under 25 mM 
(37).  
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Many enzymes require potassium as cofactor and it is also linked to bacterial 
bioenergetics, since it affects both components of the proton motive force (PMF), the pH 
gradient (∆pH, alkaline inside the cell) and the electric potential across the cellular membrane 
(∆ψ, negative inside the cell) (38). Secondary transporters involved in ∆pH generation, 
generally use the PMF generated by respiration or ATPases to actively uptake protons in 
exchange for cytoplasmic cations like Na+ or K+ (39). Therefore, potassium metabolism also 
affects pH homeostasis via cation–proton antiporters, especially crucial for non-respiring LAB, 
which acidify growth media and need to maintain alkaline values of pH inside the cells when 
extracellular values can go down to lower limits than their growing capacity (40). 
The Δψ component of the PMF is also related to potassium metabolism since in alkaline 
pH homeostasis, it enables the electrogenic influx of protons in exchange of an unequal ratio of 
Na+ or K+ efflux. Nevertheless, Na+ /H+ antiporters are more often involved in this process, 
whereas K+ /H+ antiporters take relevance under Na+ limitation (39, 41). In turn, this membrane 
potential is also important for ATP production and nutrient uptake, for which potassium 
metabolism influences cell growth as well. 
Cells also need a mechanism to alter their intracellular K+ concentrations in response to 
external solute changes. In these respect, potassium channels play a crucial role in osmotic 
stress responses. Most bacteria growing at low osmolarity use K+ as primary osmotic solute and 
when grown in high osmolarity media, potassium acts as a second messenger to trigger 
accumulation of compatible solutes. (42). In this sense bacterial cell turgor and cell viability 
under variable environmental conditions are maintained broadening colonization possibilities. 
It is important to mention that osmoregulation is also affected by the pool of compatible 
solutes. These molecules help reaching homeostasis after osmotic changes in the environment. 
Water efflux when osmolality increases outside the cell is first coped with potassium intake. 
Nevertheless, this is unsustainable when prolonged in time since it can disturb protein synthesis 
and other cellular processes and interactions affected by K+. Bacteria have therefore evolved 
developing a second phase of adaptation to osmotic stress, by synthesis of osmoprotectant 
solutes like betains, polyols, sugars, amino acids and compounds derived from them (43). A 
complex matrix is therefore established around potassium metabolism, connecting different 
cellular pathways in order to maintain homeostasis. 
15 
Introduction 
1.2.1. Potassium uptake systems 
Bacteria have evolved different systems to accumulate potassium intracellularly and 
achieve stable concentrations in order to cope with basic metabolic demands (40). Different 
high and low affinity uptake mechanisms are involved, if the bacteria are growing in media 
with low or high K+ concentrations, respectively. 
In E. coli, intracellular concentrations of K+ are kept close to 200 mM, when 
concentration in growth media is 10 mM (31). In this bacterium, there are three main potassium 
transport systems: Trk, Kdp, and Kup. Together they ensure potassium uptake in different 
growth conditions, and although mutants in the three systems cannot grow in regular media 
(unless at least 115 mM K+ is added), one of them is already enough for growth (44, 45). 
Trk system consists of four genes, which are constitutively expressed, with trkA as the 
main component and its product the predominant K+ transporter at neutral pH. It has low affinity 
for the ion and depends on ATP and proton motive force for potassium uptake (44). On the 
other hand, the KdpATPase system includes the inducible high affinity transporter KdpA, 
which is synthesized at low K+ concentrations and under osmotic stress (46). Finally, Kup 
(formerly TrkD) is also a constitutive but low affinity system and its activity increases at low 
pH, when TrkA and Kdp activities are insufficient (47). 
In other model bacterium like B. subtilis, S. aureus and L. monocytogenes, one of the 
main systems in charge of potassium uptake is Ktr, which like Trk belong to the Trk/Ktr/HKT 
family (48). Moreover, two different affinity systems can be distinguished within constitutive 
Ktr transporters: KtrCD is a low affinity system present in the three bacteria mentioned, 
whereas high affinity KtrAB is also present in B. subtilis, where it is regulated by the kimA 
riboswitch. Interestingly, another copy of the riboswitch can be found in B. subtilis, regulating 
as well kimA (formerly ydaO), coding for a member of a recently discovered potassium 
transporter family (49). An increase of K+ concentration results in accumulation of c-di-AMP 
which binds to the riboswitch and consequently represses expression of the downstream 
encoded transporters (49). Interestingly, the second messenger c-di-AMP (described in the 
following section) was proved to bind subunits KtrA and KtrC as well, upon which inhibition 
of the respective transporters occurs (50).  
As previously mentioned, potassium metabolism is an intricate network affecting 
diverse pathways, and so is potassium uptake. Even though a brief outline is made here as 
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regards major K+ transporters in model bacteria, it cannot be ignored that other minor systems 
exist as well. 
1.3.  (3’,5’) cyclic-di-adenosine-monophosphate 
(3’,5’) cyclic-di-adenosine-monophosphate (c-di-AMP) is a second messenger recently 
discovered in the crystallographic structure of DisA, a protein in charge of scanning DNA 
integrity in Thermotoga maritima (51). Therefore, the first function assigned to this compound 
was related to the DNA-damage dependent cell cycle control. Later it was also linked to cellular 
growth and cell wall homeostasis (52) as well as sporulation (53) and other cellular pathways 
like antibiotic resistance and nitrogen metabolism, among others (54).  
In pathogenic organisms, it was reported that c-di-AMP has an important role in the 
establishment of infection. For instance, in L. monocytogenes, c-di-AMP secretion after 
infection induces the immune response mediated by interferon β (55) and in Streptococcus 
pneumoniae it was observed that a double mutant strain lacking c-di-AMP degrading enzymes 
GdpP and PgpH (described below) is no longer capable of infection. Moreover, both proteins 
are involved in four key stages of pneumococcal pathogenesis: colonization, otitis media, 
pneumonia and bacteremia (56). 
c-di-AMP homeostasis is tightly controlled; low concentrations as well as its 
accumulation are detrimental for the cell. In B. subtilis, high levels of c-di-AMP lead to 
mutations that inactivate the activity or expression of its synthesizing enzyme, CdaA (see 
below) (54), and in L. monocytogenes, a double mutant in GdpP and PgpH results in growth 
defects inside and outside the host (57). Moreover, S. aureus strains lacking GdpP increase 
intracellular concentrations of c-di-AMP and are more resistant to acid stress and in general, 
higher concentrations of this second messenger are associated to increased resistance to β-
lactam antibiotics (52, 58, 59). 
The main interest on this compound was related to its essential role in rich media for 
low GC Gram-positive bacteria, since only in 2015 it was possible to obtain a mutant strain for 
the only c-di-AMP synthesizing enzyme in L. monocytogenes, in strictly controlled minimal 
media (60). 
In the last years, investigations were centered mainly in the role of c-di-AMP in 
potassium homeostasis and osmolyte transport, and even though its interaction to potassium 
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transport components was previously proven (50, 61), it was only recently that a direct 
connection was made between K+ metabolism and c-di-AMP essential role (49). In B. subtilis, 
it was shown that this second messenger also regulates synthesis of KimA (K+ importer A) via 
the kimA riboswitch, a copy of which is also found upstream ktrA, regulating its expression as 
well. Moreover, in the same study, a B. subtilis strain lacking c-di-AMP synthesizing enzymes 
was obtained under extremely low potassium concentrations (49) and in S. aureus this was 
possible in chemically defined medium and in rich medium supplemented with sodium or 
potassium chloride (62). 
1.3.1. Synthesis of c-di-AMP 
c-di-AMP is synthesized by specific di-adenilate cyclases from two ATP molecules, 
with the exception of M. tuberculosis, which can also produce it from two molecules of ADP 
(63). Three types of DAC containing enzymes are so far described, and they are all present in 
the model organism B. subtilis. The cyclase enzyme DisA, can be found in actinobacteria and 
in spore-forming firmicutes, and it associates into two interacting tetramers. It is involved in 
DNA integrity control and repair, being inhibited by damaged DNA as well as atypical DNA 
arrangements such as Holliday junctions (51). On the other hand, CdaS cyclase is only found 
in spore forming Bacillus members and in one Clostridium species, and it is exclusively 
expressed during sporulation, guaranteeing spores efficient germination. It contains two α-
helices at the N-terminal end, followed by the DAC domain at the C-terminus (64) The third c-
di-AMP synthesizing enzyme, CdaA, is the most frequently found in firmicutes. Similarly to 
CdaS, the DAC domain is located at the C-terminal end, whereas three α-helices can be found 
at the N-terminus (Fig. 3). It is important to mention that DAC containing proteins are 
extensively distributed in both Gram + and – bacteria, being much frequently found in the latter, 
and normally associated to additional domains in charge of the input and output of a variety of 
signals. Nevertheless, in the vast majority of low GC firmicutes, only one protein with a DAC 
domain is typically found.  
In many δ-proteobacteria and firmicutes, cdaA is encoded in a widely conserved gene 
cluster (described for L. lactis in section 3.1.6., Fig 42), which comprises cdaR, codifying for a 
CdaA regulatory protein, and glmM, coding for the phosphoglucosamine-6-phosphate mutase 
enzyme, capable of converting α-D-glucosamine-6-phosphate into D-glucosamine-1-
phosphate, a cell wall precursor. It is therefore not surprising that one of the first pathways 
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associated to c-di-AMP was cell wall biosynthesis, since genes responsible for the synthesis of 
related proteins are normally clustered together in the DNA. 
As previously mentioned, c-di-AMP is essential when bacteria are grown in rich media. 
Consequently, many efforts are being directed into the development of drugs able to inhibit c-
di-AMP cyclase activity and being therefore suitable for antibiotic formulation. For example, 
the anti-parasitic urea-derived drug suramin (used for African trypanosomiasis and 
onchocerciasis treatment) is proven to inhibit T. maritima DisA, competing with ATP for the 
same binding site in the enzyme (65). 
Altogether, c-di-AMP synthesis and metabolism are involved in diverse cellular 
pathways, and even though an increasing amount of information as regards this second 
messenger is being generated nowadays, its potential applications continue to expand. 
1.3.2. Degradation of c-di-AMP 
Bacteria capable of c-di-AMP synthesis also contain specific hydrolyzing enzymes in 
charge of its degradation. These proteins are phosphodiesterases, and can be divided into two 
families. The first family comprises homologues of a membrane-bound protein named GdpP, 
which consists of two transmembrane helices, a degenerate PAS domain (Per-Arnt-Sim, for 
signal transduction, (66), a modified GGDEF domain and a DHH-DHHA1 domain with a 
catalytic motif Asp-His-His. On the other hand, the second family includes an HD domain, 
where a His-Asp motif can be found, and it is separated of an N-terminal extracellular domain 
by seven transmembrane helices (Fig. 3) (67). Homologues of this group are distributed in 
cyanobacteria, bacteroidetes, fusobacteria, species of the genus Thermotoga and members of 
firmicutes, where proteins of both families are normally found together. 
The most studied phosphodiesterase, GdpP, is present in firmicutes, actinobacteria and 
spirochaetes. It degrades c-di-AMP into the dinucleotide 5’pApA and belongs to the DHH-
DHHA1 family along with another kind of phosphodiesterase, found for instance in S. 
pneumoniae, presenting a unique soluble DHH/DHHA1 domain (68). This enzyme is capable 
of degrading 5’pApA into two molecules of AMP and it is a B. subtilis NrnA homologue, 
although in this microorganism it does not hydrolyses c-di-AMP. This single domain version is 
of course smaller and cytoplasmic, and it is present in Borrelia burgdorferi y M. tuberculosis 
as the only c-di-AMP degrading phosphodiesterase (69, 70). 
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Phosphodiesterases from both groups have been proved to be controlled by the signaling 
nucleotide guanosine-tetraphosphate (ppGpp), establishing a link between c-di-AMP 
metabolism and the stringent response, designed to conserve energy during nutrient starvation. 
Both GdpP and PgpH (HD family) have been proved to be strongly inhibited by ppGpp (71, 
72)  
Biochemical characterizations have shown that phosphodiesterases have multiple 
functions and regulatory inputs, including ppGpp, heme group and nitric oxide union and 
ATPase activity (73). Moreover, gdpP mutants of S. aureus and B. subtilis were significantly 
more resistant to β-lactamic antibiotics and in general, for mutations in this enzyme phenotypes 
of stress resistance to pH, high temperatures and compounds affecting cell wall stability were 
obtained (58, 74, 75). 
 
Fig. 3. Representation of c-di-AMP synthesis and degradation. DAC containing enzymes (orange) are in charge 
of c-di-AMP synthesis. The three types of cyclases are represented: DisA, CdaA and CdaS. c-di-AMP is 
synthesized from two molecules of ATP, although M. tuberculosis and S. mutans can also use two molecules of 
ADP as substrate. The two phosphodiesterases families are depicted on the right: HD (green), hydrolyzing c-di-
AMP to AMP and DHH/DHHA1 (yellow). Within this family two types of enzymes can be distinguished: the 
most frequently membrane-bound version, which yields pApA, and the smaller soluble version, which can further 
degrade c-di-AMP to AMP. Principal pathways related to c-di-AMP metabolism are also indicated. 
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1.3.3. c-di-AMP interaction partners 
The first reported c-di-AMP interaction protein was DarR of Mycobacterium smegmatis. 
This protein is a transcriptional factor of the TetR family, which is stimulated by c-di-AMP and 
consequently binds to the promoter region of its own gene, repressing its expression. It also 
represses expression of a divergent operon, involved in fatty acid metabolism and of cspA gene, 
encoding a cold shock protein (76). 
As previously described, this second messenger has a strong influence in potassium 
homeostasis and its interaction to different potassium transporters has been reported. c-di-AMP 
binds to KtrA, the cytoplasmic regulatory component of the KtrAB potassium uptake system. 
The binding site is the regulator of conductance of K+ (RCK_C) domain, oriented towards the 
cytosol, and upon binding, it inhibits potassium uptake in B. subtilis, S. aureus and S. 
pneumoniae (50, 77). Interestingly, c-di-AMP in B. subtilis also binds to the kimA riboswitch, 
which regulates expression of ktrA as well as kimA, coding for a recently reported potassium 
importer (49). Moreover, in S. aureus this second messenger regulates all potassium uptake 
systems so far described, which includes KtrC and the KdpD subunit of the KdpDE two 
component system previously described (50, 61). 
Noteworthy, the RCK domain is present in a wide variety of proteins, like CpaA of S. 
aureus, a putative cation/proton antiporter recently proven to be regulated by c-di-AMP as well. 
Contrary to the c-di-AMP binding proteins so far described, this second messenger activates 
CpaA in S. aureus (78). On the other hand, PstA, a PII like signal transduction protein, present 
in S. aureus, L. monocytogenes and B. subtilis (where it is named DarA) also binds c-di-AMP, 
and even though several investigations were carried to elucidate its interaction to c-di-AMP, its 
function remains unknown (50, 54, 79). 
As stated, osmoregulation involves not only potassium homeostasis but also regulation 
of the synthesis and uptake of other osmolytes. c-di-AMP has been related to osmolarity 
homeostasis in both ways, i.e. potassium intake and osmoprotectants metabolism. For instance, 
c-di-AMP also interacts with OpuCA, the ATPase component of the carnitine ATP-binding 
cassette transporter OpuC (80). Interestingly, binding of c-di-AMP to OpuC occurs in the 
cystathionine-β-synthase (CBS) domain, broadening the possibilities of interactions to CBS-
containing, like L. monocytogenes CbpA and CbpB proteins of unknown function (81). 
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In L. monocytogenes, c-di-AMP also binds to CabP, a B. subtilis KtrA homologue, and 
in this bacterium as well as in L. lactis, this second messenger was linked to central metabolism, 
since it allosterically regulates pyruvate carboxylase activity (81). c-di-AMP connection to 
central metabolism and the enzymes encoded in the cdaAR glmM operon are more detailed 
described for LAB (see below). 
1.3.4. c-di-AMP and LAB 
Even though LAB importance in basic and applied science is undeniable, only a few 
approaches with regard to c-di-AMP metabolism were done so far. The synthesizing enzyme 
CdaA is encoded in the widely conserved cdaAR glmM gene cluster, in which the gene for the 
regulatory protein CdaR is also present. The third gene of the operon codes for GlmM, an 
enzyme which converts glucosamine-6-phosphate to the peptidoglycan precursor glucosamine-
1-phosphate, as previously described. 
Different combinations of L. lactis cdaA operon genes expressed in E. coli, confirmed 
that CdaR and CdaA also interact in this bacterium and evidence suggests that CdaR would 
negatively regulate CdaA (82). Moreover, GlmM also modulates CdaA activity, connecting c-
di-AMP metabolism to cell wall biosynthesis in L. lactis as well. Nevertheless, the exact 
mechanism remains unknown and, based on other model organisms, it is hypothesized that it 
would be through protein-protein interaction (82). 
One of the first studies carried out in L. lactis, allowed the identification of spontaneous 
gdpP mutants after a high temperature incubation step. Among these mutants, heat-resistant 
and salt-hypersensitive phenotypes were observed, as well as enhanced growth in sub-lethal 
concentrations of penicillin G (74). Moreover, mutants in which GdpP activity is diminished 
manifest greater acid stress resistance, and this protein was also linked to the stringent response, 
since ppGpp exerts a strong inhibition on the c-di-AMP hydrolyzing activity of the 
DHH/DHHA1 domain (72, 83). Furthermore, it has been proposed that PAS domains act as 
heme sensors, since upon binding of this compound, GdpP is strongly inhibited (84). This 
would protect cells from heme toxicity, and in accordance to this, L. lactis gdpP mutant 
manifested increased sensitivity to heme group compared to the wild type (85). 
On the other hand, it has been recently proved that pyruvate carboxylase (PC) enzyme 
from E. faecalis binds and is regulated by c-di-AMP. Interestingly, the binding site does not 
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seem to be conserved since in silico studies show that it is different from the c-di-AMP binding 
site of L. monocytogenes PC (86). This study was also extended to L. lactis and it was confirmed 
that c-di-AMP also binds to PC in this bacterium, being thus inhibited. Due to the lack of an α-
ketoglutarate and glutamate dehydrogenase enzymes, and the presence of a non-functional 
isocitrate dehydrogenase, the TCA cycle is truncated in L. lactis. Consequently, it is proposed 
that the main function of PC is the de novo synthesis of aspartate via AspC. Very importantly, 
aspartate is a precursor for other amino acids, for pyrimidine and also for peptidoglycan cross-
bridge amino acids. It is also theorized that PC is indirectly involved in osmoprotectant 
compounds synthesis, which is also one of the homeostasis mechanisms in which c-di-AMP is 
involved and would account for c-di-AMP interaction to a central metabolism enzyme (86). 
c-di-AMP synthesizing and degrading activities were confirm in CdaA and GdpP 
homologous proteins of other LAB, like Streptococcus suis and Streptococcus pyogenes (87-
89). RT-PCR studies showed in the last case that gdpP gene is expressed at least with two 
downstream genes, rpl9 and holB. The former codes for the ribosomal protein L9, whereas the 
latter encodes the δ’ subunit of DNA polymerase III (90). In the same work, a gdpP mutants 
study linked the lack of GdpP with increased resistance to the β-lactam antibiotic ampicillin, 
and the location of this enzyme inside the cell to the biosynthesis of the streptococcal virulence 
factor SpeB (secreted pyrogenic exotoxin B). Moreover, a ∆gdpP strain showed attenuated 
virulence in a murine model of subcutaneous infection. 
In S. pneumoniae one CdaA homolog was also confirmed and as previously mentioned, 
two phosphodiesterases were identified, named Pde1 and Pde2. Pde1 is the GdpP homolog, 
whereas Pde2 is the shorter cytoplasmatic version described above (Fig. 3), and although both 
can degrade c-di-AMP, the cleavage products resulting from each are different: Pde1 cleaves 
c-di-AMP into pApA and Pde2 directly hydrolyzes it to AMP. Furthermore, Pde1 as well as 
Pde2 were shown to contribute to pneumococcal virulence, and even though Pde2 orthologs 
can be found in B. subtilis, S. aureus and L. monocytogenes, degradation of c-di-AMP by these 
enzymes has not been reported yet (56, 68). 
Studies looking for c-di-AMP interaction partners in S. pneumoniae led to the 
identification of CabP, which belongs to the Trk/Ktr/HKT family of proteins and is the 
peripheral regulatory subunit of the potassium transporter SPD_0076. c-di-AMP binding to 
CabP would alter its conformation, disrupting the interaction between both parts of the K+ 
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uptake system, being thus inhibited (77). Interestingly, CabP interaction to c-di-AMP was also 
used to develop a c-di-AMP quantification method via ELISA (91). 
In S. mutans a CdaA homologue was also identified, being able to synthesize c-di-AMP 
from ATP as well as ADP. Interestingly, a cdaA mutant was obtained in the same study, 
showing increased susceptibility to peptidoglycan-targeting antibiotics and oxidative stress, and 
also higher autolytic activity than the wild type strain (92, 93). In a different study it was also 
proved that c-di-AMP mediates biofilm formation of S. mutans, and high levels of the second 
messenger up-regulates expression of gtfB, an enzyme in charge of water-insoluble glucans 
production, critical for biofilm formation and virulence of this bacterium (94). 
In the case of pathogenic bacteria, like the opportunistic LAB Group B Streptococcus 
(GBS), c-di-AMP can be secreted, activating consequently the Interferon-β (IFN-β ) response 
of the host. Interestingly, S. agalactiae, belonging to GBS, keeps extracellular c-di-AMP levels 
low thanks to CdnP, an ectonucleotidase anchored to the cell wall. It is important to mention 
that c-di-AMP degradation is different from those previously described for phosphodiesterases, 
since CdnP acts sequentially with another ectonucleotidase, NudP, to degrade c-di-AMP into 
adenosine (95). In this way, over-activation of STING and its concomitant IFN-β induction is 
avoided and virulence is promoted. 
Finally, in the opportunistic pathogen E. faecalis previously introduced, both classes of 
phosphodiesterases GdpP and PgpH where found encoded in its genome. Nevertheless, the 
obtaining of mutants involved in daptomycin resistance (an antibiotic targeting the cell 
membrane) only resulted in gdpP mutants, in agreement with previous research stating that this 
protein is more important for virulence than PgpH (57, 96). Initial mutations were also obtained 
in the liaFSR pathway, a three-component membrane stress response regulator, and it was 
observed that deletion of liaR lead to an increase in c-di-AMP intracellular levels. Even though 
the interaction between LiaFSR and c-di-AMP is not fully understood, the link between cellular 
wall damage and c-di-AMP levels was again established (96). 
1.4. American Trypanosomiasis (Chagas disease) 
American Trypanosomiasis (also known as Chagas disease) is a tropical disease caused 
by the flagellate protozoan parasite Trypanosoma cruzi. Even though the first cases were 
reported in the tropical areas of Latin America, according to the Health World Organization, an 
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estimate of 8 million people are infected worldwide with a cost of 10.000 deaths per year, 
affecting nowadays countries of North America, Europe, Asia and Australia as well (Fig. 4). 
The life cycle of T. cruzi consists of four stages: the replicative epimastigote and 
amastigote stages and the infective non-replicative metacyclic and trypomastigote stages. It also 
requires a host of the Triatomine subfamily, most commonly known as kissing bugs, or 
Vinchucas in Spanish. When these bugs bite a mammal in order to feed from its blood, they 
normally defecate nearby and the metacyclic trypomastigotes residing in the faeces (which 
normally cannot penetrate the skin) can now enter the new host through the wound. After 
infection, they transform into amastigotes so they replicate inside the host cell and differentiate 
into trypomastigotes. Once the host cell disrupts, the trypomastigotes are released to the blood 
stream and are ready to infect new cells (97). There are also other less frequent routes of 
infection, such as blood transfusion, organ transplant and vertical transmission, i.e. 2-10% of 
infants are infected by their infected mothers. Horizontal transmission is possible as well, but 
more rare, since it implies mucosal penetration through the mouse or eyes (98). 
Chagas disease manifests two clinical phases: the short acute phase of patent 
parasitemia, which is oligosymptomatic, and the chronic phase, which can remain 
asymptomatic for months or even years. The main symptoms in the chronic stage are related to 
heart failures and pathologies affecting organs of the gastrointestinal tract. For more than 40 
years, Chagas disease treatment has been based on the nitroheterocyclic compounds nifurtimox 
(NFX; 3-methyl-4-[59-nitrofurfurylideneamine] tetrahydro-4H-1,4-tiazine-1,1-dioxide; 
developed by Bayer, Germany) and benznidazole (BZ; N-benzyl-2-nitroimidazole acetamide; 
RO7-1051; developed by Laboratorio Farmacéutico do Estado de Pernambuco (LAFEPE), 
Recife, Brazil and Laboratorio ELEA, Ciudad Autónoma de Buenos Aires, Argentina), which 
have trypanocidal activity against all parasitic forms. The main drawbacks of these drugs are: 
1) their mechanisms of action are not entirely clear, 2) their side effects, which normally are 
the cause of treatment interruption and 3) the low efficacy, since during the acute phase only 
50 to 80% of patients are cured and when used in the chronic phase, percentages drop to 8-20% 
(99, 100). 
The World Health Organization (WHO) has established a set of characteristics that the 
ideal drug for Chagas disease treatment should gathered, namely: parasitological cure in both 
the acute and chronic phases, efficacy in one dose or a few doses, accessibility to affected 
population (low cost), absence of side effects or teratogenic effects, and no induction of 
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resistance. Unfortunately, there is no drug meeting all these requirements, and consequently 
new compounds are currently under investigation. Nonetheless, apart from a cure, priorities 
also fall into the improvement of diagnostics, health systems, vector control and disease 
prevention, i.e. the development of vaccines. 
 
Fig. 4 Global distribution of Chagas Disease cases. Even though it is a tropical disease which 
originally occurred in South America, it is nowadays distributed in the four continents 
represented in the picture. Numbers are based on official estimates 2006 – 2010. Adapted from 
Trends in Parasitology. 
1.4.1. Chagas prevention 
Nowadays, several investigations are directed towards the formulation of vaccines using 
as antigens key peptides or proteins involved in infection establishment. In this sense, one of 
the main candidates is the T. cruzi trans-sialidase protein (TS) (101, 102). This is an enzyme of 
160-200 kDa, which is anchored to the outer cellular membrane by 
glycosylphosphatidylinositol (GPI). It catalyzes the transfer of sialic acid from glycoproteins 
of the host to the β-Gal residues on mucine proteins covering the parasite membrane. In this 
way, T. cruzi trypomastigotes make their way into new cells upon establishment of infection, 
and they mask recognition sites for the immune system, often deriving in auto-immune 
responses. TS also helps the parasite in recognizing host cells and attaching to its sialic acids 
and/or β-Gal residues of their surface, through TS active site or other domains (103). 
TS synthesis depends on a gene superfamily, which resulting proteins range from 60 to 
more than 200 kDa. Of this superfamily, only 12 are active, and they vary by their level of 
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expression in the different stages of the parasite life cycle, their degree of glycosylation and the 
SAPA domain (shed acute phase antigen) which are tandem repeats of a 12 amino acids 
sequence. Since mammals lack TS and it is essential for the parasite because it cannot 
synthesize sialic acid the novo, this protein is currently under study as a good candidate for 
vaccine formulations. Different antigens have been developed based on this protein, and 
promising results were obtained (104). 
For example, antigens TSA-1 (Trypomastigote surface antigen-1) and Tc24 (flagellar 
calcium binding protein of 24 kDa) have been thoroughly investigated and are highly 
immunogenic. Moreover, the protective efficacy of both has been proved in mice models and 
it has been reported as well that an immunotherapeutic DNA vaccine could control Chagas 
disease, reducing parasitemia and cardiac tissue damage (105, 106). Very recently, studies 
suggested the presence of antigen-specific memory cells induced by natural infection in 
seropositive patients and, in the same work, a long lasting humoral and cellular response to 
these antigens was evidenced, even in subjects on the chronic phase, after 10 years of infection 
(107). 
1.5. Subunit vaccines  
The first world-wide spread vaccine was against smallpox in the 18th century. Upon the 
massive outbreak, it was noticed that infected people who survived the disease were immune. 
Based on this observation, a common practice of subcutaneous inoculation of smallpox virus 
into non-immune individuals was started. The virus was obtained from pustules of an infected 
person, and no regulations or thorough investigations existed for vaccination, for what 
considerable health risks existed, even though mortality caused by smallpox itself was 
significantly higher. A percentage of vaccinated patients died or contracted another disease, 
like tuberculosis or syphilis due to the lack of good hygiene conditions. Nevertheless, 
vaccination against smallpox was considered a success (108). 
During the 19th century, many others vaccines were developed, with similar strategies. 
For example, rabies virus extracted from dead infected rabbits were weakened by drying and 
then used as inocula, and killed whole cells of Vibrio cholerae were the immunization strategy 
against cholera (109, 110). Like in the former example, attenuated pathogens by drying, boiling 
or propagation through a foreign host are the base of “attenuated vaccines”. The principal 
advantages of these vaccines are their low cost and the fact that they trigger a strong, long-
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lasting immune response. Nevertheless, since the live pathogen is administered, the possibility 
exists that it can regain its virulence, and special attention needs to be paid with 
immunocompromised patients. Moreover, these vaccines need to be refrigerated, so their 
transportation and application in poor areas is an issue (111). 
An alternative to attenuated vaccines are toxoid vaccines, which do not make use of the 
pathogen at all, and are the strategy of choice for vaccine development when the disease is 
caused by a toxin synthesized by the pathogen. Such is the case of tetanus, which is caused by 
a toxin secreted by Clostridium tetani and after formaldehyde treatment, minor molecular 
changes occur and it is converted to a toxoid. The purified product is a non-toxigenic compound 
capable of stimulating the immune system to generate specific antibodies that, in the event of a 
C. tetani infection, bind to the toxin. This complex is not able to bind to the regular toxin 
receptor binding sites, so the development of the disease is prevented (112). The main benefit 
of these vaccines is the fact that there is no risk of disease nor to revert to a virulent form. 
Moreover, the compounds are normally stable and less susceptible to temperatures, light and 
humidity. Nevertheless, they normally need an adjuvant (see below) and this usually causes 
local reactions at the vaccination site. 
Another class of vaccines are the inactivated vaccines, like the case of hepatitis A 
vaccine, in which the pathogen is heated or chemically treated so that its capacity of replication 
is lost, but the antigens are still recognized by the immune system. The adaptive immune 
response is very similar to that of a toxoid vaccine, although inactivated vaccines have the 
advantage of having all antigens participating in the infection and therefore a broader range of 
antibodies is synthesized. Nevertheless, among the drawbacks of these vaccines it can be 
mentioned that one dose normally is not enough to trigger a strong signal to the adaptive 
immune system, so they are usually given in several doses and, like toxoid vaccines need to be 
adjuvanted (see below) (112). 
Finally, the latest development in vaccines are the subunit vaccines. In this case, a 
particular antigen or set of antigens are provided so they are recognized by the immune system 
and, consequently, specific B cells are produced. Subunit vaccines can be further divided into 
subgroups depending on whether the antigen is a peptidic compound or a polysaccharide, which 
will define the kind of immune response they will generate in the patient (112). If the antigen 
derives from a protein (such is the case of hepatitis B and influenza vaccines) then a T-
dependent response will be trigger, like for the case of toxoid vaccines. In the case of 
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polysaccharide derived antigens, the response will be T-independent (e.g. the pneumococcal 
vaccine Pneumovax) (113). Advantages and disadvantages are similar to those of the toxoid 
vaccines, except that with the advances of molecular biology, strategic antigens (and adjuvants) 
can be designed and combined to widen the spectra of pathogen strains against which the 
vaccine is active (114). 
1.5.1. L. lactis in the industry: its potential as delivery vector 
In the last decades, a considerable amount of research has been prompted to use food 
grade bacteria as live vaccines. The starting point to consider a bacterium suitable for antigen 
delivery is its innocuity. In this sense, L. lactis classification as GRAS and QPS as previously 
mentioned, makes it appropriate as regards safety. L. lactis can also survive its passage through 
the gastrointestinal tract (GIT) for 2-3 days, without colonizing the mucosal surface of the host 
(115). Moreover, due to its lack of lipopolysaccharide attached to their cell membrane, it does 
not stimulate the host immune response. 
This species in particular has considerable importance in medicine and the 
pharmaceutical industry, and it was in fact, the first genetically modified microorganism for the 
treatment of a human disease (116). For an outline with examples supporting L. lactis use in 
food and pharmaceutical industries, see Table I. 
In 1989 Iwaki et al. proposed for the first time the use of L. lactis for the development 
of a mucosal vaccine against caries by use of a strain expressing a surface Enterococcus mutans 
protein. When the killed recombinant bacteria were orally administered in mice, salivary IgA 
and serum IgG response to the protein were induced (117). 
Nowadays, many investigations see the use of L. lactis as an opportunity to develop 
competent treatments for diseases and conditions currently without a cure. For example, 
Inflammatory bowel diseases (IBD) like Chron’s disease and ulcerative colitis are in the urgent 
need for the formulation of an efficient and cost effective drug treatment. Even though their 
causes are not completely understood, inflammation of GIT is a common consequence. The 
first human trial with a therapeutic bacterium, genetically engineered to treat GIT inflammation 
was conducted in 2006. In this work, an L. lactis secreting interleukin-10 strain gave interesting 
immunological results and most importantly, it was demonstrated to be safe for humans (118). 
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L. lactis is therefore seen as one of the best options to deliver any molecule at the mucosa level, 
able to alleviate symptoms and provide the patient with a better life quality (119). 
Other investigations were also developed using L. lactis as a recombinant live delivery 
vector, like the study performed with the tetanus toxin fragment C (TTFC). Bacteria expressing 
TTFC anchored to the cellular membrane were subcutaneously administered in mice, and 
antibody production was proven to protect mice against the lethal infection. Nasal and oral 
administration showed similar protection efficacies. In the former, the antigen was 
intracellularly overexpressed and IgG antigen production in serum protected 75% of mice 
(120). Nevertheless, for this example, the expression system was based on E. coli T7 
bacteriophage promoter, and although it allows high expression levels of heterologous proteins 
of interest, it is not suitable for the final model of oral immunization. Since 2000 this system 
has been replaced by the nisin inducible system NICE previously described. 
Since the first reported investigations about L. lactis as a delivery vector were made, 
several others were carried using this methodology for different antigens able to elicit an 
immune response. Mice orally immunized with recombinant L. lactis secreting Brucella 
abortus superoxide dismutase were reported to develop systemic and mucosal SOD-specific 
immune responses (121). Moreover, an oral live vaccine expressing an attenuated version of 
the Staphylococcal enterotoxin type B (SEB) was also reported to elicit immune protection. In 
this study, both intracellular and secreted versions of antigen production in the intestinal mucosa 
of mice showed to stimulate production of specific IgG and IgA antibodies in the serum and 
the feces, respectively (122). Production of specific IgA in intestinal mucosa was also obtained 
when BALB/c mice were orally immunized with a strain of L. lactis constitutively expressing 
EspB, a key protein involved in the attachment of enterohemorrhagic E. coli O157-H7 (EHEC) 
to enterocytes (123). Also, a vaccine against Rhodococcus equi, the main causal agent of 
pneumonia in foals, was developed using an L. lactis recombinant strain secreting the virulence 
associated protein VapA. In this study, intragastric and intranasal routes were considered, 
obtaining both humoral and cell-mediated immune responses (124). 
As it can be appreciated, the use of L. lactis as a delivery vector of antigens synthesized 
in the cytosol, presented on the cellular membrane and secreted to the extracellular space, is a 
recently developed technology currently being exploited. Apart from its applications against 
bacterial pathogens of humans and animals with industrial relevance, interesting results were 
also obtained against the human papillomavirus and rotavirus, the most common cause of severe 
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dehydrating diarrhea in children (125, 126). When genetically modified LAB are administered 
in mucosal tissues, both mucosal and systemic immune responses are triggered. Therefore, due 
to its non-invasive application and its rather simple manipulation without the need of highly 
qualified personnel, mucosal vaccines are gaining a central position in new vaccine prototypes 
formulation. Their production would also imply a reduction in costs, since the live 
microorganism synthesizes and delivers the antigen compound of interest, without the need of 
purification (127).  
Table I. Examples of L. lactis strains and strategies with potential use in food and pharmaceutical industries 
C: cytoplasmic – S: secreted – A: cell wall anchored 
Parental 
Strain 
Strategy Product Location Application Reference 
NZ3950 NICE system L-alanine C 
Food 
sweetener 
Hols et al. 
1999 (128) 
NZ9000 Spontaneous 
mutant 
Vitamin B11 C Nutritional supplement 
Sybesma et 
al, 2003(129) 
NZ9000 
Spontaneous 
mutants / NICE 
system 
Vitamin B2 C “Vitamin factory” 
Burgess et al. 
2004 (130) 
IL1403 
pILPtuf Promoter / 
Usp45-secretion 
signal peptide  
Interleukin -6 S Adjuvant Li et al. 2015 (131) 
Not 
informed 
pUB1000 / Usp45-
secretion signal 
peptide  
Insulin analogue S Drug delivery 
Agarwal et 
al. 2014 
(132) 
MG1363 pTREX 
Anti-TNF a 
nanobodies S 
Bowel 
disease 
treatment 
Vandenbrouc
ke et al. 2010 
(119) 
NZ9000 NICE system Antigen 
S 
C 
A 
Rotavirus 
vaccine 
Marelli et al. 
2011 
IL1403 
pILPtuf promoter / 
USp45- secretion 
signal peptide  
Adjuvant S Cancer vaccine 
Kim et al. 
2015 (133) 
MG1363 P170 promoter Allergen S Allergy 
Glenting et 
al. 2007 
(134) 
NZ9000 pSEC:LEISS 
Carcinoembryonic 
antigen (CEA) 
C 
A 
Cancer 
vaccine 
Xiaowei et 
al. 2016 
(135) 
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1.5.2. c-di-AMP as Adjuvant 
A key factor for the development of human subunit vaccines is not only to define a 
suitable antigen but also to select an adequate adjuvant. Vaccine adjuvants are compounds 
added to vaccine formulations that enhance the immunogenicity of antigens in vivo. They are 
further categorized based on their mechanisms of action, being divided into delivery systems 
(or particulate adjuvants) and immune potentiators (or immune stimulators). The former 
enhance the innate immune response either directly or through pattern-recognition receptors, 
whereas the latter help with antigen presentation and localization (136). Several advantages can 
be mentioned when describing the scope of adjuvants use, namely: stronger and longer immune 
response (especially important for weakened immune system population), improved antibody 
production against a broader spectrum of pathogenic strains, mucosal immune response 
induction, and increased biological half-life of vaccines. Hence, the amount of antigen needed 
is lowered, as well as the number of doses required for proper immune response generation, 
which consequently lowers costs of vaccination programs as well (137). 
Cyclic-di-nucleotides (CDNs) have recently emerged as pathogen associated molecular 
patterns (PAMPs) and effective adjuvants. PAMPs and adjuvants are specifically important for 
the mucosal route, when antigens suffer mechanical removal and structural modifications by 
pH changes and enzymatic degradation. Particularly 3´5´-cyclic-di-adenosine monophosphate 
(c-di-AMP) was demonstrated to be a suitable candidate for vaccine adjuvant, since it has 
showed the capacity to activate in vitro dendritic cells of murine and human origin, one of the 
most important steps to stimulate the adaptive immune response. Several investigations have 
been carried out to test this second messenger action as an adjuvant when co-administered with 
an antigen of interest. Results after intra-nasal and oral immunization showed improved 
stimulation of immune responses at both systemic and local levels. Moreover, in vivo 
experiments also evidenced that c-di-AMP can promote MHC class I restricted immune 
response by CD8+ T cells, promote specific IgG and IgA production and enhance cellular 
proliferative responses (138). This consequently triggers the stimulation of Th1, Th2 and Th17 
cells, as well as the induction of cytotoxic T lymphocytes. Moreover, it was recently 
demonstrated not only that c-di-AMP triggers a type I IFN response, but also that it down-
regulates it in the inductive phase of an adaptive immune response, which is a positive 
characteristic for its use in vaccines (139). 
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In a proposed intranasal vaccine model for Chaga’s disease, where c-di-AMP was co-
administered with antigen TC52 (essential for the parasite T. cruzi), high specific Tc52-specific 
IgA titers were found in nasal lavages. Importantly, this results were significantly different from 
those obtained in the absence of the adjuvant c-di-AMP, and only in its presence, stronger 
cellular and humoral immune responses were induced (140). In another vaccine prototype based 
on archeaosomes as delivery system of a hepatitis C virus antigen, a robust T cell immune 
response was observed when adjuvanted with c-di-AMP (141). The same study also showed 
that a partial intranasal immunization regimen also triggers the immune response, opening the 
range of possibilities as regards administration. 
Another non-invasive and economically favorable regimen of vaccine administration is 
the sublingual route. As with the intranasal, the main advantages are the simple immunization 
protocol along with its consequent possibility of being handled by personnel with no advanced 
training, which would allowed massive administration. This would provide an important benefit 
for example, during an epidemic outbreak. In this regard, a virosome-based vaccine against 
influenza virus H5N1 was tested using c-di-AMP as adjuvant, and the sublingual and intranasal 
inoculation as routes of administration, evidencing strong humoral and cellular responses (142). 
In conclusion, the formulation of mucosal, live, subunits vaccines adjuvanted with c-di-
AMP and with food grade bacteria as delivery systems proposes an innovative paradigm 
currently under investigation. 
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1.6. Objectives 
Under the theoretical framework developed, the general objective of this thesis is to 
broaden the knowledge of c-di-AMP metabolism in firmicutes, and specifically in the Lactic 
Acid Bacteria Lactococcus lactis and Enterococcus faecalis. In addition, the aim of this work 
is to approach research from two perspectives: the importance of basic investigation around this 
newly discovered second messenger, as well as the vast application spectra it offers to the 
biotechnological and pharmaceutical industries. 
Specific objectives set to accomplish the aforementioned general objectives are: 
i) To identify and characterize c-di-AMP interaction partners in L. lactis 
ii) To develop engineered strains able to modify c-d-AMP levels in L. lactis and E. 
faecalis and study their physiological impact 
iii) To formulate a vaccine prototype by use of an L. lactis strains producing high 
levels of c-di-AMP 
iv) To perform a first approach into the virulence of GdpP in E. faecalis 
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2. Materials and methods 
“An experiment is a question which science poses to Nature, and a 
measurement is the recording of Nature´s answer” Max Planck 
 
 
Materials and Methods 
2.1. Materials 
Lists of chemicals, commercial kits, enzymes and oligonucleotides used in this work 
are presented in the appendix. 
2.2. Strains and plasmids 
Bacterial strains and plasmids constructed for this work are detailed in the appendix. 
2.3. Methods 
2.3.1. General methods 
General methods routinely used in this work are mentioned in Table II  
Table II. General methods 
Method Reference 
Absorption measurement Sambrook et al. 1989 (143) 
DNA gel electrophoresis Sambrook et al. 1989 (143) 
Plasmid preparation from E. coli Sambrook et al. 1989 (143) 
Ligation of DNA fragments Sambrook et al. 1989 (143) 
Protein quantification 
Bradford 1976 (144) - Lowry 
1951 (145) 
Protein gel electrophoresis (denaturing) Laemmli 1970 (146) 
Sequencing according to the chain termination method Sanger et al. 1977 (147) 
2.3.2. Storage and bacterial growth 
E. coli DH5α and BL21 were grown in Luria Bertani (LB) medium at 37 ºC in aerobic 
conditions with vigorous shaking. E. coli LB650 and 2003 were grown under similar conditions 
in LB with addition of 200 mM KCl or in M9/M9mod (see Table III) supplemented with a 
suitable carbon source and 50 mM KCl, unless otherwise stated. 
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LAB were cultivated in M17 medium supplemented with 0.5% glucose (M17G), in 
aerobic conditions without shaking. Incubation temperatures were 30 ºC and 37 ºC for L. lactis 
and E. faecalis, respectively. 
In all cases -80 ºC stocks prepared in 10% glycerol were propagated twice to obtain a 
final overnight (ON) saturated culture. This was used in turn to inoculate fresh media at an 
initial optical density (ODi) of 0.05. 
Media composition 
Media composition is detailed in Table III. pH was adjusted to 7.0 or 5.5 with NaOH or 
HCl according to the experiment. In all cases, deionized water was used, and media were 
autoclaved for 20 minutes at 121 ºC and 2 bar. Thermo-labile compounds were separately 
prepared, filter-sterilized and stored at their optimal temperature. For agar plates, 1.5 % agar 
was added. 
Table III. Growth media composition 
Medium Component Quantity 
Luria Bertani (LB) (143) 
Casein Peptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
dH2O Add to 1 Lt 
M17 
(Terzaghi and Sandine, 1975) 
(148) 
Bactopeptone 10 g 
Beef Extract 5 g 
Yeast extract 2.5 g 
Ascorbic Acid 2.5 g 
Sodium β-glycerophosphate 19 g 
MgCl2*1 5 mM 
MnCl2*1 1.6 mM 
dH2O Add to 1 Lt 
M9*2 
(Sambrook and Russell, 2001) 
(149) 
M9 base 20X 50 ml 
MgSO4 1M 1 ml 
CaCl2 0.1 M 1 ml 
FeCl3 1 mM 0.5 ml 
Carbon source 1 % 
Casaminoacids10 % 66 ml 
Proline 4 M 10 ml 
Thiamine 1 M 1 ml 
dH2O Add to 1 Lt 
Na2HPO4.2H2O 140 g 
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M9 base medium 
KH2PO4 60 g  
NH4Cl 20 g 
dH2O Add to 1 Lt 
*1 Added from 1M solutions, after autoclave. *2 In M9mod medium, KH2PO4 is 
replaced for equimolar quantities of NaH2PO4. 
When needed, growth media were supplemented with antibiotics as selective agents 
(Table IV), which were prepared in 1000-fold concentrated stock solutions. Deionized water 
was used for dissolution, except for erythromycin and chloramphenicol, in which cases ethanol 
was employed. Sterilization was performed by filtration and storage at -20 ºC. Antibiotics were 
added to media before inoculation. 
Table IV. Antibiotics 
Bacterium Antibiotic Concentration 
E. coli 
Ampicillin 100 mg/ml 
Erythromycin 150 mg/ml 
Chloramphenicol 30 mg/ml 
Kanamycin 
40 mg/ml1 
50 mg/ml2 
L. lactis and E. faecalis 
Erythromycin 5 mg/ml 
Chloramphenicol 10 mg/ml 
1 E. coli EC101 2 E. coli LB650 
For expression or gene deletion experiments, inducers and indicators were respectively 
added to media (Table V). 
Table V. Inducers and indicators 
Compound Stock Solution 
Arabinose 5 % p/v 
IPTG 0.5 M 
Nisin 50 µg/ml 
X-Gal 40 mg/ml in (DMF) 
2.3.3. E. coli electroporation 
E. coli electrocompetent cell preparation 
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5 ml of a saturated ON culture of the E. coli strain of interest were used to inoculate 500 
ml of LB medium at an ODi of 0.05. Cells were incubated in a 2 Lt. Erlenmeyer at 37 °C with 
vigorous shaking until OD reached 0.50. The culture was then cooled in ice for 20 min and 
centrifuged for 5 min at 5000 rpm and 4 °C. Two wash steps were performed afterwards with 
500 ml ice-cold dH2O and one with 10 ml glycerol 10%. Finally, the pellet was resuspended in 
1 ml glycerol 10% and separated in 100 µl aliquots. Samples were stored -80 °C. 
Electroporation 
Cells were electroporated as described in Dornan and Collins, 1990, under the following 
conditions: 25 µF, 2,5 kV y 200 Ω. After the pulse, 1 ml of LB was added to the electroporation 
cuvette and samples were incubated for 1 hour at the 37 ºC. Samples were plated in LB 
supplemented with the corresponding antibiotics and incubated ON. 
2.3.4. LAB electroporation 
LAB electrocompetent cell preparation 
Strains of LAB under study were grown in M17G supplemented with 0.5 M saccharose 
(M17SG) and 1% glycine. The ON saturated culture was diluted 50 times in fresh M17SG + 
1% glycine. Cells were incubated at 30 ºC or 37 ºC for L. lactis or E. faecalis, respectively until 
OD reached 0.4-0.6. The culture was then harvested for 5 minutes at 5000 rpm at 4 ºC. Pellets 
were washed in 0.5 M ice cold saccharose + 10% glycerol using half of the culture volume. 
Centrifugation was performed at 6000 g for 8 minutes at 4 ºC. Cells were resuspended in 0.5 M 
ice cold saccharose + 10% glycerol using 1/200 of the initial culture volume. 
Electroporation 
LAB were electroporated as described in Dornan and Collins, 1990, under the following 
conditions: 25 µF, 2,5 kV y 200 Ω. After the pulse, 1 ml of M17SG was added to the 
electroporation cuvette and samples were incubated for 1.5 hours at the optimal growth 
temperature of the strain under study (30 ºC for L. lactis and 37 ºC for E. faecalis). Cells were 
plated in M17SG supplemented with the corresponding antibiotics and incubated ON or until 
colonies appeared. 
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2.3.5. DNA manipulation 
DNA extraction 
For plasmidic DNA extraction from E. coli, 3 ml of a saturated ON culture was 
harvested at 4500 rpm for 5 minutes. The pellet was then resuspended and processed using the 
Wizard® Kit (Promega) or the NucleoSpin® Plasmid Kit (Macherey-Nagel), according to 
manufacturer’s instructions. Elution was performed with pre-warmed dH2O at 70 ºC.  
Genomic DNA was similarly prepared, using the Wizard® Genomic DNA Purification 
Kit (Promega) or the NucleoSpin® Microbial DNA Kit (Macherey-Nagel). 
When working with Gram-positive bacteria, 10 ml of an ON saturated culture were 
harvested and the pellet was incubated with 10 mg/ml lysozyme at 30 ºC for 30 minutes. The 
protocol was then completed using plasmidic or genomic DNA extraction kits. 
Polymerase Chain Reaction (PCR) 
Reactions were prepared in final volumes of 25 or 50 µl, using 0.2 µM of specific 
primers and 0.5 µM of dNTPs. Pfu, Taq or Phusion polymerase were used according to 
manufacturer’s instructions. PCRs were performed in a thermocycler with 30 cycles of 
denaturation, annealing and elongation (Table VI). 0.5 µl of plasmidic DNA or of a 10-fold 
dilution of genomic DNA were used as template. 
Oligonucleotides were designed using VectorNTI (Invitrogen) or Geneious 7.0.2 
(Biomatters) softwares and purchased from Sigma-Aldrich, Genbiotech or Invitrogen. A list of 
primers used in this work is provided in the appendix (Table XVII). 
Table VI. PCR steps 
Step Temperature (ºC) Time 
Initial denaturation 98.0 5’ 
Denaturation 98.0 1’ 
Annealing 52.0 – 59.0*1 45’’ 
Elongation 72.0 Variable*2 
Final elongation 72.0 10’ 
Hold 4.0 hold 
*1 According to primer melting temperature (5 degrees lower) 
*2 According to enzyme processivity and product length 
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DNA electrophoresis  
DNA electrophoresis was performed according to Sambrook et al., 1989. Horizontal 
gels were prepared in TAE buffer (Table XVIII) with agarose concentrations ranging from 0.8 
to 1.2 % according to DNA fragment size. For DNA visualization, 1X GelGreen (Biotium) or 
HD Green Plus DNA stain (INTAS Science Imaging Instruments GmbH) was added. 
Gels were submerged in TAE, samples previously stained in 1X sample buffer (0,25 % 
(p/v) bromophenol blue, 0,25 % (p/v) xilenecyanol and 30 % (p/v) glycerol) were loaded and 
run at 100 mA. DNA from λ phage digested with EcoRI and HindIII enzymes (PBL Productos 
Bio-lógicos) was loaded as reference and DNA bands were visualized using a blue-light or UV 
transilluminator. 
DNA purification 
Purification of linear DNA fragments after PCR or enzymatic digestion was performed 
using the QIAquick® PCR purification kit (QIAGEN, Hilden), or the Gel Band Purification Kit 
(GE Healthcare Life Sciences) when purifying DNA from agarose gels. Protocol was followed 
as specified by manufacturers and final elutions were done in pre-warmed dH2O at 70 ºC. 
DNA enzymatic digestion 
For DNA digestion with restriction enzymes, the protocol of Sambrook (1989) was 
generally followed. Fast Digest or regular endonucleases purchased from Thermo scientific 
were used. When linearizing plasmids, dephosphorylation was performed using Calf Intestinal 
Alkaline Phosphatase (CIAP, Promega) or FastAP Alkaline Phosphatase (Thermoscientific). In 
all cases, reactions were performed following manufacturer’s instructions. 
Ligation of DNA fragments 
Ligase enzyme was acquired from Takara or Thermoscientific and reactions were 
prepared in final volumes of 20 μl. Manufacturer’s protocols were followed, using in general 
100 ng of vector and a 1:5 molar ratio to calculate the volume of the fragment of interest. When 
ligating two DNA fragments, equimolar quantities were used. Before electroporation, ligase 
enzyme was heat-inactivated. 
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Clone screening 
In order to screen for positive clones, 3 ml of LB (10 ml of M17G in the case of LAB) 
supplemented with the corresponding antibiotics were inoculated with a putative positive 
colony (normally 12 colonies were analyzed) to obtain an ON saturated culture. 50 µl of these 
samples were harvested at room temperature at 5000 rpm for 5 minutes. Pellets were 
resuspended in 25 µl of EDTA 10 mM pH 8.0 and cells were disrupted by addition of 25 µl of 
freshly prepared crack buffer (Table VII). Samples were incubated for 5 minutes at 70 ºC and 
cooled in ice afterwards. Next, 2 µl of crack dye were added (Table VII). After 10 minutes of 
incubation in ice, samples were centrifuged for 5 minutes at 12000 rpm and 4 ºC, and they were 
finally analyzed by agarose electrophoresis. Plasmids with inserts of interest were evidenced 
by its differential migration in the gel when compared to the empty vector. 
Table VII. Clone screening solutions 
Solution Composition Concentration 
Crack buffer 
Sucrose 0.2 % p/v 
SDS 0.5 % 
NaOH 0.2 N 
Crack dye KCl 3 M 
Loading dye 1X 
DNA Sequencing 
Plasmids and fragments of interest were sent to the DNA sequencing facility at the 
University of Maine, or to SeqLab Sequence Laboratories, Göttingen GmbH. 
2.3.6. Gene deletion 
After electroporation with pBVGh vector (Table XVI), cells were incubated at 30°C in 
M17G Em5 X-Gal 100 µg/ml agar plates. 
A single blue colony was used to inoculate fresh M17G + 5 µg/ml Em, which was then 
incubated ON at 42 °C. This culture was diluted 1/100 in fresh media, and it was incubated 
again at 42 °C ON. 
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Then, cells were propagated in fresh media without antibiotic, inoculating 0.05 % of the 
culture volume. After inoculation, samples were incubated 4 hours at 30 °C and ON at 42 °C. 
This step was repeated twice. 
Serial dilutions (normally 10-4; 10-5; 10-6) were plated in medium with 100 µg/ml X-Gal 
and no antibiotic. Plates were incubated at 42 °C for 24-48 hours, or until colonies were 
distinguished. 
White colonies were restricked in plates with and without antibiotic, and those which 
were sensitive were checked by PCR using a pair of primers hybridizing in the adjacent up and 
downstream genes. A set of primers amplifying an internal sequence of the gene was also used 
as negative control. 
2.3.7. Protein preparation and analysis  
Cell disruption by French Press 
The cell body and the piston were kept in ice prior to use (French Pressure Cell, Thermo 
Scientific). Samples were also cooled and washed in buffer W (Table XVIII). Cell pellets were 
disrupted once when working with E. coli and three times when working with L. lactis. Pressure 
was 18000 psi in all cases. 
Cell disruption by Tissue Lyser 
5 ml of a LAB culture of interest were harvested for 10 minutes at 5500 rpm. Cells were 
washed in 1 ml of buffer W. Next, pellets were resuspended in lysis buffer and transferred into 
a 2 ml screw-cap microvial containing 0.5 g of glass beads (0.1 µm). Cell walls were disrupted 
using a mini-beadbeater-16 (Biospec, USA) in 3 cycles of 5 minutes, incubating the samples in 
ice for 3 minutes in each interval. Crude extracts were then processed according to the desired 
protocol. For larger samples, 4 ml of sample were similarly disrupted in a 5 ml screw-cap 
microvial using 0.8 g of glass beads. Buffers are listed in Table XVIII. 
Expression test of heterologous proteins in E. coli 
10 ml of a suitable medium were inoculated with the E. coli strains under study. When 
OD600 reached 0.5, 0.5 mM IPTG were added and cultures were incubated for three more hours 
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at 37 ºC and continuous vigorous shaking. Samples were normalized in 100 µl with equal cell 
amounts and spinned down in a table top centrifuge. Pellets were resuspended in 15 µl of SDS 
loading dye and boiled for 5 minutes at 95 ºC. Finally, the whole volume was loaded in an SDS-
PAGE gel for expression analysis. 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE analysis was based on Laemmli (1970) protocol. 1.0 mm polyacrylamide 
gels with concentrations ranging from 10 – 15 % were prepared according to the molecular size 
of the proteins under study (Table VIII). Samples were boiled at 95 ºC for 5 minutes in sample 
buffer. Normally, 30 μg of total protein were loaded in the gel, which was submerged in running 
buffer. Electrophoresis was performed at room temperature, at current intensity of 20 mA. 
Buffers are listed in Table XVIII. 
PageRulerTM Plus Prestained Protein Ladder (ThermoFischer Scientific) or unstained 
Low Range Molecular Marker (BioRad) were used as size standards. 
Finally, gels were analyzed by Coomassie staining, silver staining or Western Blot. 
Table VIII. SDS-PAGE Gel composition 
Solution Separating gel Stacking gel 
Acrylamide (Stock 30 % 
acrylamide-bisacrylamide 19:1) 10 % 12 % 15 % 5 % 
Tris-HCl (Stock 1.5 M) 375 mM*1 187.5 mM*2 
SDS (Stock 20 %) 0.1 % 
APS (Stock 10 %) 0.1 % 
TEMED 0.04 % (v/v) 0.1 % (v/v) 
*1 Tris HCl pH 8.8 *2 Tris HCl pH 6.8 
Coomassie Staining 
For Coomassie staining after SDS-PAGE, gels were incubated in Coomassie R-250 for 
30 minutes at room temperature in a rocking shaker. For protein visualization, gels were 
afterwards boiled or incubated in destaining solution containing 20 % v/v ethanol and 5 % v/v 
acetic acid until protein bands were evidenced. 
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Silver staining 
When protein amounts were low, visualization was accomplished by silver staining 
which allows a more sensitive detection (up to 1 ng of protein) (150). For this, the following 
protocol was followed: 
• Fixation: the gel was incubated in fixing solution, at least during 1 hour 
• Wash: 3 times with 50 % ethanol, during 20 minutes 
• Reduction: Performed in 0.02 % (p/v) Na2S2O3 
• Wash: 3 times with dH2O for 20 seconds 
• Impregnation: the gel was incubated for 15’-25’ in impregnating solution  
• Wash: 3 times with dH2O for 20 seconds 
• Development: developing solution was used until bands appeared 
• Wash: 3 times with dH2O for 20 seconds 
• Development was stopped by incubation in stopping solution 
Table IX. Silver staining solutions 
Solution Composition Concentration 
Fixing 
Methanol (100 %) 50 % (v/v) 
Acetic acid (100 %) 12 % (v/v) 
Formaldehyde (37 %) 0.1 % (v/v) 
Impregnating AgNO3 0.2 % (p/v) 
Formaldehyde (37 %) 0.037 % (v/v) 
Developing 
Na2CO3 12 % (p/v) 
Na2S2O3 0.0004 % (p/v) 
Formaldehyde (37 %) 0.05 % (v/v) 
STOP Na2-EDTA 1.86 % (p/v) 
Western blot  
After running an SDS-PAGE, the gel was incubated in transfer buffer (Table X) for 5 
minutes. Proteins were then transferred to a nitrocellulose membrane (Schleicher & Schuell 
BA85, 0,45 µm) using a mini-protean two cell unit (Bio-Rad, Hercules, CA, USA) (the sponges, 
Whatman paper and the membrane were also previously incubated in transfer buffer). Protein 
transfer was performed at 100 mA for 2 hours or at 20 mA for 12 hours, and efficiency was 
assessed by staining with Pounceau Red S (Sigma, USA). After this, the membrane was treated 
according to the following protocol: 
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• Wash: Rinse with dH2O and incubate twice in TBS for 10 minutes 
• Block: Incubate 1 hour in TBS + 5 % milk 
• Wash: Twice in TBS + 0.05 % Tween and 0.2 % Triton for 10’ minutes 
• Wash: Once in TBS for 10 minutes 
• Incubate 1 hour with Anti-His (1/200) in TBS + 5 % milk 
• Wash: Twice in TBS + 0.05 % Tween and 0.2% Triton for 10 minutes 
• Wash: Once in TBS for 10 minutes 
• Incubate 1 hour with secondary antibody in TBS + 5 % milk  
• Wash: Four times in TBS + 0,05 % Tween + 0,2 % Triton for 10 minutes 
• Wash: Once with phosphatase buffer for 10 minutes 
• Incubate in the dark in 10 ml phosphatase buffer + 33 µl 5-bromo-4-chloro-3-indoyl 
phosphate (BCIP; 50 mg/ml in 100 % DMF) + 66 µl p-nitroblue tetrazolium 
chloride (NBT; 50 mg/ml en 70 % DMF) 
Table X. Western Blot Solutions 
Solution Composition Concentration 
Transfer 
Methanol (100 %) 20 % (v/v) 
Tris 20 mM 
Glycine 150 mM 
TBS 10X 
Tris 50 mM 
NaCl 150 mM 
Adjust pH to 7.5  
Phosphatase 
buffer 
Tris 100 mM 
NaCl 100 mM 
MgCl2 10 mM 
Adjust pH to 7.5  
2.3.8. Microplate growth curves 
All microplate growth curves were performed in a final volume of 200 µl. ON saturated 
cultures were used to inoculate fresh media at an ODi of 0.05. When OD600 reached 0.5, cells 
were harvested and resuspended to inoculate microplates at an ODi of 0.05. Reads were 
performed every 15 minutes for 16 hours, at the optimal growth temperature of the 
microorganism under study. 
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Growth curves on minimal salt media 
When curves were performed in minimal salt M9mod media, strains derived from E. coli 
LB650 were propagated twice from -80 ºC stocks in M9mod supplemented with 50 mM KCl 
and 1 % glucose. The ON saturated culture thus obtained was used to inoculate fresh M9mod 
media supplemented with 10 µM IPTG and 0.1 mM KCl for strains E. coli LB09 and LB10, 50 
mM KCl for strain LB11 and 100 mM KCl for LB08 and LB12. When OD reached 0.5, cultures 
were harvested and incubated for 1 hour in the initial volume of fresh media, this time without 
KCl supplementation. Afterwards, cells were harvested and washed three times with fresh 
media with no KCl. These samples were then used to inoculate fresh M9mod media in 
microplates supplemented with 1 % glucose, 10 µM IPTG and different KCl concentrations 
under study. Microplates were incubated at 37 ºC with continuous orbital shaking. 
Co-expression of Kup transporters and c-di-AMP 
M9mod supplemented with 0,2 % Glycerol and 10 mM KCl  was inoculated with -80 ºC 
stock strains under study and propagated twice. With the ON saturated cultures, 10 ml of fresh 
media were inoculated at OD = 0.05. When strains reached OD = 0.5, cultures were harvested 
and resuspended in same volume of M9mod supplemented with 0,2 % glycerol and no KCl. 
Samples were incubated at 37 ºC for an hour, after which 2 wash steps with no potassium 
supplementation were performed. These washed samples were used for microplate inoculation 
supplemented with 0,1 mM KCl and 2.5 µM IPTG. Genes cloned in pBAD33 vector were 
induced with 0.005 % L-arabinose when indicated. Growth curves were obtained as previously 
described. 
Overproduction of proteins in E. coli BL21 
Overexpression genes in E. coli BL21 was carried as follows. Overnight cultures of 
strains under study were diluted to an OD600 = 0.05 in 2 Lt. of fresh LB media supplemented 
with 100 µg/ml ampicillin. When an OD600 of 0.5 was reached, 0.5 mM IPTG was added to the 
cultures, which were further incubated for 3 h.  
Overproduction of TScf in L. lactis 
Expression of TScf was carried as follows. Overnight cultures of recombinant L. lactis 
were diluted to an OD600 = 0.05 in 3 Lt. of fresh M17G medium supplemented with the 
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corresponding antibiotics. Cultures were incubated at 30º C until an OD600 of 0.5 was reached, 
when 5 ng/ml of nisin (Sigma, USA) was added to the cultures. Samples were further incubated 
for 3 h.  
Purification of His6X-tagged proteins from L. lactis 
After induction, L. lactis samples were collected by centrifugation and resuspended in 
lysis buffer. Cells were then lysed with a tissue lyser as previously described. The lysate was 
clarified by centrifugation, and NaH2PO4 and imidazole were added to a final concentration of 
100 mM and 5 mM, respectively, pH was adjusted to 8. 
Clarified lysates were applied to a Ni2+-NTA affinity column (Qiagen) previously 
equilibrated with lysis buffer and incubated at room temperature for 1 hour to allow binding. 
Then the protein was refolded by successive in-column incubations with buffer C containing 
decreasing concentrations of urea ranging from 6 M to 0 M. The column was then washed with 
buffer C plus 25 mM imidazole and the protein was eluted from the column with buffer C with 
500 mM imidazole. The purified protein was dialyzed against PBS plus 5 % glycerol; aliquots 
were kept at -80 ºC. Buffers are listed in Table XVIII. 
Purification of His6X-tagged proteins from E. coli 
E. coli induced pellets from 2 Lt. cultures were washed in buffer W and cells were 
resuspended in buffer C, to be disrupted via French Press as previously described. Samples 
were then centrifuged 10 minutes at 5000 rpm and remaining insoluble particles were removed 
by ultracentrifugation at 4 ºC and 35000 rpm for 1 hour. For purification of recombinant His6X-
tagged proteins the supernatant fraction was loaded onto a bed of 1000 μl of Ni2+-NTA resin 
(IBA) in a Poly-Prep Chromatography Column (BioRad) that had been pre-equilibrated in 
buffer C. After applying the cell extract, the column was washed 5 times with 5 ml of buffer C 
containing 10 mM imidazole. The elution was performed in steps of 5 ml, with increasing 
concentrations of imidazole (30 mM, 50 mM, 100 mM, 200 mM and 500 mM). Fractions were 
analyzed by SDS-PAGE and those were a band evidenced the presence of the protein of interest 
were pooled and concentrated by centrifugation in Vivaspin turbo 15 columns (Sartorius) for 
15 minutes at 4.000 rpm and 8 °C. 
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Protein concentration was determined by Bradford assay and samples were further 
purified and analyzed via Size-exclusion chromatography (SEC). Buffers are listed in Table 
XVIII. 
Size exclusion chromatography 
The experiments were performed at room temperature in a HiLoad 16/600 Superdex 
200 pg using an ÄKTAprime plus chromatography system (GE Healthcare Life Sciences). 
Purified protein was applied to the column previously equilibrated with 20 mM Tris-HCl, 50 
mM NaCl, pH 8.0 buffer. The program was set to 1 ml/min and several elution fractions were 
recovered, where protein concentration was measured by a spectrophotometer coupled to the 
column. A calibration run was performed with molecular weight standards and related to their 
elution volumes for both column sizes. The elution volume is directly proportional to the 
log10(Mw). 
Fig 5 Standard curve in a HiLoad 
16/600 Superdex 200 pg 
chromatography column. Proteins of 
different molecular weight were injected 
into the size-exclusion chromatography 
column. The grey line, corresponding to 
the secondary vertical axis represents the 
spectrum of elution. The logarithm of 
the molecular weight of each protein 
was plotted against its retention volume. 
The standard curve was then used to 
interpolate molecular weight from 
experimental retention times. 
Table XI. Standard values for HiLoad 16/600 Superdex 200 pg 
Mw (KDa) log10(Mw) 
Retention 
volume (ml) 
670 2.83 50.45 
158 2.20 64.92 
44 1.64 81.19 
17 1.23 93.02 
1.35 0.13 111.92 
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2.3.9. Protein pull-down experiment with strep-tagged magnetic beads  
Cultures of L. lactis IL1403 were grown in M17G medium until a final OD600 of 0.5, 
when cells were harvested at 10000 rpm for 5 minutes. Pellets were resuspended in 2 ml of CP1 
buffer. This suspension was disrupted using French press and centrifuged 10 minutes at 10000 
rpm and 4 ºC. The supernatant was split in two fractions of equal volume and centrifuged for 1 
hour at 68000 rpm and 4 ºC. Protein quantification of the supernatant was then performed via 
Bradford assay.  
1.2 mg of protein was then taken to a final volume of 1 ml CP1 buffer, with addition of 
glycerol 10 %, 0.004 % EDTA and 0.5 µg/ml BSA. This sample was then incubated for 0.5 
hour at room temperature in a vortex shaker with the + and – beads (see below). 
Strep-tactin beads were equilibrated with CP2 buffer. After equilibration, half of the 
tubes were incubated with biotinylated c-di-AMP in a vortex shaker for 15 minutes at room 
temperature (+ samples). Finally, the beads were washed twice with CP2. 
After incubation with pre-equilibrated beads, samples were washed four times to get rid 
of unbound proteins and finally, elution was done with 50 µl buffer E at room temperature for 
15 minutes in a vortex shaker. 
Protein elution was analyzed by SDS-PAGE and silver staining. Both + and – lanes were 
sent for peptide identification at the proteomic department of the Ernst Moritz Arndt University, 
Greifswald (Prof. Uwe Völker). Buffers are listed in Table XVIII. 
2.3.10. Differential radial capillary action of ligand assay (DrACALA) 
Genes of interest were cloned in vector pWH844 using strain E. coli BL21 as host. An 
induction test was then performed as previously described to check gene expression (Zuzanna 
Grubek Master Thesis, 2016). Plasmids under study were finally sent to Prof. Vincent Lee 
(Department of Cell Biology and Molecular Genetics, University of Maryland, U.S.A) for the 
evaluation of specific interactions between their corresponding encoded proteins and c-di-AMP 
via the DrACALA assay. 
50 
Materials and methods 
2.3.11. Determination of c-di-AMP intracellular levels 
20 ml cultures of L. lactis IL1403 were grown in M17G medium. When samples reached 
an OD600 of 0.50, cells were harvested at 4 ºC and 5000 rpm, and quickly frozen in liquid 
nitrogen. Two additional samples of 1 ml were taken for normalization purposes. Samples were 
collected and stored at -20 ºC until c-di-AMP extraction was performed. For this, pellets were 
resuspended in 150 µl 2 mg/ml lysozyme in TE buffer and incubated for 30 minutes at 25 ºC 
and 750 rpm. Afterwards, samples were frozen in liquid nitrogen and boiled at 95 ºC for 10 
minutes. First, an extraction with 800 µl acetonitrile:methanol 1:1 was done, after which two 
more extractions with 200 µl acetonitrile:methanol:water 2:2:1 were performed. Supernatants 
were collected and dried in a Speedvac at 40º C. Pellets were sent to Prof. Volkhard Kaever 
from the Medizinische Hochschule, Hannover for c-di-AMP quantification via mass 
spectrometry. Final data was normalized with respect to the amount of protein present in the 
sample, determined via Bradford assay. 
2.3.12. Bis(p-nitrophenyl)phosphate assay.  
Bis(p-nitrophenyl)phosphate (BNPP) assay was performed according to Bai et al. 
2013 (68). Briefly, the following reaction is set up in a final volume of 100 µl: 
Putative phosphodiesterase 0.1 µM 
Tris-HCl pH 7.5 100 mM 
Mn2Cl 100 µM 
NaCl 10 mM 
BNPP 2 mM 
dH2O for Vf = 100 µl 
Reactions were loaded in microplates and were followed in a microplate reader at 30 
ºC and λ = 410 nm during 4 hours. Incubation was performed with minimal reading intervals 
and medium shake. 
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2.3.13. Light microscopy 
For microscopic analysis of L. lactis samples, cells were grown in M17G medium at 30º 
C to the desired OD600. A volume of 0.3 μl was placed on a slide covered with a thin layer of 
1% agarose prepared in dH2O, and when dried, a coverslip was placed on the sample. Pictures 
were taken using the AxioImager M2 equipped with a digital camera AxioCam MRm and the 
AxioVision Rel 4.8 software for image uptake (Zeiss). The objectives used ECPlan-
NEOFLUAR 100X/1.3 (Zeiss). 
2.3.14. Survival analysis in Galleria mellonella 
Survival experiments in G. mellonella were performed as follows: larvae were selected 
according to their weight, which was between 0.18 and 0.35 grams. 32 individuals per group 
were then harvested ON at 30 °C. Each group was inoculated with bacterial suspensions made 
in PBS at a concentration of 9.106 CFU/larva. Inoculation site was the fifth proleg. 
After inoculation, larvae were monitored at 2-4 hours intervals for 72 hours. Then, data 
was plotted in Kaplan-Meier curves using SigmaPlot 12 software and employing LogRank and 
Holm-Sidak tests, for multiple comparisons. P value was set in 0.05 (151). 
2.3.15. Immunological experiments 
Preparation of live bacterial inoculum and immunization protocol 
2 Lt. cultures of M17G supplemented with the corresponding antibiotics and 15 ng/ml 
of nisin were inoculated with L. lactis strains of interest at ODi = 0.05. Samples were incubated 
at 30 ºC until OD600 reached 0.5. Cells were then centrifuged at 5000 rpm and 4 ºC for 10 
minutes and washed with PBS buffer, to be finally resuspended in PBS plus 10 % glycerol. 
CFU were determined in the samples to check concentrations of the range 2 – 4.109 CFU/ 100 
µl inoculum. In addition, an expression test was performed to corroborate the presence of TScf. 
Mice inoculation 
BALB/c female mice, aged 6 weeks, were acquired and housed in HEPA-ventilated 
racks at 21 – 22 ºC and 68 % humidity at the animal facility of the CIPREB (Center for Research 
and Production of Biological Reagents, School of Medicine, UNR). Animals had free access to 
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food and water and were maintained under a 12 hours light/dark period. All protocols for animal 
studies were performed in collaboration with Dra. Ana Rosa Pérez and Dr. Iván Marcipar 
groups from the Instituto de Investigación Clínica y Experimental de Rosario (IDICER 
CONICET-UNR) and the Laboratorio de Tecnología Inmunológica, Facultad de Bioquímica y 
Ciencias Biológicas, UNL (Universidad Nacional del Litoral), respectively. Moreover, these 
experiments were  approved by the Bioethics and Animal Care & Use Committees according 
to Institutional guidelines. 
Briefly, mice were immunized by oral route by three successive doses separated by two-
week intervals by gavage administration. The bacterial dose administered was set as a quantity 
of bacteria expressing 10 µg of TScf (0.3-1.106 CFU). Similar quantities of bacteria expressing 
the TScf antigen alone, the CdaA alone or the empty vector were administrated in parallel. For 
comparative purposes, a group of animals was subcutaneously immunized in parallel with 10 
µg of purified TScf adjuvanted with 3 µg of ISPA (“Gold standard” group), an ISCOMATRIX 
type adjuvant developed by Dr. Marcipar group (152). 
Cellular response (Delayed hypersensibility test) 
To test cellular response, mice were challenged with 5 µg of purified TScf by 
intradermal injection in the right footpads 12 days after the last immunization. The thickness of 
hind footpads was measured before and 24, 48 and 72 hours after the antigen injection with a 
digital Vernier caliper. Results of the delayed hypersensitivity test (DHT) were expressed as 
the difference in thickness of footpads after and before the inoculation. 
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3. Results 
“Nothing in life is to be feared, it is only to be understood. Now is the 
time to understand more, so that we fear less” Marie Curie 
 
 
Results 
3.1. c-di-AMP and potassium uptake in L. lactis IL1403 
3.1.1. Identification of c-di-AMP interaction partners in L. lactis IL1403 
In an attempt to identify new interaction partners of c-di-AMP in L. lactis IL1403, a 
protein pull-down experiment was performed (50). As described in Materials and Methods, cell 
extracts of this strain were incubated with strep-tagged magnetic beads previously coupled to 
biotinilated c-di-AMP (+ sample). A sample incubated with the beads without previous 
treatment was used as negative control (- sample). Elutions were analyzed by SDS-PAGE and 
silver staining (Fig. 6, I) and both lanes were sent for peptide identification by mass 
spectrometry. A list of 151 different proteins was obtained, with the ratio of their presence in 
the + lane with respect to the – lane. For the list of peptides obtained after the pull-down 
experiment, see Table XIV in the Appendix. 
It is important to mention that biotinilated proteins would also bind to the strep-tag in 
the – sample, which is probably why pyruvate carboxylase was identified almost 50 times more 
represented in the – lane. On the other hand, secondary interaction partners, i.e. proteins 
interacting with c-di-AMP binding proteins, could also be eluted depending on the strength of 
the interaction. Moreover, if the interaction to c-di-AMP is not strong enough, some binding 
partners could also be washed out, or found with a low +/- ratio. To evaluate all these 
possibilities, a bibliographic search was carried out, although the vast majority of the proteins 
on the list are either uncharacterized, or no studies about them have so far been reported. Since 
there is no information available about which proteins are biotinilated, nor which are essential 
in L. lactis (which could lead to the essential role of c-di-AMP in this bacterium), an initial 
classification was made by use of the UniProt online resource.  
Fig. 6, II shows a functional classification of the 130 peptides with the highest +/- ratio, 
based on available information and amino acid sequence homology to previously studied 
proteins from other bacteria. As the pie chart shows, the most represented groups include 
transport proteins comprising a predicted glutamine ABC transporter, a glycine-betaine 
transporter, four putative ABC transporters and two uncharacterized proteins. Also, a 
considerable amount of proteins related to DNA metabolism were identified, such as the DNA 
polymerase III, subunits β and τ, the DNA mismatch repair proteins MutS and MutL, and the 
predicted proteins RecG (DNA helicase), RecN (DNA repair) and RecA (DNA 
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repair/homologous recombination). Finally, groups of proteins related to amino acid and cell 
wall metabolism were also among the most represented, including predicted amino acid 
synthesizing enzymes and proteins involved in the formation of the septal ring and cell division 
(EzrA, FtsA and FtsE, which was proved to affect translocation of K+ in E. coli (37)). 
Considering that actually most of the proteins showed a great variety of predicted 
functions and therefore they were collected under “Miscellaneous proteins”, no clear tendency 
could be distinguished. Altogether, for the subsequent specific interaction assay, the 23 peptides 
with the highest +/- ratio were selected. In other words, this selection established a cut off of 
proteins which were at least eight times more represented in the + lane than in the – lane (Table 
XII). Due to the proximity of the ratio value to the set cut off, the uncharacterized protein with 
an accession number Q9CEI1_LACLA, and the predicted septation ring formation regulator 
EzrA were as well added to the list. 
 
Fig. 6 Protein pull-down for identification of c-di-AMP interaction partners. I. 
SDS-PAGE after pull-down experiment with strep-tagged magnetic beads (see 
Materials and Methods). Bands were visualized by silver staining. + lane: sample 
eluted from beads previously treated with biotinilated c-di-AMP. – lane: sample 
eluted from beads with no previous treatment. MWM: Molecular weight marker 
(PageRulerTM Plus Prestained Protein Ladder). This experiment was performed in 
three independent replicates. Both lanes were sent for peptide identification. II. 
Functional classification of proteins obtained after MS/MS detection. Protein 
function was assigned based on reported research and sequence homology to 
previously studied proteins. 
Furthermore, at the time this experiment was performed, an increasing amount of 
evidence was directing the essential role of cdaA (and consequently c-di-AMP) towards its 
relation to potassium metabolism (153). Consequently, a search for genes coding for putative 
potassium transporters, and proteins potentially related to potassium homeostasis in L. lactis 
IL1403 was carried out. 
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When looking for potassium transporters encoded in L. lactis IL1403 genome by use of 
the free online software UniProt (UniProtKB, UniRef and UniParc databases), proteins KupA, 
KupB and YrbD are shown as results. These three proteins are inferred from homology since 
there is currently no reported research about them. The first two belong to the KT/KUP/HAK 
family (see below), whereas YrbD could be a voltage gated channel. Since neither potassium 
metabolism, nor its relation to c-di-AMP has been thoroughly investigated in L. lactis, the 
possibility of this second messenger interacting as well with potassium channels was 
considered. Thus, these proteins were added to the list along with the putative voltage gated 
potassium channel proteins YjdJ and YncB, with more than 60% identity to the potassium 
efflux system KefA from other Lactococcus species.  
Proteins with high homology for members of the Trk/Ktr/HKT family were also 
evaluated. Interestingly, even though putative homologous proteins to B. subtilis KtrA were 
found in some members of L. lactis species, it is not present in IL1403 nor in MG1363 strains 
studied in this work. Moreover, even though the kim riboswitch was already reported to be 
absent in Lactococcus (154), the presence of the associated potassium transporter KimA, or 
possible related proteins was also considered. No KimA homologues were found encoded in L. 
lactis genome, but the protein blast showed certain homology to an amino acid permease, LysP. 
Given the recent associations of c-di-AMP to amino acids metabolism and osmoregulation 
previously described in the introduction (62, 155), both LysP and LysQ were also included in 
the list of putative c-di-AMP interaction partners. 
It was also reported that in L. monocytogenes a mutant strain for the only c-di-AMP 
synthesizing enzyme was obtained in rich media thanks to loss of function mutations occurring 
in genes clusters oppABCDF (involved in oligopeptide import) or the gbuABC (involved in 
glycine-betain import) (60). Therefore, the homologous Opp protein of L. lactis IL1403, which 
is expected to function as an oligopeptide permease, was added as well to the list. 
Lastly, and due to the close connection between potassium and sodium homeostasis, 
Nah protein, homologous to a cation:proton antiporter was also selected. In conclusion, a final 
selection of 34 genes (Table XII) was then cloned in the E. coli expression vector pWH844 
(Zuzanna Grubek Master Thesis, 2016). After checking expression of all genes using strain E. 
coli BL21 as host, the corresponding plasmids were sent to confirm c-di-AMP specific 
interaction to the respectively encoded proteins via differential radial capillary action of ligand 
assay (DrACALA) (see Materials and Methods). 
57 
Results 
Table XII. Gene selection for DrACALA analysis 
Gene Putative function Reference 
dnaH DNA polymerase III, subunits β and τ1 Bolotin et al. 2011 
ezrA Septation ring formation regulator1 Bolotin et al. 2011 
ftsE Control of cell wall synthesis; ABC transporter1 Bolotin et al. 2011 
glnP Glutamine ABC transporter permease and substrate binding protein2 
Fulyani et al. 2013 
(156) 
kupA* Potassium transporter2 This work 
kupB* Potassium transporter2 This work 
lysP* Lysine specific permease1 Bolotin et al. 2011 
lysQ* Lysine specific permease1 Bolotin et al. 2011 
mvaA 3-hydroxy-3-methylglutaryl coenzyme A reductase1 Bolotin et al. 2011 
nah* Na+/H+ antiporter1 Bolotin et al. 2011 
oppA* Oligopeptide-binding protein1 Bolotin et al. 2011 
pdp Pyrimidine-nucleoside phosphorylase1 Bolotin et al. 2011 
prfB Peptide chain release factor 21 Bolotin et al. 2011 
racD Aspartate racemase1 Bolotin et al. 2011 
recG ATP-dependent DNA helicase1 Bolotin et al. 2011 
recJ Single-stranded DNA specific exonuclease1 Bolotin et al. 2011 
recN DNA repair protein RecN1 Bolotin et al. 2011 
relA ppGpp synthetase I1 Bolotin et al. 2011 
ribH 6,7-dimethyl-8-ribityllumazine synthase1 Bolotin et al. 2011 
rpsF 30S ribosomal protein S61 Bolotin et al. 2011 
yciH Ribonuclease J1 Bolotin et al. 2011 
yeaD Initiation-control protein YabA1 Bolotin et al. 2011 
yhfC Uncharacterized protein Bolotin et al. 2011 
yjdJ* Potassium channel protein1 Bolotin et al. 2011 
yncB* Uncharacterized protein Bolotin et al. 2011 
yqaB Uncharacterized protein Bolotin et al. 2011 
yqaD Uncharacterized protein Bolotin et al. 2011 
yrbD* Uncharacterized protein Bolotin et al. 2011 
yrgI Uncharacterized protein Bolotin et al. 2011 
yrjB Oxidoreductase1 Bolotin et al. 2011 
ytcE Uncharacterized protein Bolotin et al. 2011 
ytjA Uncharacterized protein Bolotin et al. 2011 
yueF Protease1 Bolotin et al. 2011 
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ywfH Uncharacterized protein Bolotin et al. 2011 
1Proteins inferred from homology. 2Experimental evidence available. *Genes selected independently from the pull-
down experiment 
3.1.2. c-di-AMP specific interaction to different Lactococcal proteins 
Unexpectedly, the majority of the genes selected proved to have no specific interaction 
with c-di-AMP through the DrACALA assay. Nevertheless, two of the putative K+ related 
proteins threw positive results. The corresponding genes were kupA and kupB and their products 
interact specifically with c-di-AMP according to the competition DrACALA experiment (Fig. 
7). In addition, the interaction with KupA seems to be stronger than with KupB. 
 
Fig. 7 DrACALA experiment. A: Fraction of radiolabeled c-di-AMP retained 
in induced overnight cultures. KupA and KupB specifically interact to c-di-
AMP (underlined in orange). ATP competition does not interfere with c-di-
AMP interaction in overnight (B) or subcultures lysates (C). Fresh c-di-AMP 
competition results in no 32P-c-di-AMP detected, indicating specific 
interaction. Induction of all samples was checked in overnight and midlog 
cultures (not shown). 
Because of the lack of previously reported potassium transporters in L. lactis IL1403, a 
bioinformatic search was first performed. An initial approach showed that Kup proteins are 
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widely found in bacteria as well as in species of fungi and plants. Nevertheless, the only 
reported investigation related to a Kup protein in L. lactis dates from 1997 when Quintero and 
Blatt analyzed a new transporters family in Arabidopsis and they see that it is conserved among 
different filos, since homologous sequences were found in different plant species, in L. lactis 
and also in Homo sapiens (157). However, up to date no other information can be found, which 
is why an in silico analysis of KupA and KupB was carried out. 
In the model organism E. coli, Kup acts as a potassium intake system with particular 
characteristics that distinguish it from the potassium transporter families Ktr and Kdp, 
previously described. It belongs to the Kup/HAK/KT family and, as Fig. 8 represents, it is a 
622 residues protein with 12 transmembrane fragments at the N-terminal end (158). 
A first study of the nucleotidic sequence of L. lactis IL1403 genome shows two adjacent 
genes of 2013 and 2016 base pairs, corresponding to kupA and kupB respectively, separated by 
223 bp (Fig. 8, I). The amino acid sequence alignment between them shows a 73% identity, 
whereas topology prediction using the free software Protter threw very similar structures with 
12 transmembrane segments for both proteins under study, which correlates with E. coli Kup 
protein. Moreover, as Fig. 8 II shows, the majority of conserved residues are located in the N-
terminus and particularly in the transmembrane regions. This makes sense provided E. coli does 
not synthesize c-di-AMP and, consequently, its Kup protein does not need to sense it. It is hence 
likely that in L. lactis the sensory domain has evolved from a common ancestor in the 
cytoplasmic C-terminal region, to acquire the capacity of c-di-AMP sensing and responding 
accordingly, modifying K+ intake activity. 
On the other hand, and even though the presence of acidic amino acids has been shown 
to be important for potassium transport, in Kup they are found in the transmembrane fragments 
of the protein. This has been reported as a unique feature of the Kup/HAK/KT family, not 
occurring neither for transporters of the Trk/Ktr/HKT nor for the Kdp family (158). Moreover, 
it was also proved that E. coli Kup residues D23, E116, E229 and D408 have a crucial role for 
Kup activity and its substitution for alanines resulted in a peptide that could not complement 
mutations in E. coli LB2003 to allow growth at low K+ concentrations (see below). 
Interestingly, D23 and E229 are conserved in both Kup proteins of L. lactis IL1403 and despite 
E116 and D408 are not, in both KupA and KupB an aspartic acid and a glutamic acid residue 
are found instead respectively, so conservation of acidic residues remains (Fig. 8). 
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On the other hand, sequence alignment of well-studied c-di-AMP binding potassium 
transporters shows a conserved glycine region, characteristic of Ktr family proteins. This 
GXGXXG consensus motif, typically present for nucleotide binding is not exactly conserved 
in Kup proteins but a GXXGXG inverted domain is found instead in both KupA and KupB 
(Fig. 8, II). This domain could be involved in c-di-AMP binding or could also suggest that Kup 
transporters need a cofactor like NAD for their activity (159). 
Taken together, the evidence here presented supports the fact that proteins under study 
belong to the Kup/HAK/KT family but whether they are both active potassium transporters 
needed to be further studied. 
 
Fig. 8 KupA and KupB in silico analysis. I: Gene arrangement in L. lactis IL1403 genome. kupA and kupB are 
2013 and 2016 base pairs genes respectively and are adjacently encoded. II: Predicted membrane conformation of 
KupA. Adapted from the free topology prediction Protter software. Amino acids conserved in both Kup proteins 
from L. lactis are highlighted in green, whereas those conserved in E. coli as well are represented in red. Conserved 
acidic amino acids are depicted in yellow. The cellular membrane is shown in light blue. Extra: extracellular, intra: 
intracellular. The purple box indicate a putative GXXGXG c–di-AMP binding site. 
3.1.3. KupA and KupB of L. lactis 1403 restore growth of E. coli LB650 
Heterologous expression of proteins in the model bacterium E. coli has always been one 
of the first choices when studying unknown protein functions. Consequently, a first approach 
into the functional properties of the proteins encoded by both kup genes was explored using E. 
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coli LB650 (160). This strain is a triple mutant for the main potassium transporter systems, 
having a ∆kdpABC5 ∆trkH ∆trkG genotype (see Table XV). Hence, it is unable to grow at low 
K+ concentrations. 
kupA and kupB genes were respectively cloned in a modified version of plasmid 
pWH844, lacking the N-terminal His6X-tag after digestion with EcoRI restriction enzyme, 
which site is located upstream the His6X -tag codifying sequence. For this, primers IQ682 and 
IQ683 were used, which introduce an EcoRI restriction site as well as ribosome binding site. In 
this way, any functional interference produced by the histidine residues in the proteins was 
ruled out. The resulting plasmids pIQ309 and pIQ310, (carrying kupA and kupB genes, see 
Table XVI), were electroporated in E. coli LB650, originating strains LB09 and LB10 
respectively, to check if their expression could restore growth in rich media when no KCl is 
added. As Fig. 9 shows, the strain harboring pWH844 vector cannot grow in LB, unless it is 
supplemented with 200 mM KCl. On the other hand, when a trans copy of kupA or kupB is 
present, colonies appear on the plates without extra addition of KCl, even when IPTG is not 
present. As mentioned in Material and Methods, pWH844 vector used for these constructions 
has the multiple cloning site under control of the lactose operon promoter (Plac), which is 
widely known to be leaky. Consequently, this basal expression of kupA and kupB is already 
enough to allow growth. These results show not only that the proteins under study are potassium 
transporters but also suggest that both transporters have high affinity for K+. 
 
Fig. 9 KupA and KupB restore growth of E. 
coli LB650 in LB. Left: strain LB08 carrying 
pWH884 vector grows only when 200 mM KCl 
is added to the medium (down). Center and right 
strains LB09 and LB10 carrying a trans copy of 
kupA and kupB, respectively. Both evidence 
growth with or without potassium 
supplementation. 
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3.1.4. KupA and KupB are high affinity transporters 
In order to estimate the affinity of KupA and KupB proteins for K+, a comparison to 
previously characterized transporters was made. For this, the high affinity potassium transporter 
KtrA/B from B. subtilis and the low affinity KtrC/D system from L. monocytogenes were 
employed (48, 161). The corresponding genes had been previously cloned in the modified 
version of pWH844 plasmid described in the former section, lacking the His6X-tag. The 
resulting plasmids pBP372 and pBP371 were available at Prof. Stülke’s lab and were 
electroporated in strain E. coli LB650, originating strains LB11 and LB12, respectively. 
Growth curves were then performed in minimal salt media M9 modified, where 
potassium salts were replaced by equimolar quantities of the respective sodium salt (M9mod, 
see Materials and Methods). KCl was then added to the media, to reach final concentrations 
between 0.025 – 50.0 mM, and determine in this way the concentration at which growth was 
possible. ODmax and µmax were then determined for strains E. coli LB08, LB09 and LB10, 
harboring the empty vector, and kupA and kupB genes, respectively. Strains LB11 and LB12 
were included as reference of the response of a high and a low affinity system under the 
conditions here studied.  
Both Kup proteins showed similar phenotypes, manifesting growth even at 
concentrations below 0.1 mM KCl, although growth rate and final OD600 were low (Fig. 10 and 
Table XIII) Moreover, at 1.0 mM KCl, values close to the highest ODmax and µmax are already 
reached, and coincide with values obtained for the high affinity system KtrA/B of B. subtilis. 
On the other hand, for the case of KtrC/D, growth is only possible at 10 mM K+ or higher, and 
maximum ODmax and µmax values are obtained when at least 50 mM K+ is present in the media. 
A marked difference is then established with respect to high affinity KtrA/B and Kup proteins, 
being more closely related to strain LB08 harboring the empty vector. Taken together, these 
results support the theory that both Kup proteins are high affinity potassium transporters. 
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Fig. 10 Growth parameters of E. coli LB650 derived strains. Growth curves were performed in a microplate 
reader and in minimal salt M9mod medium. ODmax (I) and µmax (II) were determined at different KCl 
concentrations. The arrow highlights parameters obtained at 1.0 mM KCl, where the different potassium 
transporter systems show clear distinct phenotypes. Both Kup proteins behaved similarly to the high affinity 
KtrA/B system. 
  Table XIII. ODmax and µmax values for E. coli LB650 derivative strains 
3.1.5.  c-di-AMP down-regulates Kup proteins 
Once specific interaction with c-di-AMP was confirmed, and KupA and KupB were 
identified as potassium transporters, the next step was to analyze the impact of this metabolite 
on the activity of both Kup proteins. To this aim, a co-expression system was established in the 
model bacterium E. coli 2003. This strain is deficient in the three major potassium uptake 
systems Trk, Kup and Kdp (∆kdpABC5 kupD1 ∆trkA, see Table XV), and is not able to grow 
in minimal salt media at low K+ concentrations without a trans complementation of a potassium 
transporter coding gene. Very importantly, and in contrast to strain LB650 (Km50 – Cm30), its 
mutations are clean, so there is no need for antibiotic supplementation of growth media. 
Moreover, E. coli lacks c-di-AMP synthesizing enzymes, for which the co-expression of cdaA 
and kup genes allows the analysis of the phenotypic effect of c-di-AMP on Kup proteins, 
without interference of host-synthesized c-di-AMP. 
 pWH844 KupA KupB KtrA/B KtrC/D 
[K+] [mM] ODmax µmax ODmax µmax ODmax µmax ODmax µmax ODmax µmax 
- ND ND 0.3 5.0E-3 0.1 3.7E-3 0.4 5.0E-3 ND ND 
0.025 ND ND 0.4 5.0E-3 0.2 7.1E-3 0.5 7.0E-3 ND ND 
0.50 ND ND 0.4 8.9E-3 0.3 1.0E-2 0.7 8.0E-3 ND ND 
0.075 ND ND 0.5 1.1E-2 0.3 1.1E-2 0.7 1.0E-2 ND ND 
0.50 ND ND 0.8 1.3E-2 0.8 1.4E-2 0.9 1.0E-2 ND ND 
1.0 ND ND 1.0 1.6E-2 1.0 1.3E-2 0.9 7.0E-3 ND ND 
10.0 0.8 4.7E-3 1.0 1.5E-3 1.0 9.0E-3 1.0 6.0E-3 1.1 9.0E-3 
50.0 1.3 1.2E-2 1.0 1.6E-2 1.1 7.0E-3 1.1 1.2E-2 1.2 1.3E-2 
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At the beginning of this thesis, several attempts were made to heterologously produce 
CdaA enzyme from L. lactis IL1403 in E. coli. Since no successful results were obtained, and 
taking into account that for the practical scope of the experiment only the production of c-di-
AMP was necessary, independently of the synthesizing enzyme, CdaA from L. monocytogenes 
(from now on CdaAlmo) was used instead. A non-active defective version of it, CdaAlmo*, was 
used as well, as negative control.  
Plasmids pIQ309 and pIQ310 (Amp100) were used for kup genes induction via IPTG, 
whereas cdaAlmo and cdaAlmo* were induced from plasmids pBP370 and pBP373 respectively 
(kindly supplied by Prof. Stülke laboratory). These plasmids are pBAD33 derivatives (Cm30, 
see Table XVI), allowing expression of genes under control of the arabinose Para promoter, 
and being therefore compatible with pWH844 derivatives previously mentioned. A system of 
co-expression was then established where potassium transporters could be induced by IPTG 
and c-di-AMP cyclases by arabinose. 
In the previous section, where growth experiments were performed in E. coli LB650 
harboring a trans copy of kupA and kupB, addition of 0.1 mM KCl to M9mod medium was 
enough for the strains under study to grow. Hence, this concentration was selected to 
supplement M9mod medium for the growth curves performed on the E. coli 2003 derivative 
strains. It is important to mention that under this potassium concentration, strain E. coli 0380, 
harboring vectors pWH844 and pBP370 (cdaAlmo), is not able to grow, which is why it was 
used as negative control. 
As seen in Fig 11, IPTG induction of kupA gene allowed growth of strains E. coli 0390 
and 0393. Nevertheless, when cdaAlmo (present in strain 0390) is also induced via arabinose 
supplementation in growth media, a severe growth detriment is evidenced (Fig 11, left). On the 
other hand, either when the inductor (arabinose) is not present (Fig 11, right), or when cdaA 
gene carries a mutation that results in an inactive enzyme (strain 0393), growth is possible 
again. 
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Fig 11 c-di-AMP effect on KupA. Growth curves were performed in minimal salt 
M9mod media, supplemented with 2.5 µM IPTG for kupA induction and with 0.005% L-
arabinose (left) or without it (right). Strain 0390 and 0393 harbor a copy of cdaAlmo and 
cdaAlmo*, respectively. Both carry as well a copy of kupA. E. coli 0380 with the 
empty vector pWH844 and pBP370 was used as negative control. 
The same experiment was performed to study the impact of c-di-AMP on KupB. In this 
case, results obtained were similar, but the growth inhibition exerted on strain 0300 (harboring 
plasmids pIQ310 with a copy of kupB and pBP370, with wild type cdaAlmo) in induced 
conditions, was milder (Fig 12, left). 
 
Fig 12 c-di-AMP effect on KupB Growth curves were performed in minimal salt M9mod 
media, supplemented with 2.5 µM IPTG for kupB induction and with 0.005% L-arabinose 
(left) or without it (right). Strain 0300 and 0303 harbor a copy cdaAlmo and cdaAlmo*, 
respectively. Both carry as well a copy of kupB. E. coli 0380 with the empty vectors 
pWH844 and pBP370 was used as negative control. 
It is important to mention that the growth inhibition observed in both cases could be 
caused by high intracellular c-di-AMP concentrations, which have been reported to be toxic for 
bacteria (54). On the other hand, it could also be due to the production of the heterologous 
CdaAlmo enzyme, which could be toxic for the cell independently of c-di-AMP concentration 
or the presence of the potassium transporters under study. This was ruled out by performing 
similar growth curves of E. coli 0380 harboring an empty copy of vector pWH844 and plasmid 
pBP370. This time, 50 mM KCl was added to growth media, and wild type growth was possible 
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under arabinose induction as well as no-induction conditions (Fig 13). As expected, strain 0383 
harboring the mutated cdaAlmo*, was not inhibited either and both strains evidenced similar 
growth phenotypes to strain 4433, with both empty vectors pWH844 and pBAD33. Altogether, 
the evidence here presented confirms that c-di-AMP downregulates KupA and KupB proteins. 
 
Fig 13 Control curves on M9mod supplemented with 50 mM KCl. High potassium 
concentrations allowed similar growth under arabinose induction (left) and no-induction 
conditions (right). 0380: pWH844 plus pBP370 (cdaAlmo), 0383: pWH844 plus pBP373 
(cdaAlmo*), 4433: pWH844 plus pBAD33. 
3.1.6. Conclusions 
In this chapter, a pull-down experiment with strep-tagged magnetic beads coupled to 
biotinilated c-di-AMP was performed in order to identify novel interaction partners of this 
second messenger in L. lactis IL1403. Even though no specific binging protein was recovered 
from this experiment, the DrACALA assay permitted the identification of two novel potassium 
transporters, which specifically interact with c-di-AMP: KupA and KupB. Minimal KCl 
concentrations restoring growth of mutant strains E. coli LB650 and 2003 in M9mod medium, 
as well as comparisons to previously studied high and low affinity systems (B. subtilis KtrA/B 
and L. monocytogenes KtrC/D, respectively) provide evidence that, unlike in E. coli, L. lactis 
Kup proteins are high affinity potassium transporters.  
An in silico analysis showed that KupA and KupB share 73% identity and when 
compared to E. coli Kup, the most conserved regions are in the transmembrane fragments, 
whereas the major variability occurs in the cytosolic C-terminal end. Moreover, after sequence 
analysis of other c-di-AMP binding proteins, a putative c-di-AMP binding domain was 
hypothesized. 
Finally, a co-expression system was constructed, allowing controlled induction of kup 
genes under study and cdaA, by use of an IPTG and an arabinose inducible promoter, 
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respectively. Growth curves performed under low potassium concentrations confirmed that c-
di-AMP has an inhibitory effect on both KupA and KupB. 
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3.2. Studies on c-di-AMP synthesizing and degrading enzymes in L. 
lactis IL1403 
3.2.1. Strain engineering for modification of intracellular c-di-AMP levels 
The first approach aiming to modify intracellular levels of c-di-AMP in L. lactis was 
directed towards deletion of the gene encoding its only synthesizing enzyme, cdaA. Several 
attempts were made by use of vector pBVGh, previously developed in our laboratory and 
described below. Since deletion in rich medium M17G was not possible, and mutants for c-di-
AMP cyclases were reported on strictly controlled minimal media, the deletion protocol was 
tuned to be performed in defined media. As previously described, lactic acid bacteria lack many 
anabolic pathways and, consequently, a considerable amount of nutrients have to be provided 
in growth media, in order to satisfy their complex metabolic requirements. Different conditions 
were thus tried, to establish a suitable defined medium, which allowed regulation of potassium 
concentration and, at the same time, high L. lactis cellular density. 
Minimal medium MS15 was employed as described by Cocaign‐Bousquet et al. (162) 
and using the same criteria as for M9 minimal salt medium in the previous chapter, potassium 
salts were replaced by equimolar quantities of the corresponding sodium salt, resulting in 
MS15m medium. Different KCl concentrations were then used to supplement MS15m and 
determine the minimum potassium molarity allowing an OD600 high enough to perform the 
different steps of the deletion protocol. Fig 14, I shows the final OD600 obtained for L. lactis 
IL1403 and NZ9000 strains after 5 days of incubation at 30º, when 1.0 – 5.0 – 10 – 100 and 
200 mM KCl were added to MS15m. Since the original protocol requires several ON incubation 
steps, use of this medium would be practically unviable.  
On the other hand, Zhang et al developed another minimal medium, which permitted 
high density growth of lactococci (163). This medium, called ZMB2 was also modified to avoid 
use of potassium salts in its initial composition, resulting in ZMB2m medium. This time, optical 
densities above 1.0 were obtained for KCl concentrations between 1.0 and 100 mM in ON 
cultures of both strains under study (Fig 14, II and III). Hence, ZMB2m medium and KCl 
concentrations of 0.25, 0.50 and 1 mM were selected to perform the deletion protocol.  
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Fig 14 L. lactis growth on minimal media. Strains IL1403 and NZ9000 were cultured in modified minimal media 
without potassium salts. KCl was added prior to inoculation at the concentrations detailed in the graphs. I: Final 
OD600 obtained in MS15m after 5 days. II and III: Final OD600 obtained in ZMB2m ON cultures. KCl 
concentrations used in the deletion protocol are marked with an asterisk. 
Even though mutants lacking c-di-AMP synthesizing enzymes were reported to be 
obtained in minimal media at low K+ concentrations (49, 60, 62), cdaA deletion was not possible 
for neither of L. lactis strains under study in this work. A second approach was also tried, where 
by use of the nisin inducible pNZ8048 vector, genomic cdaA deletion was tried when a trans 
copy was being expressed. In this way, in the absence of nisin, cells would be depleted of CdaA 
enzymes, and mutants and possible suppressors could be studied. Unfortunately, this strategy 
was not successful either, for what the focus of this research was now directed towards the 
modification of c-di-AMP intracellular pools and the obtaining of maximum and minimum 
levels compatible with growth in rich media for L. lactis IL1403. 
The starting point to this aim was the development of genetically engineered strains for 
homologous and heterologous expression of genes encoding c-di-AMP synthesizing and 
degrading enzymes. Thus, cdaA and gdpP genes from L. lactis IL1403 and E. faecalis JH2-2 
(cdaAll, gdpPll, cdaAef and gdpPef, respectively) were cloned in vector pBV153 (Fig 15, I). This 
vector was developed in our laboratory and it has the Pcit promoter upstream of the multiple 
cloning site, leaving the gene of interest under pH regulation (164). That is to say, as the pH of 
the growth medium decreases, expression of the desired protein increases. The resulting 
plasmids were named pQI101, pQI102, pQI103 and pQI104, respectively and were 
electroporated in L. lactis IL1403 originating strains LL03, LL04, LL05 and LL06, respectively 
(see Table XV). 
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Fig 15 Strain development for modification of c-di-AMP intracellular levels. I: Vector pBV153 was used for 
homologous and heterologous expression of cdaAll, gdpPll, cdaAef and gdpPef. Only cdaA is represented, but the 
same system was used in a similar way to clone gdpP genes as well. II: pBVGh vector employed for gene deletion. 
This system allows a clean deletion of the gene of interest via a double recombination event. Primers JN404 and 
JN405 as well as JN406 and JN407 were used for deletion check. 
Another strategy considered for modifying intracellular c-di-AMP concentrations was 
mutation of its degrading enzyme, GdpP. Since this is the only c-di-AMP phosphodiesterase 
reported in L. lactis, deletion of its gene via homologous recombination by use of vector pBVGh 
was performed (Fig 15, II). The selected thermosensitive vector was previously developed in 
our laboratory as well, and it allows deletion of the gene of interest via a series of incubations 
at the permissive and non-permissive temperature, without incorporation of antibiotic 
resistances in the strain under study (165). Briefly, an up and a downstream region of the gene 
are adjacently cloned in the plasmid, so homology enables the integration of the plasmid in the 
chromosome when incubating at the non-permissive temperature. When temperature is 
lowered, the plasmid jumps out and it carries the gene of interest with it. An easy white/blue 
colony screen allows identification of putative mutants, which are then checked by antibiotic 
sensitivity and by two different PCR. The first one is performed with a pair of primers 
hybridizing outside the fragments cloned (JN406 and JN407 in Fig 15, II), and the second one 
is a negative control for which primers amplifying a central region of the gene of interest are 
used (JN404 and JN405 in Fig 15, II). 
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Once deletion of gdpP was confirmed, the selected strains were restricked three times 
to check colony morphology and growth stability. Interestingly, in this process, two slightly 
different colony sizes were obtained, for which both samples were kept for later c-di-AMP 
levels determination. These strains were named L. lactis LL07 (smaller colonies) and LL08 
(bigger colonies). 
3.2.2. Phenotypic analysis of the strains developed 
The first analysis of strains constructed was performed on morphology developed in 
rich media M17G during exponential growth (Fig 16, up) and also once the stationary phase 
was reached (Fig 16, down). In the first case, the wild type phenotype can be described as short 
chains of two or four bacteria, with homogeneous and well-defined round shape. This is also 
true for strains LL05 and LL06, respectively carrying gdpPll and gdpPef genes, where no 
particular phenotype is observed. The main differences, on the other hand, were obtained for 
strains LL03 and LL04, harboring a trans copy of cdaAll and cdaAef, respectively. In both these 
cases, a slight increase in cell size can be visualized, as well as no clear division of each cell in 
dimeric chains. As previously mentioned and as it is widely known, c-di-AMP metabolism is 
closely related to cell wall biosynthesis, which is why this phenotype would indicate that cdaA 
genes are being expressed. 
 
Fig 16 Morphology of L. lactis LL00, LL03-LL06 strains. Phase contrast microscopy of strains LL00, LL03-
LL06. Bacteria were grown in M17G medium at 30 ºC and samples were taken at mid-exponential phase (up) 
and at stationary phase (down). Arrows indicate abnormal morphology. Scale bar, 2 µm. 
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Clearer phenotypes were evidenced for the stationary phase, although they were similar 
for all strains under study. Control strain LL00 harboring the empty vector formed long cocci 
shaped strains, whereas strains LL03-LL6 evidenced heterogeneous bacterial sizes and shapes, 
as well as a higher number of non-viable cells. These results indicate that morphology is more 
affected in the late exponential phase, probably due to accumulation of c-di-AMP (for strains 
LL03 and LL04) or long time exposure to low levels of this second messenger (for strains LL05 
and LL06). 
After analyzing morphology of strains developed to alter c-di-AMP intracellular levels, 
a second study was done on growth curves obtained in rich media M17G upon addition of 
different stress factors. Although induction of Pcit promoter increases as the pH of the media 
decreases, these experiments were performed at initial pH of 7.0 to avoid raising c-di-AMP 
concentrations into toxic levels. Indeed, the capacity of LAB to acidify media as result of their 
lactic acid production was ideal to increase induction gradually along growth. 
Control curves in M17G grown at 30ºC can be seen in Fig 17, where strain LL03 
carrying cdaAll gene, already shows a growth disadvantage with respect to strain LL00 
harboring vector pBV153. This detriment is evidenced by a particularly long lag phase, which 
is enhanced when temperature is raised to 37ºC. Interestingly, Smith et al. reported heat resistant 
L. lactis strains obtained after construction of gdpP mutants by use of a protocol which involved 
an incubation step at 37.5ºC (74). Taking into account that a defective gdpP strain and a strain 
with an extra copy of cdaA would have the same effect of increasing c-di-AMP concentration, 
similar phenotypes were expected. Therefore, the growth defect manifested by strain LL03, 
could suggest that an even a higher c-di-AMP concentration was reached with respect to the 
gdpP mutants, resulting toxic for the cell, or a mutation in another gene involved in heat 
resistance. 
Strains L. lactis LL05 and LL06 (gdpPll and gdpPef, respectively) also evidenced a 
growth disadvantage, although to a lesser extent than strain LL03.This time, results are in 
accordance with the heat resistance phenotype of gdpP mutants, since an extra copy of the gene 
would decrease c-di-AMP intracellular pools, causing the opposite effect. Taken together, 
evidence here presented agree with previous findings about low as well as high concentrations 
of c-di-AMP being toxic for bacteria (54). Lastly, strain LL04 harboring a trans copy of cdaAef 
gene seems to have no effect on growth, suggesting that it could be inactive in the system here 
studied. 
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Fig 17 Temperature sensitivity of strains LL00, LL03 – LL06. Growth curves were performed in 
rich media M17G at 30 ºC (left) and 37 ºC (right). Strain L. lactis LL00 harbors the empty vector 
pBV153, whereas the series LL03, LL04, LL05 and LL06 carry a trans copy of genes cdaAll, cdaAef, 
gdpPll, and gdpPef, respectively. 
Moreover, saline hypersensitivity was also reported by Smith et al. for gdpP mutant 
strains of L. lactis, and was therefore evaluated for the strains developed in this work (74). 
Concentrations of 0.25 and 0.50 M NaCl were selected to analyze their impact on growth. As 
Fig 18 shows, strain LL03 develops an unusually long lag phase of 8 hours and reaches 
stationary phase after 12 hours. Moreover, when media is supplemented with NaCl 0.50 M, a 
general detriment in growth is observed, since maximum OD600 is lowered, and strain LL03 is 
not able to grow anymore. On the other hand, strain LL05 (harboring a trans copy of gdpPll) 
also shows impaired growth, although the effect is not as marked as the one just described. 
Conversely, neither the presence of cdaAef in strain LL04, nor of gdpPef in strain LL06seems to 
have an evident impact on growth under these conditions, since in both cases growth is similar 
to strain LL00, carrying the empty vector. 
Impact of β-lactam antibiotics on strains under study was also tested. These are a class 
of antibiotics active against a group of proteins called “penicillin-binding proteins” or PBP. A 
subgroup of essential PBP are the transpeptidases, which are serine proteases in charge of the 
last step in cell wall biosynthesis: the cross-linking of neighboring peptidoglycan strands (166). 
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The β-lactam ring of these antibiotics mimics the cell wall strand, but once in contact with the 
enzyme, it forms a stable intermediate that inactivates the transpeptidase. Consequently, an 
imbalance occurs between the incorporation of new building blocks to the cell wall and the 
recycling activity of autolysins, leading to cell lysis (167). 
 
Fig 18 Saline sensitivity of strains LL00, LL03 – LL06. Growth curves were performed at 30 ºC in 
rich media M17G supplemented with 0.25 M (left) and 0.50 M (right) NaCl. Strain L. lactis LL00 
harbors the empty vector pBV153, whereas the series LL03, LL04, LL05 and LL06 carry a trans copy 
of genes cdaAll, gdpPll, cdaAef and gdpPef, respectively. 
c-di-AMP homeostasis has been reported to be connected to cell wall metabolism, and 
in fact, CdaA is modulated by GlmM, an enzyme in charge of synthesizing the cell wall 
precursor glucosamine-1-phosphate (82). Moreover, gdpP mutants in L. lactis have also been 
found to be more resistant to sublethal concentrations of penicillin G (74). Taking this into 
account, response to sublethal concentrations of penicillin and ampicillin (two β-lactam 
antibiotics) was tested for strains LL03-06.  
Once more, no significant effect was observed for strain LL04 and a growth 
disadvantage was evidenced for strain LL03 when media were supplemented with 0.25 µg/ml 
ampicillin or 0.10 µg/ml penicillin, showing a more severe effect for the latter case. On the 
other hand, even though both strains LL05 and LL06 manifested impaired growth in presence 
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of 0.25 µg/ml ampicillin, strain LL06 grew more similar to the LL00 control strain when 0.10 
µg/ml penicillin was added to the medium instead Fig 19. 
So far, only the response to β-lactam antibiotics has been reported for L. lactis strains 
with mutations altering c-di-AMP intracellular levels. Since response to different stress factors 
could also allow the identification of other pathways related to c-di-AMP metabolism, growth 
curves in presence of compounds with a different mechanism of action was evaluated. 
 
Fig 19 Response of strains LL00, LL03 – LL06 to β-lactamic antibiotics. Growth curves were 
performed at 30 ºC in rich media M17G supplemented with 0.25 µg/ml ampicillin (left) and 0.10 µg/ml 
penicillin (right). L. lactis LL00 harbors the empty vector pBV153, whereas the series LL03, LL04, 
LL05 and LL06 carry a trans copy of genes cdaAll, gdpPll, cdaAef and gdpPef, respectively. 
Vancomycin is a glycopeptide active against the second phase of cell wall synthesis, i.e. 
it binds to D-Ala-D-Ala ends of monomers being processed for its later addition to the cell wall. 
Nevertheless, once vancomycin is bound, the complex formed is no longer a substrate for 
subsequent enzymes and consequently lipid intermediates accumulate in the membrane (168). 
Considering that it affects a different stage of cell wall biosynthesis, its impact on cells with 
modified intracellular pool of c-di-AMP could give insights as regards the importance of this 
second messenger in the different stages. 
76 
Results 
As Fig 20 shows, only strains LL03 and LL05, harboring an extra copy of cdaAll and 
gdpPll, respectively, evidenced a negative impact on growth, when media were supplemented 
with 0.50 µg/ml vancomycin. E. faecalis enzymes seem not to affect the response, having a 
behavior similar to the control with the empty vector. 
On the other hand, lysozyme is an enzyme capable of hydrolyzing the glycosidic bonds 
on the cell wall, releasing a disaccharide formed by acetylglucosamine and muramic acid (169). 
Its impact as an antimicrobial agent has long been studied, and it has also been reported that in 
L. monocytogenes the lack of CdaR increased resistance to this compound (170). Taking into 
account that in the same work it was proved that CdaR negatively regulates CdaA in this 
bacterium, this would mean that high amounts of c-di-AMP could favor lysozyme resistance. 
Therefore, this hypothesis was tested for the strains here developed. 
In Fig 20, it can be observed that an extra copy of gdpP gene (LL05 and LL06) increased 
susceptibility to lysozyme. At a concentration of 0.10 µg/ml, LL05 and LL06 (gdpPll and 
gdpPef, respectively) strains are no longer able to grow in the time interval here presented, 
whereas the control strain reaches a final OD600 of 1.0. Taking into account that both strains are 
expected to produce higher amounts of GdpP proteins, and consequently lower their c-di-AMP 
levels inside the cell, these results agree with the ones previously described for L. 
monocytogenes. 
Interestingly, different phenotypes were evidenced for strains harboring an extra copy 
of cdaAll and cdaAef. Even though trans-expression of the former impedes growth of strain 
LL03, the phenotype observed due to expression of latter in strain LL04, agrees with the 
published results mentioned, since it confers a growth advantage with respect to the control 
LL00 strain, harboring the empty vector. 
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Fig 20 Impact of vancomycin and lysozyme on strains LL00, LL03 – LL06. Growth curves were 
performed at 30 ºC in rich media M17G supplemented with 0.50 µg/ml vancomycin (left) and 0.10 
µg/ml lysozyme (right). L. lactis LL00 harbors the empty vector pBV153, whereas the series LL03, 
LL04, LL05 and LL06 carry a trans copy of genes cdaAll, gdpPll, cdaAef and gdpPef, respectively. 
Finally, the two isolated gdpP mutants (strains LL07 and LL08) were also analyzed by 
phase contrast microscopy in order to evaluate differences in morphology. In Fig 21, images of 
bacteria during mid-exponential growth are presented (down), where a slight decrease in size 
can be seen for strain LL07, which showed smaller colonies. In addition, for both samples under 
study, well defined round shaped cells were evidenced, with no significant differences with 
respect to the control strain LL00 harboring the empty vector pBV153. 
As previously mentioned, gdpP mutants analyzed by Smith et al. showed improved 
growth at sublethal concentrations of the β-lactamic antibiotic penicillin. Therefore, both 
mutant strains LL07 and LL08 were grown in presence of ampicillin to further study possible 
phenotypic differences between them. In Fig 21, growth curves obtained in M17G 
supplemented with 5.0 µg/ml ampicillin are presented, where a detriment is evidenced for both 
strains. Interestingly, the opposite phenotype was observed in these conditions, and even a slight 
difference is observed in ∆gdpP strains LL07 and LL08, being the former more sensitive to the 
antibiotic than the latter. 
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Fig 21 Phenotypic analysis of ∆gdpP mutants Up: Growth curves performed in rich media M17G 
without (left) and with supplementation of 5.0 µg/ml ampicillin (right). Down: Phase contrast 
microscopy of strains LL00, LL07 and LL08. Bacteria were grown in M17G medium at 30 ºC and 
samples were taken at mid-exponential phase. Scale bar, 2 µm. 
3.2.3. Intracellular levels of c-di-AMP are modified in strains L. lactis 
LL03-LL08 
After analyzing phenotypes and stability of strains developed in the previous section, 
their c-di-AMP intracellular levels were determined. As mentioned, pBV153 vector is induced 
at low pH, which is why strains LL00, LL03-06 harboring this plasmid and its derivatives were 
grown at initial pH (pH0) of 7.0 and 5.5 for later c-di-AMP quantification. Briefly, cells were 
grown in M17G supplemented with 10 µg/ml Cm for strains LL00, LL03-06 and without 
antibiotic for strains LL07 and LL08. OD600 measurements were taken every hour to check 
growth (not shown). When OD600 reached 0.5, cells were harvested and pellets stored for c-di-
AMP extraction and determination. Results were normalized by the amount of protein present 
in the samples (see Materials and Methods). 
Values obtained for strain LL00 as well as IL1403 indicate that basal levels of c-di-
AMP are in the range of 19.9 – 41.3 and 28.0 – 34.1 ng of c-di-AMP per mg of protein at pH0 
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7.0 and 5.5, respectively. These levels could be significantly increased when strain LL03 with 
plasmid pIQ101 harboring cdaAll gene was grown at pH0 = 7.0. Average values obtained in 
these conditions, for three technical replicates were 334.0 and 350.0 ng of c-di-AMP per mg of 
protein in biological duplicates (Fig 22). This means that at least 8 times higher values are 
possible to obtain in L. lactis IL1403 without reaching toxic levels. Furthermore, when plasmid 
was pIQ101 was induced at pH0 5.5, c-di-AMP concentrations were almost doubled reaching 
average values of 698.4 and 652.5 ng of c-di-AMP per mg of protein in biological duplicates, 
more than 15 times higher than basal levels just mentioned. 
Accordingly to results described in the previous section, where strain LL04 with plasmid 
pIQ102 harboring a copy of cdaAef showed no particular phenotypes when grown in presence 
of different stress factors, no impact on c-di-AMP levels was manifested in this experiment 
either. At both pH0 similar values to the ones observed for the control strain LL00 were 
obtained, suggesting once more that CdaAef enzyme is not active under the working conditions 
of this study. 
 
Fig 22. c-di-AMP intracellular levels of strains LL00, LL03-06. Cells were grown in rich 
M17G medium and harvested at OD = 0.5 for c-di-AMP extraction and quantification. Strains 
were grown at pH0 = 5.5 (left) and 7.0 (right). Circles, squares and triangles correspond to 
technical triplicates. 1 and 2 indicate biological duplicates.  
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On the other hand, the presence of a trans copy of gpdPll gene in strain LL05 allowed 
reduction of intracellular c-di-AMP values to 14.4 – 29.0 and 5.7 – 11.0 ng of c-di-AMP per 
mg of protein at pH0 of 5.5 and 7.0, respectively. These values indicate that the enzyme could 
be more active at pH0 7.0, and coincide with the ones obtained for strain LL06, which were also 
lower at pH0 7.0, although results above described suggest a higher induction of the expression 
system at pH0 5.5. 
Interestingly, different results were obtained for the two gdpP mutant strains LL07 and 
LL08. In the first case, values in the range of wild type strain IL1403 were registered (Fig 23), 
whereas in the second case, intracellular c-di-AMP concentrations were almost doubled (63.6 
– 85.1 ng of c-di-AMP per mg of protein). It is important to mention that the fact that c-di-AMP 
levels are held close to wild type ones even in the absence of gdpP, suggests that there could 
be another c-di-AMP degrading enzyme encoded in L. lactis genome. 
 
Finally, the impact of ampicillin on c-di-AMP levels was analyzed for strains LL05 and 
LL06. Both were grown in rich media M17G in presence of 0.25 µg/ml and since LL06 in the 
previous section evidenced more resistance to β-lactamic antibiotics, a concentration of 0.5 
µg/ml was selected in this case as well. Fig. 25 shows that ampicillin supplementation of media 
causes a decrease of c-di-AMP levels, being the lowest concentration in the range 3.7 – 12.4 ng 
of c-di-AMP per mg of protein at pH0 7.0 for strain LL06, harboring a trans copy of cdaAef 
gene. 
Fig. 24 Intracellular concentrations of c-di-AMP in L. 
lactis ∆gdpP mutants. Strains were grown at pH0 = 7.0 and 
haversted when OD600 reached 0.5. Different c-di-AMP 
values were obtained for both gdpP mutant strains. Circles, 
squares and triangles correspond to technical triplicates. 1 
and 2 indicate biological duplicates 
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Fig. 25 Ampicillin impact on strains L. lactis LL05 and LL06. Strains were grown in in rich medium M17G 
at pH0 = 5.5 (left) and pH0 = 7.0 (right). c-di-AMP levels were taken at OD600 = 0.5. The lowest c-di-AMP 
levels are seen for strain LL06 at pH0 = 7.0. Circles, squares and triangles correspond to technical triplicates. 
1 and 2 indicate biological duplicates. 
Altogether, these results allowed us to establish working conditions where c-di-AMP 
are increased more than 15 times. Therefore, for the immunological experiments in the 
following chapter, strain LL03 as well as the system of expression with pIQ101 vector induced 
at pH0 = 5.50 were selected.  
3.2.4. Phosphodiesterases c-di-AMP in L. lactis 
In the previous section, the maintenance of wild type c-di-AMP intracellular levels in 
∆gdpP mutant strains suggests the possibility of other enzymes encoded in L. lactis genomes 
capable of degrading this second messenger. As mentioned in the introduction, the second 
family of c-di-AMP phosphodiesterases, which comprises B. subtilis PgpH, contains an HD-
domain and a His-Asp motif. Even though homologues are found in many members of 
firmicutes, a protein blast in L. lactis using this protein as query, threw no positive results. 
Another group of smaller phosphodiesterases presents only a soluble DHH/DHHA1 
domain and was found for example in S. pneumoniae and B. subtilis, although in the latter this 
enzyme does not degrade c-di-AMP. This time the protein threw a protein encoded by yheB of 
L. lactis IL1403 with 48% identity to B. subtilis NrnA and 64% to S. pneumoniae Pde2, albeit 
no further information about its function is available.  
With the aim of starting a characterization of YheB protein and evaluating whether it 
can degrade c-di-AMP, yheB gene from L. lactis IL1403 and NZ9000 was cloned in the 
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expression vector pWH844 (see Table XVI Plasmids). This vector allows E. coli overexpression 
of heterologous genes with an N-terminal His6X-tag for purification purposes. Moreover, GdpP 
proteins from both strains were cloned as well to be used as positive control of c-di-AMP 
hydrolyzing enzymes, although these experiments could not be performed due to time restraints. 
Resulting plasmids pIQ401, pIQ402, pIQ403 and pIQ404 containing genes yheBNZ, gdpPNZ, 
yheBIL and gdpPIL were electroporated in E. coli BL21, originating strains E. coli YB01, GP01, 
YB02 and GP02, respectively. 
After checking all gene sequences, an expression test was performed in rich LB medium 
at 37º. Briefly, strains were grown until OD600 reached 0.5, when 0.5 mM IPTG was added and 
cultures were incubated for three more hours. Fig 26 shows an SDS-PAGE were bands of circa 
35 kDa and 74 kDa evidence the presence of YheB and GdpP for strains YB01 – 02 and GP 
01-02, respectively. 
 
Fig 26 Expression test of strains E. coli YB01 -02 and 
GP01 -02. SDS-PAGE gel after Coomasie staining. 
Arrows indicate the presence of expression bands 
corresponding to proteins YheBNZ and YheBIL in lanes 2 
and 4, respectively as well as GdpPNZ and GdpPIL in lanes 
3 and 5, respectively. MWM: molecular weight marker. 
Once production of proteins was confirmed, both YheB proteins were purified using a 
Ni2+-NTA resin (see Materials and Methods). Fig 27 shows SDS-PAGE gels were the 
purification process is evidenced and the proteins of interest are present in fractions E3 and E4 
for YheBIL (left) and E2, E3 and E4 for YheBNZ (right). Afterwards, proteins were further 
purified via size exclusion chromatography (SEC) by use of the Äkta system to eliminate 
imidazole of the media. Samples were then concentrated and frozen in liquid nitrogen to be 
finally stored at -80º C until used. 
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Fig 27 Purification of YheBIL and YheBNZ proteins. Elutions further purified via size exclusion 
chromatography are highlighted in orange. CE: crude extract, FT: Flow through, E: elution, MWM: 
molecular weight marker. E1 – E5: 30 – 50 – 100 – 200 – 500 mM imidazole, respectively. 
A first approach into function determination of YheB proteins was performed via the 
BNPP assay. bis(4-nitrophenyl)phosphate can be cleaved by phosphodiesterases yielding 
paranitrophenol, which production can be followed colorimetrically at 410 nm ((171), Materials 
and Methods). Reactions were performed at different pH and adding Mn2+ to the media to 
analyze optimal conditions for further studies. As seen in Fig 28, YheBNZ enzyme seems to be 
more active, and both proteins evidenced increased activity when pH was raised. These results 
suggest that YheB protein could be a c-di-AMP phosphodiesterase. 
 
Fig 28 BNPP assay for YheB proteins. YheBIL (left) and YheBNZ (right) were analyzed via BNPP 
assay. Reads were performed for four hours in a microplate reader. The arrow shows increasing pH 
in the reaction media. Both graphs show higher activity when pH is raised. 
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3.2.5. Conclusions 
The aim of this chapter was to evaluate the physiological consequences when c-di-AMP 
intracellular pools are altered in L. lactis IL1403. Depletion of this secondary messenger via 
cdaA deletion was not possible in rich, nor in minimal media. The strategy was thus changed 
and responses obtained along the different experiments here presented, evidenced 
overexpression of heterologous and homologous cdaA and gdpP genes by use of pBV153 
vector.  
In general, strains here developed were more sensitive on rich media and upon the 
presence of stress factors such as NaCl, antibiotics and high temperature. The only exception 
was cdaAef overexpressed in presence of 0.1 µg/ml lysozyme, which provided a growth 
advantage. Since the resulting CdaAEF enzyme showed no great impact on c-di-AMP levels, it 
could be said that in this conditions, its activity is diminished. If this is the case, detrimental 
phenotypes obtained in the other growth curves could be due to a system were c-di-AMP levels 
are too low or too high, which has already been reported to result in impaired growth (172). 
The highest average values of c-di-AMP obtained in this work reached 698.4 and 652.5 
ng of c-di-AMP per mg of protein in biological duplicates for strain LL03. Although these 
differences could be due to methodological variations, an increment of more than 15 times with 
respect to basal levels was obtained. L. lactis LL03 was therefore selected for further studies 
on the development of a live vaccine prototype in next chapter. 
On the other hand, reduction of c-di-AMP intracellular levels by expression of gdpP 
genes was more significant at pH0 7.0. Despite the fact that the induction of the expression 
system used is higher when pH is lowered, these results lead to the hypothesis that GdpP 
enzyme activity in L. lactis would prevail when extracellular pH is closer to physiological 
values. Moreover, the biggest impact in this way was accomplished by strain LL06 grown in 
rich media M17G supplemented with 0.50 µg/ml ampicillin. Average values of technical 
triplicates were 7.4 and 7.8 ng of c-di-AMP per mg of protein, linking the impact of a β-lactamic 
antibiotic to c-di-AMP levels in L. lactis IL1403. 
Finally, the fact that ∆gdpP mutants are able to maintain c-di-AMP levels close to wild 
type ones, supports the hypothesis of the existence of at least another enzyme capable of 
hydrolyzing c-di-AMP. The main candidate found in this work is the uncharacterized YheB 
protein, which was proved here to degrade BNPP. Nevertheless, this compound is an unspecific 
85 
Results 
substrate for phosphodiesterases, and even though phosphodiesterase activity is evidenced here, 
and proved to increase at higher pH, further specific studies are needed to confirm it can degrade 
c-di-AMP (68). 
.
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3.3.  Development of an oral subunit vaccine prototype against Chagas 
disease 
3.3.1. Antigen design and production in L. lactis 
As mentioned in the introduction, T. cruzi trans-sialidase (TS) enzyme plays a vital role 
upon infection of the mammal host, since it catalyzes the transfer of sialic acid from the host 
glycoconjugates to the terminal β-galactopyranosyl residues of mucin-like molecules on the 
parasite's cell surface. It is also involved in different pathways leading to successful parasite 
infection and down-regulation of the host immune response (173). Therefore, TS was selected 
to develop a suitable antigen for the vaccine prototype against Chagas disease. 
The high performance of the whole TS protein as a T. cruzi antigen in vaccine prototypes 
has already been reported (174, 175). Nevertheless, considering that protein overexpression in 
LAB is not as straight forward as normally is in other bacterial models such as E. coli, an 
abbreviated fraction of the antigen was selected instead of the entire TS protein. In addition, the 
engineered L. lactis strain was designed to co-express the synthesizing enzyme of the adjuvant 
as well, which adds a detrimental factor to bacterial growth and protein expression. Altogether, 
in order to facilitate protein co-expression in L. lactis, the smallest TS protein size possible was 
selected, having at the same time the highest epitope concentration able to trigger a TS-specific 
immune response. 
Based on these criteria, an epitope prediction within the complete TS antigen sequence 
was performed by Ivan Marcipar group in Laboratorio de Tecnología Inmunológica, Facultad 
de Bioquímica y Ciencias Biológicas, UNL (Universidad Nacional del Litoral). T epitopes 
against H-2Kd MHC-I were selected for prediction, and a total of 7 epitopes were identified, 
with four of them in the central region of the protein, ranging from amino acid 326 to 497. 
Interestingly, IYNVGQVSI epitope was included in this region, which has been described as 
the main MHC-I T-cell epitope that provides protection against T. cruzi infections in BALB/c 
mice (176, 177). On the other hand, B-epitopes have shown to comprise key amino acids 
responsible for enzymatic catalysis (178), which is why antibodies developed against this 
region may potentially neutralize TS activity. Therefore, prediction of B epitopes was also 
carried out, identifying 15 out of the 50 epitopes with the highest score within the same central 
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region. These predictions lead to the final TS fragment selection, ranging from amino acid 326 
to 497 (Fig. 29). 
Given that synthesis of heterologous proteins may result in amino acid unbalance, the 
designed peptide was submitted to GenScript synthesis service (U.S.A.) to optimize codon 
usage for L. lactis and to incorporate NcoI and HindIII restriction sites required for cloning, as 
well as an N-terminal His6x tag to allow detection by Western blot. The resulting gene was 
named tscf and cloned into the nisin inducible pNZ8048 vector previously described (pNZTS, 
Table XVI, Fig. 29), to be finally electroporated in L. lactis NZ9000 (strain NZTS, Table XV). 
After checking the genetic construction by sequencing, several conditions of expression were 
tested. Protein overproduction was proved in some of them, but it was not possible to detect it 
again in new trials of expression (not shown). 
 
Fig. 29 Development of an optimized TS derived antigen. A: complete sequence of trans-sialidase protein. The 
selected fragment is highlighted in purple and colored amino acids within this sequence indicate epitopes. 
Underlined amino acids refer to superimposed epitopes. B: Structure modelling of whole TS (right) and the two 
sections conforming the synthetic antigen (left). C: cloning representation of his6x-tscf in plasmid pNZ8048. D: 
Expression check by SDS-PAGE (left) and Western blot analysis (right). 
As mentioned in the introduction, L. lactis clpP-htrA strain favors expression of 
heterologous genes since it lacks the two major proteases ClpP and HtrA, reducing degradation 
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of heterologous proteins. Plasmid pNZTS was electroporated in this strain, resulting in strain 
LL02 (Table XV), and this time stable overproduction of TScf peptide was obtained. Briefly, 
cells were grown in 3 liters of M17G broth at 30 ºC until OD600 reached 0.50 and induced with 
5 or 50 ng/ml nisin during 1 or 3 hours. As shown in Fig. 29, Western blot analysis using anti-
his antibodies allowed visualization of a clear band when cultures were induced for 3 hours. 
Protein identity was determined by mass spectrometry (MS/MS), confirming overproduction 
of TScf. 
3.3.2. Immune response after mucosal co-administration of L. lactis 
strains producing TScf antigen and c-di-AMP adjuvant 
Once a strain able to produce the designed antigen (LL02) as well as a strain 
synthesizing high adjuvant levels (Chapter II, strain LL03) were obtained, the next step was to 
evaluate the effectiveness of their co-administration, as proof of concept for the development 
of a new prototype of mucosal vaccine. In collaboration with Dra. Ana Rosa Perez’s group, 
from the Instituto de Investigación Clínica y Experimental de Rosario (IDICER CONICET-
UNR), three successive oral immunizations were performed in mice (see Materials and 
Methods). Studied groups were: Non-immunized (NI, mice receiving only PBS); LL02, mice 
immunized with bacteria producing the TScf antigen (L. lactis LL02, Table XV); LL02+LL03 
group, mice co-administered with L. lactis LL02 plus bacteria over-producing c-di-AMP (L. 
lactis LL03, Table XV). L. lactis LL01 strain harboring the empty pNZ8048 plasmid was also 
orally administered as control. In addition, since earlier studies showed a higher specific anti-
TS cellular response after immunization with TS plus ISCOMATRIX adjuvant by subcutaneous 
immunization (174), for comparative purposes a group of mice was also immunized with 
purified TScf  adjuvanted with ISPA (C+, Gold standard group), an ISCOMATRIX type 
adjuvant developed by Dr. Marcipar group (152). 
As shown in Fig. 30, 15 days after the last immunization, 48 hours footpad testing 
showed that L. lactis LL02+LL03 immunized group elicited a clear TS-specific cell-mediated 
immune response compared to PBS and LL01, while this difference is less significant compared 
with the L. lactis LL02 group. Interestingly, the increase in footpad thickness were similar 
between L. lactis LL02+LL03 and the Gold standard group. These results support that TScf 
sequence contains MHC-I T-cell epitopes, as was previously mentioned, but also suggest that 
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orally-administered L. lactis over-expressing cdaA gene (LL03) could be used as immune 
stimulator of the response against this antigen. 
 
Fig. 30 Graphic representation of BALB/C mice oral immunization protocol. 
A: Oral immunization scheme. Three doses were administered with 15 days 
intervals. 48 hours after the last immunization, footpad swelling and DHT were 
measured. B: Co-administration of LL02+LL03 shows a significant difference 
with respect to LL02 as well as LL01 groups. C: Morphological difference in 
footpad swelling in non-immunized mice (up) and LL01+LL02 group (down). NI: 
non-immunized. 
3.3.3. A single engineered L. lactis strain producing c-di-AMP antigen 
and TScf adjuvant: a vaccine prototype. 
Aiming to the development of a fully integrated mucosal vaccine prototype, a single 
vector carrying both genes encoding the TScf antigen and the CdaA enzyme responsible for c-
di-AMP production was designed. The first attempt to reach this consisted on amplifying from 
pIQ101 plasmid a DNA region containing the Pcit promoter, the cdaA gene and its terminator. 
After several unsuccessful attempts of cloning this fragment in the BglII restriction site 
upstream the Pnis promoter in vector pNZTS, the strategy was changed. Instead, TScf coding 
gene was amplified including the Pnis promoter and terminator of pNZTS plasmid and 
subcloned in the SalI-PstI restriction sites of vector pIQ101. The resulting p10TS plasmid 
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containing both genes was finally electroporated in L. lactis clpP-htrA strain, and the resulting 
strain was named L. lactis LL10 (Fig 31 and Table XV). 
 
Fig 31 L. lactis LL10 strain construction and growth response. Up: cloning scheme for p10TS 
obtaining. This plasmid contains tscf gene under PnisA control and cdaA gene under PcitM control. 
Down: Growth curves performed in rich medium M17G. LL00: L. lactis IL1403 + pBV153, LL01: 
L. lactis NZ9000 clpP-htrA + pNZ8048, LL02: L. lactis NZ9000 clpP-htrA + pNZTS, LL03: L. 
lactis IL1403 + pIQ101, LL09: L. lactis NZ9000 clpP-htrA + pIQ101, LL10: L. lactis NZ9000 clpP-
htrA + p10TS 
In order to standardize conditions for the following immunological experiments, 
plasmid pIQ101 harboring cdaA gene was electroporated in strain L. lactis clpP-htrA, 
originating strain LL09. Since the main target of this chapter is the formulation of a live vaccine, 
comparative growth curves were performed to check response of L. lactis IL1403 and L. lactis 
clpP-htrA strains harboring a trans copy of cdaA (Fig 31, down – left). On the other hand the 
same comparison was done for L. lactis clpP-htrA derivative strains harboring tscf gene (LL09) 
and both tscf and cdaA genes (LL10). Fig 31 shows similar responses in all cases, with 
homologous behavior for L. lactis IL1403 and L. lactis clpP-htrA derivative strains. 
Moreover, and due to the presence of two different induction systems in strain LL10, an 
expression test was performed. In the previous chapter, the highest intracellular concentration 
of c-di-AMP was obtained at pH0 = 5.5, and cultures were grown until OD600 reached 0.50. 
Since expression of tscf was induced once OD600 = 0.50 and cultures were then incubated for 3 
more hours, the following step was to set up effective conditions for both systems. Therefore, 
nisin induction for strain LL10 was tested at two time points: simultaneously with inoculation 
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(OD = 0.05) and at OD600 = 0.30, until a final OD600 of 0.50 for both cases. Three nisin 
concentrations were also evaluated; 5, 15 and 50 ng/ml, and strain LL02 induced with 0.5 ng/ml 
was used as control, for this was the condition in which TScf production was obtained in section 
3.3.1. 
As seen in Fig 32, the highest overproduction of TScf was evidenced in the crude extract 
as well as the supernatant fractions when 15 ng/ml nisin was added to growth media at the 
moment of inoculation (OD600 = 0.05). 
 
Fig 32 Synthesis of TScf in L. lactis LL10. Cultures of L. lactis LL10 were grown in rich M17G 
media supplemented with different nisin concentrations and at different times. Cells were harvested 
at OD600 = 0.5 in all cases. Crude extract (CE, left) and supernatant (Sn, right) fractions evidence a 
greater expression when 15 ng/ml nisin were added simultaneously with media inoculation. Orange 
arrows indicate TScf bands. ev: empty vector pNZ8048, MWM: molecular weight marker. 
In conclusion, for the immunological experiments performed in the following 
section inocula were prepared as follows: 2 liters of fresh M17G medium supplemented 
with the corresponding antibiotics and 15 ng/ml nisin were inoculated with the desired 
strains at OD600 = 0.05 and incubated at 30 ºC until OD600 reached 0.5. Cultures were then 
harvested and washed with PBS, to be finally resuspended at final OD600 of 2-3.109 
CFU/100 µl. An expression check to corroborate TScf presence was finally performed 
and aliquots were stored at -80 ºC until used (see Materials and Methods). 
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3.3.4.  Immune response of engineered L. lactis co-expressing antigen and 
adjuvant after mucosal administration 
With a similar protocol to the one used in section 3.3.2., BALB/C mice were inoculated 
to analyze the in vivo cell-mediated immune response of strain LL10 developed in the previous 
section. This time inoculated groups were: Non-immunized (NI, mice receiving only PBS); 
LL10, mice immunized with L. lactis LL10 (co-producing TScf and CdaA), LL02, a group of 
mice receiving bacteria producing the TScf antigen alone (L. lactis LL02) and LL09, mice 
immunized only with the c-di-AMP producer strain (L. lactis LL09). A group of mice 
immunized with L. lactis LL01 strain harboring the empty pNZ8048 plasmid and a group 
receiving TS plus the ISCOMATRIX adjuvant were included as control. 
A scheme of three doses separated by 15 days intervals, similar to the one described in 
the previous section was again used (Fig. 30, A) and footpad swelling was determined 48 hours 
after the last immunization. In Fig 33 values obtained are plotted for the groups under study, 
and a clear, significant immune response is obtained for LL10 group. These results evidence 
that live administration of L. lactis LL10 strains elicits a similar response to the control group 
immunized with purified TS and the ISCOMATRIX adjuvant. 
Fig 33 Immune response to L. lactis LL10 
strain. The immunization protocol as shown 
in Fig. 30, A was again used to evaluate the 
response of strain L. lactis LL10, co-
producing TScf antigen and c-di-AMP 
adjuvant at the same time. A: Footpad 
swelling is significantly higher for this group 
than for NI and control group LL01. B: 
Footpad swelling developed by LL10 group. 
NI: Non-immunized. 
 
93 
Results 
3.3.5. Conclusions 
In this chapter, an engineered L. lactis strain was constructed to express tscf gene coding 
a heterologous, immunogenic trans-sialidase (TS) derived peptide (LL02). TScf peptide 
condenses important T and B epitopes, and Western blot analyses confirmed its production. 
Furthermore, mice oral inoculation with a combination of strains LL02 and LL09 (derived from 
strain LL03, obtained in the previous chapter) elicited a clear immune response. This 
encouraging results lead to the development of strain L. lactis LL10, which co-produces in the 
cytosol the c-di-AMP adjuvant and the optimized TScf antigen. 
BALB/c mice oral inoculation with three doses of L. lactis LL10, triggered an immune 
response evidenced by footpad swelling. A diagram of the LL10-based vaccine explaining the 
combination of the two expression systems employed is presented in Fig 34. These results show 
that the engineered strain LL10 could result in an effective vaccine for Chagas disease, which 
is a serious public health problem in South America. 
 
Fig 34 Strain L. lactis LL10: an oral vaccine prototype. Presence of nisRK two-component system 
in L. lactis genome allows nisin sensing via NisK, upon which NisR is phosphorylated and activates 
PnisA promoter in pIQ10TS plasmid. On the other hand, low pH activates in turn PcitM promoter, 
regulating cdaA. CdaA is thus synthesized and c-di-AMP produced. Consequently, both TScf 
antigen and the adjuvant c-di-AMP are co-produced in the cytosol. 
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3.4. An approach into c-di-AMP metabolism in E. faecalis JH2-2 
3.4.1. Initial studies into cdaA metabolism 
As in most low GC firmicutes, only one c-di-AMP synthesizing enzyme is found in E. 
faecalis JH2-2 genome. Being a cdaA homologue, it is encoded in the cdaARglmM operon, as 
expected. Interestingly, glmM gene in the laboratory model strain E. faecalis JH2-2 used in this 
work, encodes a full 1356 bp open reading frame, whereas the vancomycin-resistant strain 
V583, presents a shorter version of 1026 bp in its genome, which would result in a 342 amino 
acids peptide (being the wild type version of 452 amino acids) (Fig 35). 
Fig 35 cdaARglmM operon in E. faecalis. Up: JH2-
2 strain shows full version genes (up) whereas in strain 
V583 (down) a premature stop codon occurs in glmM 
gene. 
Moreover, a search for genes present in E. faecalis genome coding for proteins with 
high homology for c-di-AMP degrading enzymes, revealed the presence of a gdpP as well as a 
pgpH homologue (Fig 36). Interestingly, the cytosolic version of the DHH family of 
phosphodiesterases was also found encoded in E. faecalis JH2-2 genome. As previously 
mentioned, the NrnA homologue in B. subtilis is not capable of degrading c-di-AMP, but the 
corresponding protein named Pde2 in S. pneumoniae possesses c-di-AMP phosphodiesterase 
activity, and it was proved that Pde1 (a GdpP homologue) as well as Pde2 affect bacterial 
growth and virulence (68). In conclusion, E. faecalis could count on three c-di-AMP degrading 
enzymes, and c-di-AMP metabolism in this species could be also related to virulence. 
Fig 36 Phosphodiesterases encoded in E. faecalis 
JH2-2 genome. 1: DNA binding protein. 2: SSU 
ribosomal protein S18p. 3: LSU ribosomal protein 
L9p. 4: dnaB. 5: gatB. 6: phoH. 7: metal-dependent 
hydrolase ybeY. 8: diacylglycerol kinase. 9: metal-
dependent hydrolase. 10: CBS containing protein. 11: 
phnA. 12: hypothetical protein 
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In the first chapter of this thesis, L. lactis Kup proteins were identified as c-di-AMP 
interaction partners. A search for genes coding for Kup homologues was therefore performed 
in E. faecalis JH2-2, which revealed one copy of kup in its genome (Fig 37). Moreover, the 
presence of other potassium transporters was as well considered in this species. Neither Kdp, 
nor Ktr homologues were found, but two genes coding for putative members of the Trk 
potassium transporter family were found. These proteins are predicted as TrkA and TrkH and 
their genetic contexts are detailed in Fig 37. Interestingly, a homologue to KimA, a novel 
potassium transporter recently described, was also found encoded in E. faecalis JH2-2 genome 
(49). 
 
Fig 37 Putative potassium transporters in E. 
faecalis JH2-2. 1: cation-transporting ATPase. 2: 
transcriptional regulator. 3: Pb, Cd, Zn and Hg 
transporting ATPase. 4: Co-Zn-Cd resistance protein. 
5: acetyl-transferase. 6: L-carnitine choline ABC 
transporter. 7: liaS. 8: liaR. 9: hypothetical protein. 10: 
bactoprenol glucosyl transferase. 11: transcriptional 
regulator. 12: dihydrofolate reductase. 13: Na+/H+ 
antiporter. 14: transcriptional regulator. 
At present, no studies about E. faecalis JH2-2 potassium transporters are available. 
Hence, kup gene was cloned in vector pWH844, similarly to kupA and kupB of L. lactis IL1403 
in chapter 1. The resulting pIQ311 plasmid was electroporated in E. coli LB650 and strain E. 
coli LB13 thus obtained was grown on rich LBG medium to check if a trans complementation 
with kup gene could restore growth at low potassium concentrations. 
As seen in Fig 38, E. coli LB13 strain restores growth on LBG supplemented with 10 
mM KCl under induced conditions. Moreover, this strain behaved similarly to LB09-LB11 
strains, harboring trans copies of high affinity potassium uptake systems. This suggests that E. 
faecalis, similarly to L. lactis, counts on the potassium transporter Kup as a high affinity K+ 
intake system. However, whether this protein, as well as the rest of the putative potassium 
transporters previously presented interact with c-di-AMP, remains unknown and proposes 
interesting future investigations. 
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Fig 38 Growth of E. coli LB derived strains on LB. LB09 – LB13: E coli 
LB650 complemented with a trans copy of kupA, kupB, ktrA/B, ktrC/D, kup, 
respectively. LB08 contains plasmid pWH844, used as negative control. 
Strains were plated on LB-agar plates supplemented with 10 mM KCl and 10 
µM IPTG (left) and 100 mM KCl and no IPTG (right). Low affinity potassium 
system KtrC/D as well as the negative control with the empty vector only grow 
at high K+ concentrations. Expression of kup genes and ktrA/B system restore 
growth under low concentrations of KCl. 
3.4.2. ∆gdpP mutant in E. faecalis JH2-2 
In order to study the response of ∆gdpP mutation in E. faecalis, deletion by use of the 
homologous recombination system previously described in section 3.2.1. and Materials and 
Methods, was performed. Briefly, up and downstream regions of gdpP gene were cloned in the 
thermosensitive vector pBVGh, and after a series of incubations at the permissive and non-
permissive temperatures, a clean deletion occurs. Antibiotic sensitive colonies are isolated, and 
mutation is checked via internal and external PCR, as well as sequencing (Fig 15). 
After confirming strain E. faecalis JH12 as a ∆gdpP mutant, a phenotypic analysis was 
carried out on growth curves performed in rich LBG media, supplemented with different stress 
factors. As seen in Fig 39, this strain does not show a particular phenotype with respect to JH2-
2 wild type strain when grown in LBG. Nevertheless, in presence of 5.0 µg/ml ampicillin, a 
hypersentivity phenotype is evidenced. This response was expected, since similar results were 
obtained for L. lactis ∆gdpP mutants. 
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Fig 39 E. faecalis JH12 growth in presence of stress factors. Growth curves were performed in 
rich LBG medium in a microplate reader. Supplements added are indicated above each graph. 
Similar growth is observed under control LBG conditions. Hypersensitivity phenotype is obtained 
in presence of 5 µg/ml ampicillin, whereas improved growth was manifested when 7.5% ethanol 
and 0.75 mM H2O2 were added to media. Wild type strain E. faecalis JH2-2 was used as control. 
Interestingly, a growth advantage is observed for the mutant strain JH12 when LBG is 
supplemented with 7.5% ethanol and 0.75 mM hydrogen peroxide. On the other hand, even 
though in LB no clear phenotype was observed when 300 mM KCl was added (not shown), in 
M17G there was a marked difference, since a hypersensitive phenotype is observed in these 
conditions (Fig 40). Noteworthy, in M17G control condition, strain JH12 evidences impair 
growth. 
In conclusion, evidence here presented, confirms that in E. faecalis c-di-AMP 
metabolism affects bacterial response to different stress factors. Altered c-di-AMP levels can 
confer a growth advantage, but it can also be deleterious for the cell. Due to the diversity of 
pathways influenced by this second messenger, effects on growth curves experiments are hard 
to analyze and more specific studies are needed. Even in rich control media LBG and M17G, 
different phenotypes were observed: the lack of GdpP seems not to affect growth in the former, 
whereas it results deleterious in the latter. 
Lastly, whether Kup, as well as the rest of putative potassium transporters previously 
presented, interact to c-di-AMP remains unknown and proposes interesting future 
investigations.  
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Fig 40 Saline sensitivity in M17G. Growth curves were performed in rich M17G medium 
in a microplate reader. Addition of 300 mM KCl results in impaired growth for E. faecalis 
JH12 (right). 
3.4.3. Virulence analysis of gdpP mutant strain E. faecalis JH2-2 using the 
greater wax moth Galleria mellonella. 
Historically, the use of invertebrate animals, like the silkworm Bombyx mori and the 
fruit fly Drosophila melanogaster, has been a very important tool for the development of model 
microorganisms enabling the study of pathogen-host interactions (179, 180). For instance, the 
development of the greater wax moth Galleria mellonella as an infection model dates from 
1938 (181), and due to its adaptability and high proliferation it is a very suitable tool to establish 
a first approach into the study of pathogenesis and virulence factors (182, 183). 
Among the most important advantages for the use of G. mellonella larvae, easy 
manipulation, low cost of colony maintenance and its accepted ethical use can be mentioned. It 
is also of great relevance the fact that these larvae can be grown at 37ºC, temperature at which 
human pathogens are adapted and therefore synthesis of most virulence factors occur (184). 
Moreover, and unlike nematode models, which lack phagocytic immune response (185), the 
insect G. mellonella is capable of eliciting humoral and cellular immune responses. Altogether, 
G. mellonella is a suitable infection model for the analysis of bacterial virulence factors 
affecting humans and other mammals (186). 
E. faecalis JH12 strain was therefore used to inoculate G. mellonella larvae and analyze 
the response and possible phenotypic differences due to the lack of the c-di-AMP degrading 
enzyme, GdpP (see Materials and Methods). Strain JH13 complemented with a trans copy of 
wild type gdpP gene cloned in vector pBV153 was use to check if, in case of obtaining a distinct 
phenotype for JH12 mutant strain, complementation occurred. 
99 
Results 
Fig 41 shows survival curves obtained after inoculations with 9.106 CFU per larvae. 
Length of horizontal lines along the x-axis corresponds to serial time, or survival duration until 
a larva dies. Vertical distances between horizontal lines show accumulated probability changes. 
Censured subjects are shown as black dots. 
In the case under study, the first dead individual occurs at approximately 20 hours after 
inoculation, in all three cases. Nevertheless, at t = 40 hours, 50% of larvae still survive for the 
complemented strain JH13, whereas in JH12 mutant and JH2-2 wild type strains the majority 
of larvae are already dead. Also, Kaplan-Meier survival analysis indicates a significant 
differences between the three curves, for which it can be said that the absence of gdpP gene 
diminishes virulence in E. faecalis, and complementation with vector pIQ104, harboring a wild 
type copy of gdpP, results in an even less virulent strain. Within 50 hours, JH2-2 and JH12 
groups are reduced by 90 and 80%, respectively, while 50% of JH13 group remain alive. 
A negative control was inoculated with PBS solution, which is completely innocuous 
(not shown). 
 
Fig 41 Survival Kaplan-Meier curves for 
E. faecalis strains under study. G. 
mellonella larvae were inoculated with 
9.106 CFU/larvae. E. faecalis JH2-2 (black) was 
used as control. Green: ∆gdpP mutant strain E. 
faecalis JH12. Red: E. faecalis JH13 (∆gdpP 
complemented in trans with a wild type copy of 
gdpP gene). 
  
100 
Results 
3.4.4. Conclusions and Discussion 
In this last chapter, an approach was made into c-di-AMP metabolism in E. faecalis 
JH2-2. A bioinformatic analysis of genes related to this second messenger shows that glmM 
could be interrupted in some species of the genus, just as cdaR is in L. lactis (see below). 
Furthermore, putative potassium transporters were found encoded in E. faecalis 
genome. The product of one of them, Kup, was identified as a potassium transporter, and it is 
likely to have high affinity for this cation like KupA and KupB proteins from L. lactis, 
previously described. 
On the other hand, the analysis of ∆gdpP on growth curves performed in rich media 
showed once more for this kind of mutant, a higher susceptibility to ampicillin in LBG and to 
KCl in M17G. Noteworthy, growth advantage phenotypes were evidenced in presence of 
ethanol and H2O2. Even though a complemented strain was constructed, wild type phenotypes 
restoration was not achieved (not shown). 
Finally, assays in G. mellonella showed lower virulence for ∆gdpP mutant strain JH12, 
and even though complemented strain JH13 did not restore wild type phenotype in these 
experiments either, an even lower virulence was observed. Considering that, as previously 
mentioned, c-di-AMP levels are tightly regulated, this could be due to the overexpression of 
gdpP resulting in c-di-AMP concentrations below wild type values. Nevertheless, a clear link 
between c-di-AMP metabolism and virulence was established for E. faecalis JH2-2. 
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4. General Discussions 
“Science makes people reach selflessly for truth and objectivity; it 
teaches people to accept reality, with wonder and admiration, not to 
mention the deep awe and joy that the natural order of things brings 
to the true scientist” Lise Meitner 
  
 
Discussion 
4.1. Novel potassium transporters in L. lactis IL1403 
Even though potassium is the most abundant cation in the cell and it is essential for life, 
no K+ transporter systems have so far been described for L. lactis IL1403. In silico research 
showed different systems encoded in other L. lactis strains, such as Kdp and Ktr systems, both 
well studied in model microorganisms like B. subtilis and L. monocytogenes. Nevertheless, no 
kup gene was found in their genomes, and the absence of this system is also verified in S. aureus 
and S. pneumonia. However, it is widely disseminated in numerous species of Lactobacillus 
and Enterococcus and it is also present in a few species of Streptococcus and Staphylococcus. 
Interestingly, in the L. lactis group, strains with three full copies of the kup gene can be 
found, although the most represented gene arrangement is the two-copy kupA kupB cluster, as 
for the case of L. lactis IL1403 presented in this thesis. Nonetheless, some strains only have 
one copy of the gene, like MG1363 and its derivative NZ9000, the strain of choice for genetic 
engineering in L. lactis. In these cases, a spontaneous mutation in kupB originates a stop codon, 
confirming that only one copy of the gene would be enough to regulate potassium uptake and 
satisfy the vital metabolic needs of the cell concerning cell turgor, proton motive force, and 
others. 
In the Gram-negative model bacterium E. coli, Trchounian and Kobayashi determined 
in 1999 that the main function of the only Kup in this bacterium (previously known as TrkD) 
is to uptake K+ in hyperosmotic conditions at low pH, being a constitutive, low affinity and low 
rate system (47). Moreover, it is also the case for Gram – bacteria that different amounts of kup 
gene copies can be found in the same genome. In Legionella pneumophila, the causal agent of 
legionelosis, three genes with high similarity to E. coli kup gene were found and named kupA, 
kupB and kupC (187). 
As previously mentioned, topology prediction showed that conserved residues are 
concentrated at the N-terminal end, which was expected since the cytosolic C-terminal end was 
proved to be non-essential for potassium translocation, whereas truncation of the protein in the 
loop between membrane regions 10 and 11 resulted in a non-functional peptide (158). Provided 
E. coli has no c-di-AMP synthesizing enzymes and consequently potassium transporters are not 
expected to bind the second messenger in this bacterium, it is reasonable to expect that the c-
di-AMP binding site in L. lactis has been acquired at the C-terminal cytosolic half of the protein. 
103 
Discussion 
4.2. An updated overview of c-di-AMP in L. lactis IL1403 
Even though it is well known that synthesis and degradation of c-di-AMP occurs 
through specific cyclases and phosphodiesterases (CdaA and GdpP respectively) regulation of 
CdaA by CdaR is still not exactly understood in L. lactis. Zhu et al. have suggested that CdaR 
could be a negative regulator, due to experiments carried out in E. coli with different 
combinations of the cdaA operon fragments, although further investigations are needed to 
confirm these data (82). In the same work, they report that strain MG1363 has a nucleotide 
deletion in cdaR gene, leading to a premature stop codon, and, consequently, to a shorter version 
of cdaR, which is actually annotated as a pseudogene. The resulting peptide would be 96 amino 
acids long, considerably shorter than the wild type 320 amino acid protein. They also state that 
no other L. lactis strain shows this mutation. 
Nonetheless, it seems to be also the case for L. lactis IL1403, where a different mutation 
is found, resulting in a second shorter version of cdaR, which would encode a 194 amino acid 
peptide. From the currently sequenced and assembled 35 L. lactis genomes available in the 
Genbank database, no other L. lactis strain shows this unusual genotype, i.e. excluding strains 
IL1403, MG1363 and its derivative NZ9000, the remaining 32 have the typical gene 
arrangement, which is represented in Fig 42 by the one present in SK11 strain. 
 
Fig 42 cdaARglmM operon in L. lactis. Three variations of cdaR gene 
are found among the 35 L. lactis sequenced and assembled strains 
available in the Genbank database. 
To discard the possibility that this different version of cdaR gene could be due to an 
annotation error, the whole cdaARglmM operon was sequenced, using genomic DNA and 
primers JN373, JN374, JN385, JN386, JN387, JN388 (see Table XVII). Sequences were 
assembled and alignment to the theoretical operon available in the Genbank database, allowed 
confirmation of the premature stop codon. 
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So far, only one c-di-AMP degrading enzyme was reported in L. lactis, GdpP. In this 
work, levels of c-di-AMP in ∆gdpP are maintained close to wild type ones, suggesting that 
there could be another enzyme in charge of this metabolite hydrolysis. YheB, a S. pneumonia 
Pde2 homologue is therefore proposed, and even though its phosphodiesterase activity was 
confirmed via the BNPP assay, further more specific studies are needed to confirm if it can 
degrade c-di-AMP. 
 
Fig 43. Schematic representation of pathways currently proved to be influenced by c-di-AMP in L. lactis 
IL1403. Red lines represent inhibitory effect. Black curved arrows indicate synthesis of metabolites. Black dashed 
arrows stand for transcription and translation of indicated genes to obtain the resulting protein. Question marks 
denote the lack of data to assess the modulation of CdaA by CdaR and of the stringent response metabolite 
(p)ppGpp by pApA, which has been proved in other model bacteria to modulate the c-di-AMP degrading enzyme 
GdpP. 
Moreover, it is nowadays well known that degradation of c-di-AMP yields 
phosphoadenylyl phosphoadenosine (pApA) (Fig 43). This metabolite intervenes in turn in the 
stringent response, a survival pathway activated under carbon source deprivation, although its 
specific role and its connection to the stringent response metabolite (p)ppGpp which has been 
proven to modulate GdpP activity in other model organisms (71), remains unknown in L. lactis. 
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The first confirmed modulator of c-di-AMP levels in L. lactis IL1403 was GlmM, 
negatively modulates CdaA. In this way, c-di-AMP metabolism was first linked to cell wall 
homeostasis in L. lactis. Moreover, c-di-AMP was recently proved to be involved in central 
metabolism in L. lactis IL1403 due to the negative regulation it exerts on PycA, the pyruvate 
carboxylase enzyme in charge of oxaloacetate synthesis (81). This is the first metabolite 
entering the tricarboxylic acid cycle for CO2 fixation. Nevertheless, it is important to mention 
that due to the incomplete Krebs cycle present in L. lactis, the main impact of pyruvate 
carboxylase enzyme is thought to be involved in amino acids synthesis, since oxaloacetate is 
an aspartate precursor. 
Finally, Fig 43 also depicts the novel role of c-di-AMP in L. lactis osmoregulation via 
inhibition of KupA and KupB, identified and described in this thesis. Since other potassium 
transporters are present in different strains of L. lactis, the question remains whether all these 
systems are also regulated by c-di-AMP, as KupA and KupB were proved to be. 
4.3. L. lactis + c-di-AMP: a novel vaccine delivery system 
Vaccination is one of the most important inventions in the field of public health. As 
described in the introduction, the first vaccines were obtained based on the use of attenuated or 
inactivated microorganisms. More recently, molecular techniques opened the possibility to 
develop vaccines using purified fragments of proteins and recombinant antigens. Even though 
one of the main advantages of this technology are the fewer risks for the patients, they usually 
show poor immunogenic properties, making the use of adjuvants necessary to potentiate the 
specific immune response. In addition, most of the currently used vaccines are administered via 
parenteral routes, and only a few examples of vaccines administered through mucous 
membranes are commercially available. Since several pathogens enter their hosts through 
mucosal surfaces, the development of innovative mucosal vaccines is a challenging paradigm.  
L. lactis is a versatile bacterium, which counts on decades of experimental research as 
well as industrial applications ((188), also developed in the introduction). It is a good candidate 
when considering the delivery of biologically active immunomodulatory proteins or the 
production of active biological compounds. Very importantly, the safety of L. lactis is well 
established, having GRAS and QPS status by the Food and Drugs Administration (U.S.A.) and 
the European Food Safety Authority, respectively. Hence, this microorganism offers a 
substantial potential as a delivery vector system for vaccines, particularly because it can be 
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administrated by diverse mucosal routes like oral, nasal or intravaginal, and it survives passage 
through GIT as well (189). 
In this thesis, L. lactis LL02 was constructed, allowing overproduction of c-di-AMP 
more than 15 times above wild type levels. Thus, this tool was combined with the nisin 
inducible expression system widely study in L. lactis to develop strain L. lactis LL10. This is a 
single novel bacterium designed to deliver the TScf antigen adjuvanted by c-di-AMP in the 
cytosol. Three successive oral immunizations with this prototype of L. lactis live vaccine 
elicited a clear anti-TS cellular response, indicating that oral formulations with this 
microorganism could be used as delivery of diverse heterologous antigens adjuvanted by c-di-
AMP in order to trigger specific immune protection. 
The co-existence of both molecules in the same strain of L. lactis, not only may favor 
the development of a specific immune response (by exposing immunocompetent cells to both 
molecules at the same time), but also may help to reduce the cost vaccination programs in 
developing countries. Moreover, this prototype of L. lactis overproducing c-di-AMP can be 
combined with other antigens, avoiding expensive and laborious procedures for c-di-AMP 
production, and enabling systematic research of a variety of antigens. 
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6. Appendix 
“Valid criticism does you a favor” Carl Sagan 
  
 
Appendix 
6.1. Peptide identification after c-di-AMP pull-down experiment. 
Table XIV Peptide identification after c-di-AMP pull-down experiment 
Identified Protein Accession Number Molecular Weight + - 
Ratio 
+/- 
DNA polymerase III, subunits beta and 
tau  
Q9CDM5_LACLA 61 kDa 34 < 0.5 69,00 
30S ribosomal protein S6 RS6_LACLA 11 kDa 15 < 0.5 31,00 
Uncharacterized protein Q9CIR6_LACLA 62 kDa 13 < 0.5 27,00 
PpGpp synthetase I  Q9CJ94_LACLA 84 kDa 11 < 0.5 23,00 
Protease Q9CE72_LACLA 47 kDa 11 < 0.5 23,00 
Uncharacterized protein Q9CED1_LACLA 12 kDa 11 < 0.5 23,00 
3-hydroxy-3-methylglutaryl coenzyme A 
reductase  
Q9CFB1_LACLA 45 kDa 10 
< 0.5 
21,00 
6,7-dimethyl-8-ribityllumazine synthase RISB_LACLA 17 kDa 10 < 0.5 21,00 
Aspartate racemase Q9CDJ4_LACLA 28 kDa 8 < 0.5 17,00 
Uncharacterized protein Q9CEX0_LACLA 22 kDa 8 < 0.5 17,00 
Initiation-control protein YabA YABA_LACLA 13 kDa 8 < 0.5 17,00 
ATP-dependent DNA helicase RecG Q9CDH6_LACLA 75 kDa 7 < 0.5 15,00 
Pyrimidine-nucleoside phosphorylase Q9CFM5_LACLA 47 kDa 7 < 0.5 15,00 
Oxidoreductase Q9CEV1_LACLA 28 kDa 7 < 0.5 15,00 
Uncharacterized protein Q9CFC1_LACLA 21 kDa 7 < 0.5 15,00 
Uncharacterized protein Q9CDN8_LACLA 17 kDa 7 < 0.5 15,00 
Single-stranded DNA specific 
exonuclease 
Q9CHT6_LACLA 84 kDa 6 
< 0.5 
13,00 
Glutamine ABC transporter permease and 
substrate binding protein 
Q9CES5_LACLA 78 kDa 6 
< 0.5 
13,00 
Peptide chain release factor 2  RF2_LACLA 42 kDa 6 < 0.5 13,00 
Uncharacterized protein Q9CHI4_LACLA 10 kDa 6 < 0.5 13,00 
Cell-division ATP-binding protein FtsE Q9CGX0_LACLA 26 kDa 6 < 0.5 13,00 
DNA repair protein RecN Q9CH78_LACLA 63 kDa 34 3 9,86 
Uncharacterized protein Q9CFB8_LACLA 15 kDa 45 5 8,27 
Aspartate--tRNA ligase SYD_LACLA 67 kDa 164 20 8,02 
Uncharacterized protein Q9CEI1_LACLA 13 kDa 26 3 7,57 
DNA mismatch repair protein MutL  MUTL_LACLA 74 kDa 30 4 6,78 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 
GLMS_LACLA 66 kDa 206 31 6,56 
126 
Appendix 
Phosphoenolpyruvate-protein 
phosphotransferase 
PT1_LACLA 63 kDa 126 19 6,49 
Septation ring formation regulator EzrA EZRA_LACLA 66 kDa 35 5 6,45 
NADH oxidase Q9CIG9_LACLA 49 kDa 38 6 5,92 
Elongation factor 4 LEPA_LACLA 68 kDa 32 5 5,91 
ABC transporter ATP binding protein Q9CJA0_LACLA 58 kDa 61 10 5,86 
Uncharacterized protein Q9CGM2_LACLA 14 kDa 14 2 5,80 
N-acetylmuramidase Q9CED5_LACLA 50 kDa 14 2 5,80 
Universal stress protein Q9CEI3_LACLA 16 kDa 120 21 5,60 
Arginine--tRNA ligase SYR_LACLA 63 kDa 30 5 5,55 
Folylpolyglutamate synthase Q9CGE0_LACLA 48 kDa 12 2 5,00 
Homoserine dehydrogenase DHOM_LACLA 47 kDa 21 4 4,78 
Uncharacterized protein Q9CGJ5_LACLA 19 kDa 11 2 4,60 
Hydroxymethylglutaryl-CoA synthase Q9CFA9_LACLA 43 kDa 11 2 4,60 
Gamma-glutamyl phosphate reductase PROA_LACLA 45 kDa 24 5 4,45 
Sugar ABC transporter ATP binding 
protein 
Q9CFY3_LACLA 56 kDa 15 3 4,43 
ABC transporter ATP binding protein Q9CFC6_LACLA 70 kDa 31 7 4,20 
Glucose-6-phosphate isomerase G6PI_LACLA 50 kDa 10 2 4,20 
Peptide-binding protein Q9CI27_LACLA 60 kDa 14 3 4,14 
Uncharacterized protein Q9CJ15_LACLA 13 kDa 18 4 4,11 
Peptide chain release factor 3 RF3_LACLA 60 kDa 30 7 4,07 
ABC transporter ATP binding protein Q9CJC5_LACLA 61 kDa 62 15 4,03 
Chaperone protein DnaK DNAK_LACLA 65 kDa 150 37 4,01 
Lysine--tRNA ligase SYK_LACLA 57 kDa 21 5 3,91 
Probable phosphoketolase PHK_LACLA 93 kDa 9 2 3,80 
Uncharacterized protein Q9CDZ4_LACLA 18 kDa 43 11 3,78 
Uncharacterized protein Q9CID7_LACLA 17 kDa 68 18 3,70 
Peptide chain release factor 1 RF1_LACLA 40 kDa 27 7 3,67 
Uncharacterized protein Q9CFU3_LACLA 15 kDa 16 4 3,67 
UPF0145 protein YjfJ YJFJ_LACLA 12 kDa 30 8 3,59 
Signal recognition particle receptor FtsY Q9CHB9_LACLA 51 kDa 392 109 3,58 
Uncharacterized protein Q9CF71_LACLA 56 kDa 12 3 3,57 
Polysaccharide biosynthesis protein Q9CIZ9_LACLA 70 kDa 12 3 3,57 
UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 2 
MURA2_LACLA 45 kDa 12 3 3,57 
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Aromatic amino acid specific 
aminotransferase 
Q9CJE0_LACLA 43 kDa 60 17 3,46 
S-adenosylmethionine synthase METK_LACLA 43 kDa 170 49 3,44 
Glycosyltransferase Q9CJ00_LACLA 38 kDa 15 4 3,44 
Uncharacterized protein Q9CDS4_LACLA 9 kDa 15 4 3,44 
Asparagine synthetase Q9CDJ2_LACLA 72 kDa 32 9 3,42 
Probable serine/threonine-protein kinase PKNB_LACLA 68 kDa 8 2 3,40 
Adenylosuccinate synthetase PURA_LACLA 47 kDa 143 43 3,30 
NifU protein Q9CEP7_LACLA 13 kDa 11 3 3,29 
ATP-dependent protease ATP-binding 
subunit 
Q9CHS9_LACLA 90 kDa 66 20 3,24 
Nicotinate phosphoribosyltransferase Q9CGJ6_LACLA 56 kDa 82 25 3,24 
Segregation and condensation protein B SCPB_LACLA 21 kDa 27 8 3,24 
50S ribosomal protein L5 RL5_LACLA 20 kDa 14 4 3,22 
Uncharacterized protein Q9CDS3_LACLA 37 kDa 36 11 3,17 
Uncharacterized protein Q9CJ16_LACLA 58 kDa 155 50 3,08 
Flotillin-like protein Q9CHJ2_LACLA 54 kDa 41 13 3,07 
Cell division protein ftsA Q9CEH1_LACLA 49 kDa 91 30 3,00 
Uncharacterized protein Q9CF27_LACLA 38 kDa 10 3 3,00 
Transcriptional regulator Q9CE68_LACLA 15 kDa 10 3 3,00 
Tagatose-6-phosphate kinase Q9CGY4_LACLA 34 kDa 7 2 3,00 
Alpha-subunit L-serine dehydratase Q9CHA7_LACLA 30 kDa 7 2 3,00 
Uncharacterized protein Q9CF30_LACLA 43 kDa 7 2 3,00 
Probable nicotinate-nucleotide 
adenylyltransferase 
Q9CIY1_LACLA 23 kDa 7 2 3,00 
Uncharacterized protein Q9CF63_LACLA 64 kDa 7 2 3,00 
Lipoprotein Q9CIN8_LACLA 31 kDa 7 2 3,00 
Uncharacterized protein Q9CEF2_LACLA 18 kDa 243 81 2,99 
tRNA uridine 5-
carboxymethylaminomethyl modification 
enzyme 
MNMG_LACLA 69 kDa 27 9 2,89 
ATP-dependent Clp protease ATP-
binding subunit 
CLPE_LACLA 83 kDa 481 168 2,86 
ATP synthase subunit delta ATPD_LACLA 19 kDa 18 6 2,85 
Endonuclease MutS2 MUTS2_LACLA 87 kDa 15 5 2,82 
30S ribosomal protein S4 RS4_LACLA 23 kDa 15 5 2,82 
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ATP-dependent Clp protease ATP-
binding subunit ClpX 
CLPX_LACLA 46 kDa 270 96 2,80 
UDP-N-acetylglucosamine--N-
acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase 
MURG_LACLA 39 kDa 9 3 2,71 
Uncharacterized protein Q9CEP4_LACLA 45 kDa 105 39 2,67 
Replicative DNA helicase Q9CHI5_LACLA 50 kDa 53 20 2,61 
Uncharacterized protein Q9CGB4_LACLA 48 kDa 19 7 2,60 
Aminopeptidase C PEPC_LACLA 50 kDa 6 2 2,60 
Amino acid aminohydrolase Q9CGY6_LACLA 42 kDa 6 2 2,60 
Mannose-specific PTS system component 
IID 
Q9CEX6_LACLA 34 kDa 6 2 2,60 
60 kDa chaperonin CH60_LACLA 57 kDa 219 84 2,60 
Prophage pi2 protein 02 Q9CGT3_LACLA 21 kDa 24 9 2,58 
Uncharacterized protein Q9CG71_LACLA 20 kDa 29 11 2,57 
Biotin carboxylase Q9CHF3_LACLA 49 kDa 52 20 2,56 
DNA gyrase subunit A Q9CGI5_LACLA 93 kDa 11 4 2,56 
Asparagine synthetase B Q9CIK5_LACLA 60 kDa 205 81 2,52 
UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 1 
MURA1_LACLA 46 kDa 94 37 2,52 
UvrABC system protein B  UVRB_LACLA 79 kDa 76 30 2,51 
Protein RecA, chromosomal  RECA_LACLA 41 kDa 136 54 2,50 
30S ribosomal protein S10  RS10_LACLA 12 kDa 50 20 2,46 
DNA mismatch repair protein MutS  MUTS_LACLA 94 kDa 13 5 2,45 
Diadenosine 5',5'''-P1,P4-tetraphosphate 
hydrolase 
Q9CI07_LACLA 18 kDa 13 5 2,45 
Alpha-acetolactate synthase  Q7DAV2_LACLA 61 kDa 164 67 2,44 
Riboflavin biosynthesis protein RibBA  Q9CGU7_LACLA 44 kDa 8 3 2,43 
Glutamate--tRNA ligase SYE_LACLA 55 kDa 8 3 2,43 
Oligopeptide ABC transporter substrate 
binding protein 
Q9CIL2_LACLA 60 kDa 117 48 2,42 
Maltose ABC transporter substrate 
binding protein 
Q9CEZ8_LACLA 44 kDa 292 123 2,37 
GTPase HflX Q9CIY3_LACLA 43 kDa 29 12 2,36 
Uncharacterized protein Q9CDF6_LACLA 22 kDa 10 4 2,33 
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30S ribosomal protein S7 RS7_LACLA 18 kDa 10 4 2,33 
Nitrogen regulatory protein P-II Q9CF90_LACLA 13 kDa 10 4 2,33 
GTPase Der DER_LACLA 49 kDa 63 27 2,31 
Glycine betaine transport ATP-binding 
protein OpuAA 
OPUAA_LACLA 46 kDa 48 21 2,26 
Alkyl hydroperoxide reductase Q9CIL9_LACLA 21 kDa 211 94 2,24 
DNA polymerase III subunit beta DPO3B_LACLA 42 kDa 14 6 2,23 
Universal stress protein Q9CH60_LACLA 16 kDa 14 6 2,23 
Formate acetyltransferase PFL_LACLA 89 kDa 36 16 2,21 
ABC transporter ATP binding protein Q9CGN4_LACLA 72 kDa 18 8 2,18 
Spermidine/putrescine import ATP-
binding protein PotA 
POTA_LACLA 48 kDa 22 10 2,14 
Cysteine--tRNA ligase SYC_LACLA 51 kDa 7 3 2,14 
Fumarate reductase flavoprotein subunit Q9CGH2_LACLA 53 kDa 26 12 2,12 
Uncharacterized protein Q9CED6_LACLA 41 kDa 81 38 2,12 
Glucose kinase Q9CE25_LACLA 34 kDa 9 4 2,11 
Ribonuclease Y RNY_LACLA 60 kDa 11 5 2,09 
Acetate-SH-citrate lyase ligase Q9CGB0_LACLA 39 kDa 11 5 2,09 
50S ribosomal protein L14 RL14_LACLA 13 kDa 11 5 2,09 
Amino acid ABC transporter substrate 
binding protein 
Q9CDZ9_LACLA 31 kDa 13 6 2,08 
Foldase protein PrsA PRSA_LACLA 34 kDa 13 6 2,08 
NH(3)-dependent NAD(+) synthetase NADE_LACLA 30 kDa 44 21 2,07 
S-adenosylmethionine:tRNA 
ribosyltransferase-isomerase 
QUEA_LACLA 39 kDa 75 36 2,07 
Thymidylate synthase TYSY_LACLA 33 kDa 15 7 2,07 
Uncharacterized protein Q9CEI5_LACLA 40 kDa 15 7 2,07 
Uncharacterized protein Q9CIK0_LACLA 15 kDa 15 7 2,07 
30S ribosomal protein S5 RS5_LACLA 18 kDa 157 76 2,06 
UDP-N-acetylmuramoylalanine--D-
glutamate ligase 
MURD_LACLA 49 kDa 19 9 2,05 
Mannose-specific PTS system component 
IIAB 
Q9CEX8_LACLA 35 kDa 79 39 2,01 
Triosephosphate isomerase TPIS_LACLA 27 kDa 7 15 0,48 
Malonyl CoA-acyl carrier protein 
transacylase 
Q9CHF8_LACLA 34 kDa 4 9 0,47 
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Protein-tyrosine phosphatase Q9CEK1_LACLA 28 kDa 4 9 0,47 
1,4-dihydroxy-2-naphthoyl-CoA synthase Q9CHK2_LACLA 31 kDa 18 39 0,47 
Isoleucine--tRNA ligase SYI_LACLA 107 kDa 3 7 0,47 
3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ 
FABZ2_LACLA 16 kDa 3 7 0,47 
Transcription termination/antitermination 
protein NusA 
Q9CHG7_LACLA 43 kDa 100 220 0,46 
Exodeoxyribonuclease A Q9CHE1_LACLA 38 kDa 6 14 0,45 
Dihydrolipoamide acetyltransferase 
component of PDH complex 
Q9CJD7_LACLA 56 kDa 42 95 0,45 
Uncharacterized protein Q9CIG7_LACLA 31 kDa 5 12 0,44 
DNA replication protein DnaD Q9CGM6_LACLA 26 kDa 8 19 0,44 
Ribonuclease 3 RNC_LACLA 26 kDa 10 25 0,41 
Uncharacterized protein Q9CE54_LACLA 32 kDa 7 18 0,41 
Ferrous ion transport protein A Q9CJ18_LACLA 17 kDa 8 21 0,40 
Uncharacterized protein Q9CHB7_LACLA 26 kDa 4 11 0,39 
Mevalonate kinase Q9CIF6_LACLA 36 kDa 2 6 0,38 
Uncharacterized protein Q9CEM6_LACLA 31 kDa 2 6 0,38 
tRNA dimethylallyltransferase MIAA_LACLA 34 kDa 2 6 0,38 
DNA-directed RNA polymerase subunit 
omega 
RPOZ_LACLA 13 kDa 2 6 0,38 
Uncharacterized protein Q9CIJ7_LACLA 23 kDa 19 52 0,37 
Putative gluconeogenesis factor GNGF_LACLA 36 kDa 3 9 0,37 
Uncharacterized protein Q9CJ34_LACLA 41 kDa 4 12 0,36 
Bifunctional protein GlmU GLMU_LACLA 49 kDa 8 27 0,31 
Uncharacterized protein Q9CHZ8_LACLA 28 kDa 2 9 0,26 
Valine--tRNA ligase SYV_LACLA 101 kDa 3 13 0,26 
Leucine--tRNA ligase SYL_LACLA 94 kDa 3 13 0,26 
DNA polymerase III PolC-type DPO3_LACLA 185 kDa 11 69 0,17 
Non-heme chloride peroxidase Q9CHB2_LACLA 31 kDa  6 0,08 
Endoribonuclease YbeY YBEY_LACLA 19 kDa  7 0,07 
Transcriptional regulator Q9CIF1_LACLA 28 kDa  8 0,06 
Uncharacterized protein Q9CHI3_LACLA 30 kDa  8 0,06 
Prophage pi3 protein 57, cI-like repressor Q9CFN7_LACLA 20 kDa  10 0,05 
Pyruvate carboxylase Q9CHQ7_LACLA 126 kDa 51 2531 0,02 
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Biotin carboxyl carrier protein of acetyl-
CoA carboxylase 
Q9CHF5_LACLA 16 kDa  32 0,02 
The dashed line indicates the cut off established for specific c-di-AMP interaction assay. 
6.2. Bacterial strains 
Table XV Bacterial strains 
Bacterial Strain Genotype/Characteristics Reference 
E. coli strains   
E coli 2003 ∆kdpABC5 kupD1 ∆trkA Hamann 1991 (174) 
E coli BL21  
E. coli B F– ompT gal dcm lon hsdSB(rB–mB–) 
[malB+]K-12(λS) 
Studier and Moffatt 
1986 (175) 
E. coli 0300 E. coli 2003 + pIQ310 and pBP370 - Cm30 – Amp100 This work 
E. coli 0303 E. coli 2003 + pIQ310 and pBP373 - Cm30 – Amp100 This work 
E. coli 0380 E. coli 2003 + pWH844 and pBP370 - Cm30 – 
Amp100 
This work 
E. coli 0383 E. coli 2003 + pWH844 and pBP373 - Cm30 – 
Amp100 
This work 
E. coli 0390 E. coli 2003 + pIQ309 and pBP370 - Cm30 – Amp100 This work 
E. coli 0393 E. coli 2003 + pIQ309 and pBP373 - Cm30 – Amp100 This work 
E. coli DH5α 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
Hanahan, 1983 (176) 
E. coli EC101 
E. coli JM101 derived. repA+ (from pWV01 
integrated in chromosome) Km40 
Law et al. 1995 (177) 
E. coli GP01 E. coli BL21 + pIQ402 This work 
E. coli GP02 E. coli BL21 + pIQ404 This work 
E. coli LB08 E. coli LB650 + pWH844 - Km50 – Cm30 – Amp100 This work 
E. coli LB09 E. coli LB650 + pIQ309 - Km50 – Cm30 – Amp100 This work 
E. coli LB10 E. coli LB650 + pIQ310 - Km50 – Cm30 – Amp100 This work 
E. coli LB11 E. coli LB650 + pBP372 - Km50 – Cm30 – Amp100 This work 
E. coli LB12 E. coli LB650 + pBP371 - Km50 – Cm30 – Amp100 This work 
E. coli LB13 E. coli LB650 + pIQ311 - Km50 – Cm30 – Amp100 This work 
E. coli LB650 ∆kdpABC5 ∆trkH ∆trkG – Km50 – Cm30 Schlösser et al. 1995 
E. coli YB01 E. coli BL21 + pIQ401 This work 
E. coli YB02 E. coli BL21 + pIQ403 This work 
E. faecalis strains   
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E. faecalis JH2-2 Cit+; RifR; FusR; plasmid free Jacob and Hobbs, 1974 
L. lactis strains   
L. lactis htrA-clpP 
NZ9000 transconjugant carrying clpP and htrA 
disruption, plasmid free - Em5 
Cortes-Perez 2006 
L. lactis IL1403 Derived from IL594 strain. Plasmid free, Trp+ Chopin et al., 1984 
L. lactis LL00 L. lactis IL1403 + pBV153  This work 
L. lactis LL01 L. lactis NZ9000 clpP-htrA + pNZ8048 This work 
L. lactis LL02 L. lactis NZ9000 clpP-htrA + pNZTS This work 
L. lactis LL03 L. lactis IL1403 + pIQ101 This work 
L. lactis LL04 L. lactis IL1403 + pIQ102 This work 
L. lactis LL05 L. lactis IL1403 + pIQ103 This work 
L. lactis LL06 L. lactis IL1403 + pIQ104 This work 
L. lactis LL07 L. lactis IL1403 ∆gdpP1s This work 
L. lactis LL08 L. lactis IL1403 ∆gdpP1b This work 
L. lactis LL09 L. lactis NZ9000 clpP-htrA + pIQ101 This work 
L. lactis LL10 L. lactis NZ9000 clpP-htrA + pIQ10TS This work 
L. lactis NZ9000 
L. lactis MG1363 containing nisKR genes integrated 
into pepN locus, plasmid free 
Kuipers 1998 
L. lactis NZTS L. lactis NZ9000 + pNZTS  This work 
6.3. Plasmids 
Table XVI Plasmids 
Plasmid Description Reference 
pBAD33 arabinose inducible - CmR 
Guzman et al. 1995 
(178) 
pBP371 pWH844 ktrC/D L. monocytogenes Stülke Lab 
pBP372 pWH844 ktrA/B B. subtilis Stülke Lab 
pBV153 
PcitM promoter, pH inducible AmpR in E. coli, 
CmR in LAB 
Marelli and Magni 
2009 
pBVGh Thermosensitive vector for gene deletion EmR 
Blancato and Magni 
2010 
pIQ101 pBV153 + L. lactis cdaAll (Pcit promoter) This work 
pIQ102 pBV153 + L. lactis cdaAef (Pcit promoter) This work 
pIQ103 pBV153 + L. lactis gdpPll (Pcit promoter) This work 
pIQ104 pBV153 + L. lactis gdpPef (Pcit promoter) This work 
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pIQ10TS 
pIQ101 derived plasmid encoding cdaA gene 
under PcitM promoter and trans-sialidase 
fragment under Pnis promoter 
This work 
pIQ309 pWH844 no His-tag + kupA IL1403 This work 
pIQ310 pWH844 no His-tag + kupB IL1403 This work 
pIQ311 pWH844 + kup JH2-2 This work 
pIQ370 pBAD33 + cdaAlmo This work 
pIQ373 pBAD33 + cdaA D171N Lmo This work 
pIQ401 pWH844 + yheB L. lactis NZ9000 This work 
pIQ402 pWH844 + gdpP L. lactis NZ9000 This work 
pIQ403 pWH844 + yheB L. lactis IL1403 This work 
pIQ404 pWH844 + gdpP L. lactis IL1403 This work 
pNZ8048 Nisin inducible expression, CmR 
De Ruyter et al. 
1996 (179) 
pNZTS 
pNZ8048 + codon optimized His6x-tagged trans-
sialidase fragment 
This work 
pUC57-TS 
pUC57 + codon optimized His6x-tagged trans-
sialidase fragment 
This work 
pWH844 IPTG inducible – N terminal His tag, AmpR Stülke Lab 
pWHdnaH pWH844 no His-tag + RBS + dnaH 
Grubek, Z. 2016 
(180) 
pWHezrA pWH844 no His-tag + RBS + ezrA Grubek, Z. 2016 
pWHftsE pWH844 no His-tag + RBS + ftsE Grubek, Z. 2016 
pWHglnP pWH844 no His-tag + RBS + glnP Grubek, Z. 2016 
pWHkupA pWH844 no His-tag + RBS + kupA Grubek, Z. 2016 
pWHkupB pWH844 no His-tag + RBS + kupB Grubek, Z. 2016 
pWHlysP pWH844 no His-tag + RBS + lysP Grubek, Z. 2016 
pWHlysQ pWH844 no His-tag + RBS + lysQ Grubek, Z. 2016 
pWHmvaA pWH844 no His-tag + RBS + mvaA Grubek, Z. 2016 
pWHnah pWH844 no His-tag + RBS + nah Grubek, Z. 2016 
pWHoppA pWH844 no His-tag + RBS + oppA Grubek, Z. 2016 
pWHpdp pWH844 no His-tag + RBS + pdp Grubek, Z. 2016 
pWHprfB pWH844 no His-tag + RBS + prfB Grubek, Z. 2016 
pWHracD pWH844 no His-tag + RBS + racD Grubek, Z. 2016 
pWHrecG pWH844 no His-tag + RBS + recG Grubek, Z. 2016 
pWHrecJ pWH844 no His-tag + RBS + recJ Grubek, Z. 2016 
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pWHrecN pWH844 no His-tag + RBS + recN Grubek, Z. 2016 
pWHrelA pWH844 no His-tag + RBS + relA Grubek, Z. 2016 
pWHribH pWH844 no His-tag + RBS + ribH Grubek, Z. 2016 
pWHrpsF pWH844 no His-tag + RBS + rpsF Grubek, Z. 2016 
pWHyciH pWH844 no His-tag + RBS + yciH Grubek, Z. 2016 
pWHyeaD pWH844 no His-tag + RBS + yeaD Grubek, Z. 2016 
pWHyhfC pWH844 no His-tag + RBS + yhfC Grubek, Z. 2016 
pWHyjdJ pWH844 no His-tag + RBS + yjdJ Grubek, Z. 2016 
pWHyncB pWH844 no His-tag + RBS + yncB Grubek, Z. 2016 
pWHyqaB pWH844 no His-tag + RBS + yqaB Grubek, Z. 2016 
pWHyqaD pWH844 no His-tag + RBS + yqaD Grubek, Z. 2016 
pWHyrbD pWH844 no His-tag + RBS + yrbD Grubek, Z. 2016 
pWHyrgI pWH844 no His-tag + RBS + yrgI Grubek, Z. 2016 
pWHyrjB pWH844 no His-tag + RBS + yrjB Grubek, Z. 2016 
pWHytcE pWH844 no His-tag + RBS + ytcE Grubek, Z. 2016 
pWHytjA pWH844 no His-tag + RBS + ytjA Grubek, Z. 2016 
pWHyueF pWH844 no His-tag + RBS + yueF Grubek, Z. 2016 
pWHywfH pWH844 no His-tag + RBS + ywfH Grubek, Z. 2016 
6.4. Oligonucleotides 
Homologous sequences hybridizing with template DNA are in italics, restriction sites are 
underlined. Fwd: forward. Rv: reverse. 
Table XVII Oligonucleotides 
Name Sequence (5’ -> 3’) Purpose 
IQ365 ACAAGTACATATGATGCTTGTTGTGGAAC (Fwd) cdaA - E. faecalis JH2-2 
IQ366 GCACTAGTAAGCTTTCATTTTGCGTTTAACC (Rv) cdaA - E. faecalis JH2-2 
IQ367 AACTAGACATATGATGCAAAAGAAGAGAATTC (Fwd) gdpP - E. faecalis JH2-2 
IQ368 CGACTAGTAAGCTTTCACTCCTGTTCATAC (Rv) gdpP - E. faecalis JH2-2 
IQ369 ACGTAACCATATGTTGACCGACTTCAATC (Fwd) cdaA - L. lactis IL1403 
IQ370 GCTCTAGAAAGCTTTTATTTGCCATTTTTC (Rv) cdaA - L. lactis IL1403 
JN371 AAACCATGGAGAACGTGAAGCAAAAGCACT (Fwd) Upstream region of cdaA - 
L. lactis IL1403 
JN372 TTTAAGCTTCGAACAAGCGTCATTAATTTTGT (Rv) Upstream region of cdaA - L. 
lactis IL1403 
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JN373 AAAAAGCTTTTGCTCACAATGGAGAATTTTTCG (Fwd) Downstream region of 
cdaA - L. lactis IL1403 
JN374 TTTCCATGGCAGAAAGATGAACCGTCGCA (Rv) Downstream region of cdaA 
- L. lactis IL1403 
JN375 AAACCATGGCCGTTTGGGCAATTGAAGACA (Fwd) Upstream region of gdpP - 
L. lactis IL1403 
JN376 TTTAAGCTTATTAAAACGGATGACCCCAATTG (Rv) Upstream region of gdpP - 
L. lactis IL1403  
JN377 AAAAAGCTTATTATGGAGCAAATGGGTGGG (Fwd) Downstream region of 
gdpP - L. lactis IL1403 
JN378 TTTCCATGGGCTTTTCTTTTTCCTTAGCTTTGG (Rv) Downstream region of gdpP 
- L. lactis IL1403 
JN379 AAACATATGGGAGTAATATTATGAATTTTGTCC
G 
(Fwd) gdpP - L. lactis IL1403 
JN380 TTTACTAGTAAGAATACAACTTTCATTTTTCGTT (Rv) gdpP - L. lactis IL1403 
JN384 TTTTCTAGATTATTTGCCATTTTTCTTTCCTCCT (Rv) cdaA - L. lactis IL1403 
(pNZ8048) 
JN385 TATTTGGGAATAAAGCAGTTCACTTAAAA (Fwd) cdaA operon sequencing 
JN386 GAAAGTAACTGTTCCTATACGTGC (Fwd) cdaA operon sequencing 
JN387 CAAAAGTCCTGAAATCAAACTGCT (Rv) cdaA operon sequencing 
JN388 AAAAAAGATAAAAAAGCTCTCCCAATAAG (Rv) cdaA operon sequencing 
JN389 TGGTTGACATTTTTCTTTGATTGTTATC (Rv) gdpP IL1403 sequencing 
JN400 AAACCATGGCCGTTTGGG (Fwd) ligation 58 amplification 
with JN401 
JN401 TTTCCATGGGCTTTTCTTTTTCC (Rv) ligation 58 amplification 
with JN400 
JN402 AAACCATGGAGAACGTGAAG (Fwd) ligation 14 amplification 
with JN403 
JN403 TTTCCATGGCAGAAAGATGAA (Rv) ligation 14 amplification 
with JN402 
JN404 AAAATGCGAGCGATGACCAA (Fwd) gdpP internal fragment - L. 
lactis IL1403 
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JN405 TTAATGGCTGTTCGACCGCT (Rv) gdpP internal fragment - L. 
lactis IL1403 
JN406 GGTTCTATGAAATTTAAAGCAGTGATTT (Fwd) gene upstream gdpP 
IL1403 Deletion check 
JN407 TTAGGCCTCGCTAATTTTGACTT (Rv)  gene downstream gdpP 
IL1403 Deletion check 
JN408 AAAACTAGTAGTTGACCCTGAACGTGAA (Fwd) Upstream region of cdaA L. 
lactis NZ9000 / deletion with 
pBVGh 
JN409 TTTGAATTCAAGCGTCATTAATTTTGTTCCT (Rv) Upstream region of cdaA L. 
lactis NZ9000 / deletion with 
pBVGh 
JN410 AAAGAATTCTAGCACATAATGGCGAGTTT (Fwd) Downstream region of 
cdaA L. lactis NZ9000 / deletion 
with pBVGh 
JN411 TTTGAGCTCTAAATGAACTGTTGCACTGC (Rv) Downstream region of cdaA 
L. lactis NZ9000 / deletion with 
pBVGh 
JN414 AAACCATGGATGAATTTTGTCCGTCGGTT (Fwd) cdaA - L. lactis IL1403 
(pNZ8048) 
JN416 CGATAACGCGAGCATAATAAAC (Fwd) pNZ8048 checking 
JN417 GCCTTGGTTTTCTAATTTTGGTTC (Rv) pNZ8048 checking 
JN418 GTTTAAACGCTTTGGGACGT (Fwd) recJ check 
JN419 GTATCGACGTTGACTTGCTT (Fwd) glnP check 
JN500 TTTGGATCCATGACCTATCGGATGGTTGA (Rv) pdp / construction in 
pWH844 / DRaCALA 
JN501 AAAAAGCTTTTATCTGATAATTTCTAGAATTTCT
TTTTGA 
(Fwd) pdp / construction in 
pWH844 / DRaCALA 
JN502 AAAGGATCCATGGAATTATCAGAAATTAGAAAT
TTACTT 
(Fwd) prfB / construction in 
pWH844 / DRaCALA 
JN503 TTTAAGCTTCTACAAGTTCCAACGGAGATA (Rv) prfB / construction in 
pWH844 / DRaCALA 
JN504 TTTGGATCCATGGCATATCAAGCATTATATAGAA
AAT 
(Rv) dnaH / construction in 
pWH844 / DRaCALA 
JN505 AAAGTCGACTTAATCATTAATTTCAACTACTTTT
TCACC 
(Fwd) dnaH / construction in 
pWH844 / DRaCALA 
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JN506 TTTGGATCCATGAAATTAACAGATTCAGTGCAAT
TTTT 
(Rv) recG / construction in 
pWH844 / DRaCALA 
JN507 AAAAAGCTTTCAATCAAAGCCCCCGTCA (Fwd) recG / construction in 
pWH844 / DRaCALA 
JN508 AAAGGATCCATGATAAAAGCAAAATATGATTGG
AAA 
(Fwd) recJ / construction in 
pWH844 / DRaCALA 
JN509 TTTAAGCTTTTATTTTTCTAATAAATTTTGATAAA
TTTCTTT 
(Rv) recJ / construction in 
pWH844 / DRaCALA 
JN510 AAAGGATCCATGTTACAAGAGATTTCAATCAAA
AATTT 
(Fwd) recN / construction in 
pWH844 / DRaCALA 
JN511 TTTGTCGACTTATTTGCTCAATAAACGTTTAGCC (Rv) recN / construction in 
pWH844 / DRaCALA 
JN512 AAAGGATCCATGGCTGATAAATATAATGTTTTC
GA 
(Fwd) yeaD / construction in 
pWH844 / DRaCALA 
JN513 TTTAAGCTTTCAGCGATACAAAAGCTCCA (Rv) yeaD / construction in 
pWH844 / DRaCALA 
JN514 TTTGGATCCATGACTAAATACGAAATTCTTTATA
TTATTCG 
(Rv) rpsF / construction in 
pWH844 / DRaCALA 
JN515 AAAGTCGACTTAAGCTTCAACTTTAACGATCATA
TG 
(Fwd) rpsF / construction in 
pWH844 / DRaCALA 
JN516 TTTGGATCCATGCCAAAGCAACTTAAAATAAAAG (Rv) yciH / construction in 
pWH844 / DRaCALA 
JN517 AAAGTCGACTTATTCATCAGGTGTCATAATCATT
G 
(Fwd) yciH / construction in 
pWH844 / DRaCALA 
JN518 AAAGGATCCATGAGTATTATAAAATTAAGCAAC
GTTTC 
(Fwd) ftsE / construction in 
pWH844 / DRaCALA 
JN519 TTTAAGCTTCTAATCATCGTAGCCGTAAACT (Rv) ftsE / construction in 
pWH844 / DRaCALA 
JN520 TTTGGATCCATGAATAAAAAATCGAGTGCTCTTT (Rv) ywfH / construction in 
pWH844 / DRaCALA 
JN521 AAAAAGCTTCTACTCCATTATAGTAAGTATCCA
GC 
(Fwd) ywfH / construction in 
pWH844 / DRaCALA 
JN522 AAAGGATCCATGAAGAAATTATTTTTCGCTCTG
G 
(Fwd) glnP / construction in 
pWH844 / DRaCALA 
JN523 TTTAAGCTTTTATTTCATTCTTTTTTCTACGCGA (Rv) glnP / construction in 
pWH844 / DRaCALA 
JN524 TTTGGATCCATGGAAAACTTCTTTACAATCTTGG (Rv) racD / construction in 
pWH844 / DRaCALA 
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JN525 AAAAAGCTTTTAATAGTCATCTAATAAATCTTTT
TTTCCC 
(Fwd) racD / construction in 
pWH844 / DRaCALA 
JN526 TTTGGATCCATGAGAAAAAAATTTTATCAAATGT
CGC 
(Rv) mvaA / construction in 
pWH844 / DRaCALA 
JN527 AAAGTCGACTTAGTTTCTGAGACTATTTAATAAA
CGG 
(Fwd) mvaA / construction in 
pWH844 / DRaCALA 
JN528 AAAGGATCCATGAAAGTTTCAATATTCTCCACTT
G 
(Fwd) yrjB / construction in 
pWH844 / DRaCALA 
JN529 TTTAAGCTTCTATGCTTTGATAAATGCTGGGT (Rv) yrjB / construction in 
pWH844 / DRaCALA 
JN530 TTTGGATCCATGCAAGCAAAATTAGTTAATAAAG
TAG 
(Rv) ytjA / construction in 
pWH844 / DRaCALA 
JN531 AAAAAGCTTTTAATGTCTTTGCTCAATATTTTGC
T 
(Fwd) ytjA / construction in 
pWH844 / DRaCALA 
JN532 TTTGGATCCATGCTTCATCTCATTAAAGAAAGC (Rv) yueF / construction in 
pWH844 / DRaCALA 
JN533 AAAAAGCTTTTACTTTTCAAGGCTGACCTC (Fwd) yueF / construction in 
pWH844 / DRaCALA 
JN534 AAAGGATCCATGCCTAAAGAACCAGATTTAACC (Fwd) relA / construction in 
pWH844 / DRaCALA 
JN535 TTTGTCGACTTAAGCATTTGTCCGTTTTACAGA (Rv) relA / construction in 
pWH844 / DRaCALA 
JN536 AAAGGATCCATGACAATTATTGAAGGAAATTTA
AGAAC 
(Fwd) ribH / construction in 
pWH844 / DRaCALA 
JN537 TTTAAGCTTTTAGCCAATCTTTCTCATTAAATCA
A 
(Rv) ribH / construction in 
pWH844 / DRaCALA 
JN538 AAAGGATCCATGACTGAAGTTTATTTTATTCGAC
AT 
(Fwd) yrgI / construction in 
pWH844 / DRaCALA 
JN539 TTTAAGCTTTTATTGCTCATAATCAATTTCAATG
ACT 
(Rv) yrgI / construction in 
pWH844 / DRaCALA 
JN540 TTTGGATCCATGAGTGAATTAGAGATTCGTAGA
TT 
(Rv)  yqaB / construction in 
pWH844 / DRaCALA 
JN541 AAAGTCGACCTATTGCTCTTCTAAATTAATCCAG
TAA 
(Fwd) yqaB / construction in 
pWH844 / DRaCALA 
JN542 AAAGGATCCATGGATAACCAAAATCAAGAAATA
GG 
(Fwd) yhfC / construction in 
pWH844 / DRaCALA 
JN543 TTTAAGCTTTTATGCGTTTGGATAGTGAATTAAA
A 
(Rv) yhfC / construction in 
pWH844 / DRaCALA 
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JN544 TTTGGATCCATGTCAAGTACTGTCATTATCCTC (Rv) ezrA / construction in 
pWH844 / DRaCALA 
JN545 AAAAAGCTTTTATAAGTAATCAGGAGTAGGTTT
ATTTTT 
(Fwd) ezrA / construction in 
pWH844 / DRaCALA 
JN546 AAAGGATCCATGGCATTTATCACCGAAAAAC (Fwd) ytcE / construction in 
pWH844 / DRaCALA 
JN547 TTTAAGCTTTTAAATTTCTGATTTTGTAAATACAC
CG 
(Rv) ytcE / construction in 
pWH844 / DRaCALA 
JN548 TTTGGATCCATGGCTTTAACGATCGAACG (Rv) yqaD / construction in 
pWH844 / DRaCALA 
JN549 AAAAAGCTTTTAAAATCCCAAGTTTATTCCAGG
C 
(Fwd) yqaD / construction in 
pWH844 / DRaCALA 
JN550 TTTGGATCCATGAAATTAAAAGATATAGAGAAAT
CAACAAA 
(Rv) yrbD / construction in 
pWH844 / DRaCALA 
JN551 AAAAAGCTTTTATTTTTCATTTAAAACCTGACGA
AG 
(Fwd) yrbD / construction in 
pWH844 / DRaCALA 
JN552 AAAGGATCCATGTTTGGAAAGTTTAATCGCTC (Fwd)  yjdJ / construction in 
pWH844 / DRaCALA 
JN553 TTTAAGCTTTCATTTATTTTTTCTATTATTTCCTT
CTAAGG 
(Rv) yjdJ / construction in 
pWH844 / DRaCALA 
JN554 TTTGGATCCATGAATGATATTTTACAACTCACAA
TTG 
(Rv) nah / construction in 
pWH844 / DRaCALA 
JN555 AAAGTCGACTTAATTATCATATTTTTTCAAGACC
ATTTTAATT 
(Fwd) nah / construction in 
pWH844 / DRaCALA 
JN556 AAAGTCGACTTGAGTCTGAGTCAAACAAGTC (Fwd) lysP / construction in 
pWH844 / DRaCALA 
JN557 TTTAAGCTTTTAATCTTTATGACGACTTAAATCA
ACC 
(Rv) lysP / construction in 
pWH844 / DRaCALA 
JN558 AAAGGATCCATGGAAAATCAAAATCAGGTCAAG (Fwd) lysQ / construction in 
pWH844 / DRaCALA 
JN559 TTTAAGCTTTTATTTTTCCCGACTCAAATCTACT (Rv) lysQ / construction in 
pWH844 / DRaCALA 
JN560 AAAGGATCCATGGGTTATGAATCTAATCGCTC (Fwd) kupA / construction in 
pWH844 / DRaCALA 
JN561 TTTGTCGACTTATGATTCTCCTTGATTTTCTTCT
G 
(Rv) kupA / construction in 
pWH844 / DRaCALA 
JN562 AAAGGATCCGTGGGTCAAGTACACTTACATAA (Fwd) kupB / construction in 
pWH844 / DRaCALA 
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JN563 TTTGTCGACTTAATGAGTTGCTGAAGCTTCT (Rv) kupB / construction in 
pWH844 / DRaCALA 
JN564 AAAGGATCCATGAACTTATTAAAAACAAACTGG
GA 
(Fwd) yncB / construction in 
pWH844 / DRaCALA 
JN565 TTTAAGCTTTTATTTTTCATAATATTTATCTAAAA
TCTCCATTTT 
(Rv) yncB / construction in 
pWH844 / DRaCALA 
JN566 TTTGGATCCATGAAAAAATTAAAAGTAACTTTAT
TGGCA 
(Rv) oppA / construction in 
pWH844 / DRaCALA 
JN567 AAAAAGCTTCTATTTGGTTGCCATCTTATCAGA (Fwd) oppA / construction in 
pWH844 / DRaCALA 
JN568 AAAGGATCCATGATAAAAGCAAAATATGATTGG
AAAG 
(Fwd) recJ / construction in 
pWH844 / DRaCALA 
JN569 TTTAAGCTTACGAAATTATTTTTCTAATAAATTTT
GATAAATTTC 
(Rv) recJ / construction in 
pWH844 / DRaCALA 
JN581 AGGTTATATTCATGACCTTTGGAAA (Fwd) relA check 
JN586 CGCTTGTTCGTGGTGTGATT (Fwd) internal fragment cdaA - L. 
lactis IL1403 
JN587 CGTAAGCTGAAATATGCCCATCA (Rv) internal fragment cdaA - L. 
lactis IL1403 
IQ668 AAAGGATCCAAGGTACCAATGAACGAAATTTTA
GAAAAAATAAAAGC 
(Fwd) yheB - L. lactis IL1403 
(pWH844) 
IQ669 TTTGGATCCCTGCAGTTATTTTAAATTATCTTGT
AATTCTTGCC 
(Rv) yheB - L. lactis IL1403 
(pWH844) 
IQ670 TTTGGATCCTTGGTACCAATGAACGAAATTTTAG
AAAAAATTAAAGCC 
(Rv) yheB - L. lactis NZ9000 
(pWH844) 
IQ671 AAAGGATCCCTGCAGTTATTTCAAGTTATCTTGT
AACTCTTG 
(Fwd) yheB - L. lactis NZ9000 
(pWH844) 
IQ682 AAAGAATTCATTAAAGAGGAGAAAATTAGAATG
GGTTATGAATCTAATCG 
(Fwd) RBS+kupA L. lactis 
IL1403 (pWH844) 
IQ683 AAAGAATTCATTAAAGAGGAGAAAACAAAAGTG
GGTCAAGTACAC 
(Fwd) RBS+kupB L. lactis 
IL1403 (pWH844) 
IQ684 AAAAGATCTAGGTTTTTATATTACAGCTCCAGG
A 
(Fwd) PcitM+cdaA from pIQ101 
IQ685 TTTAGATCTCTGGTATCTTTATAGTCCTGTCG (Rv) PcitM+cdaA from pIQ101 
IQ687 AAAGGATCCGTGTTACACAAAGCAGAGGGG (Fwd) kup - E. faecalis JH2-2 
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IQ688 TTTGTCGACATTTCTTCTATTTATGAACGATTCTT
TC 
(Rv) kup - E. faecalis JH2-2 
IQ696 AAACTGCAGGTTGAAGAAGGTTTTTATATTACA
GC 
(Fwd) hisTScf 
IQ697 TTTGTCGACGGTGGACAAATTTACATTAGTCTC (Rv ) hisTScf 
IQ706 ACAGGTACTGGCGCTAAAAAC (Fwd) External check (E. faecalis 
JH2-2 gdpP deletion) 
IQ707 GCTACGACATGAACCTTAATTTTC (Rv) External check (E. faecalis 
JH2-2 gdpP deletion) 
IQ708 CGGCTCAAACAAACCTAGATAC (Fwd) Internal check (E. faecalis 
JH2-2 gdpP deletion) 
IQ709 CTTTTGACATCGGGAATGATTTC (Rv) Internal check (E. faecalis 
JH2-2 gdpP deletion) 
6.5. Materials 
6.5.1. Buffers used in this work 
Table XVIII Buffers routinely used 
Solution Composition Concentration 
TAE 
Tris-HCl pH 8.0 40 mM 
EDTA 10 mM 
Acetic acid 0.057 % 
TE Tris-HCl pH 8.0 10 mM 
EDTA 1 mM 
Wash (W) Tris-HCl pH 7.5 100 mM 
NaCl 150 mM 
Lysis buffer 
Tris-HCl 30 mM 
Urea 8 M 
Adjust to pH 8.0  
Sample Buffer 
Tris-HCl pH 7.0 50 mM 
Dithiothreitol (DTT) 0.5 mM 
β-mercaptoethanol 4 % (v/v) 
SDS 2 % (p/v) 
Bromophenol blue 0,005 % (p/v) 
Glycerol 15 % (v/v) 
Running buffer 
Tris Base pH 8.3 25 mM 
Glycine (pH 8,3) 192 mM 
EDTA 1 mM 
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SDS 0,1 % (p/v). 
Buffer C 
Tris–HCl pH 7.4 50 mM 
NaCl 500 mM 
Glycerol 5 % 
PBS 
NaCl 8 g/l 
KCl 0.2 g/l 
Na2HPO4 1.44 g/l 
KH2PO4 0.24 g/l 
Adjust pH to 7.3  
CP1 buffer 
MgCl2 1 mM 
Tris-HCl pH 8.0 5 mM 
NaCl 230 mM 
DTT 0.5 mM 
Protease inhibitor tablet 1 unit 
CP2 buffer 
CP1 buffer 1X 
glycerol 10 % 
BSA 50 µg/ml 
EDTA 0.004 % 
Buffer E 
Tris-HCl pH 8.0 100 mM 
NaCl 1 mM 
EDTA 1 mM 
D-desthiobiotin 5 mM 
 
6.5.2. Chemicals 
Acetic acid ChemSolute/Merck 
Acryl:Bisacrylamide Roth 
L-Arabinose Sigma-Aldrich 
c-di-AMP Biolog 
Agar Roth 
Agarose PEQLAB/Genbiotech 
AgNO3 Roth 
Ammonium peroxydisulfate Roth 
Ampicillin Roth 
BCIP Sigma-Aldrich 
Biotinylated c-di-AMP Biolog 
Bromophenol blue Riedel-de Haën 
BSA AppliChem 
CaCl2 2H2O Roth 
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Casamino acids (CAA) Roth 
CDP-Star Roche 
Chloramphenicol Serva/Sigma-Aldrich 
Coomassie Brilliant Blue, G-250 Roth 
DAPI AppliChem 
D-desthiobiotin IBA 
DMSO Roth 
dNTPs Thermo Scientific 
Ethanol VWR Prolabo chemicals/Merck 
Formaldehyde Roth 
D-(+)-Glucose AppliChem 
L-glutamic acid Roth 
Glycerol Roth/Merck 
Glycine AppliChem/Sigma-Aldrich 
c-di-NMP Sigma-Aldrich 
HCl Biolog 
HDGreen Plus DNA stain Intas 
Imidazole Sigma-Aldrich 
Isopropyl β-D-1-thiogalactopyranoside PEQLAB/Sigma-Aldrich  
Kanamycin AppliChem 
KCl Roth/Merck 
KH2PO4 Roth/Merck 
K2HPO4 · 3H2O Roth/Merk 
KOH Roth/Merck 
λ-DNA Thermo Scientific 
β-mercaptoethanol Roth 
Methanol VWR Chemicals/Merck 
MgCl2 · 3H2O Roth/Sigma-Aldrich 
MgSO4 · 7H2O Roth/ Sigma-Aldrich 
MnCl2 · 4H2O Roth/ Sigma-Aldrich 
NaCl Roth/ Sigma-Aldrich 
Na2CO3 Roth/ Sigma-Aldrich 
Na2-EDTA · 2H2O Roth/ Sigma-Aldrich 
(NH4)2SO4 Fluka 
NaOH Roth/ Sigma-Aldrich 
Na2S2O3 · 5H2O Merck 
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Ni2+-NTA Sepharose Sigma-Aldrich 
NBT IBA ICN 
PageRulerTM Plus Protein Ladder Thermo Scientific 
Protease Inhibitor Tablet Sigma 
Sodium dodecyl sulfate (SDS) Roth 
Strep-Tactin Sepharose IBA 
D-(+)-Sucrose AppliChem/Sigma-Aldrich 
Tris Roth/Sigma-Aldrich 
Tryptone Roth/Oxoid 
L-Tryptophan AppliChem 
Tween-20 Sigma-Aldrich 
Yeast extract Oxoid 
X-Gal Sigma-Aldrich 
Xylene cyanol Merck 
6.5.3. Auxiliary material 
Centrifuge cups Beckmann 
Cuvettes (microlitre, plastic) Greiner 
Eppendorf tubes Greiner 
Falcon tubes Starstedt/ 
Glass beads 0.1 mm Roth 
Glass pipettes Brad 
Micropipettes Eppendorf 
Petri dishes Greiner 
Pipette tips Greiner 
Poly-prep chromatography columns BioRad 
PVDF membrane BioRad 
Nitrocellulose membrane GE Healthcare 
Vivaspin® turbo 15 Sartorius 
6.5.4. Instrumentation 
ÄKTAprime plus GE Healthcare 
Autoclave LTA 2x3x4 Zirbus Technology 
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AxioCam MRm Zeiss 
AxioImager M2 Microscope Zeiss 
Axioskop 40 Microscope Zeiss  
Gene Pulser Xcell and PC Module Bio-Rad 
Centrifuge Heraeus FRESCO 21 Thermo Scientific 
Centrifuge Heraeus Megafuge 16R Thermo Scientific 
Centrifuge Sorvall RC 6+ Thermo Scientific 
Centrifuge Sorvall WX Ultraseries Thermo Scientific 
Chrom. Data System LC-NetII/ADC Jasco 
ECPlan-NEOFLUAR 100X/1.3 Zeiss 
French pressure cell press Thermo Scientific 
Horizontal shaker 3006 GFL 
Microplate reader BioTek 
Ice machine MF 36  Scotsman 
Incubator Heraeus  Thermo Scientific 
Incubator shaker  Innova®44 series Eppendorf 
Labcycler  SensoQuest 
Magnetic stirrer KMO 2 basic  IKA-Werke 
Mini PROTEAN® System  BioRad 
Molecular Imager® Gel Doc™XR+ BioRad 
NanoDrop ND-1000  PeqLab Biotechnologie 
pH-meter Calimatic 766  Knick 
Plan Neofluar 100x/1.30  Zeiss 
Plan Neofluar 40x/0.75  Zeiss 
Power Pac Basic™  BioRad 
Press machine G.  Heinemann 
Scale CP22025  Sartorius 
Ultrospec 2100 pro spectroph. Amersham Biosciences 
UV Detector UV-2075Plus Jasco 
Sterile bench HERA safe KS12 Thermo Scientific 
HiLoad 16/600 Superdex 200 pg GE Healthcare 
ThermoStat Plus Eppendorf 
Tyssue Lyser II QIAGEN 
Vortex Schütt Labortechnik 
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Water desalination plant Millipore 
6.5.5. Commercial systems 
DNeasy® Blood & Tissue Kit QIAGEN 
NucleoSpin® Plasmid Macherey-Nagel 
peqGOLD Bacterial DNA kit PEQLAB 
QIAquick® PCR purification Kit QIAGEN 
Roti®-Quant Roth 
6.5.6. Enzymes and antibodies 
Alkaline phosphatase (AP) Thermo Scientific 
DNase I Roche 
Phusion DNA polymerase Thermo Scientific 
RNase A Roche 
Restriction enzymes Thermo Scientific 
T4-DNA ligase Thermo Scientific 
Anti-Rabbit IgG Promega 
6.6. Informatic tools 
6.6.1. Websites 
Tabla XIX Websites 
URL Provider Purpose 
http://biotools.nubic.northwestern.e
du/OligoCalc.html 
Northwestern University, USA Pimer properties analysis 
https://www.ncbi.nlm.nih.gov/pub
med/ 
National Institute of Health, 
Bethesda, USA 
Literature 
http://www.uniprot.org/ 
European Bioinformatic Institute 
(EMBL-EBI), Swiss Institute of 
Bioinformatic (SIB), Protein 
Information Resource (PIR) 
Protein information and 
analysis 
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http://www.insilico.uni-
duesseldorf.de/Lig_Input.html 
Düsseldorf University 
Insert:Vector ratio 
calculation in PCR 
https://www.expasy.org/ 
Swiss Institute of Bioinformatics 
(SIB) 
Protein topology prediction 
http://wlab.ethz.ch/protter/start/ Wollscheid Laboratory Protein topology prediction 
http://subtiwiki.uni-goettingen.de/ 
General Microbiology department, 
Göttingen University 
Literature about B. subtilis 
6.6.2. Softwares 
Table XX Softwares 
Software Provider Purpose 
Microsoft Office 2010 Microsoft Inc. Primer properties analysis 
ImageLab™ Software BioRad Image processing 
EndNote 
Clarivate 
analytics 
References 
SigmaPlot 
Systat software, 
Inc 
Plotting 
ChemoStar Imager Intas Image processing 
Image J 1.49p NIH Image processing 
AxioVision Rel. 4.8 Zeiss Image Uptake 
Geneious 7.0.2 Biomatters Ltd Bioinformatics 
 
6.7. Abbreviations 
Tabla XXI Abbreviations 
General abbreviations 
% (vol/vol)  % (volume/volume) 
Ampr Ampicillin Resistance 
APS Ammonium persulfate 
ATP adenosine triphosphate 
Au Absorption units 
Biovar. Biovariety 
BSA Bovine Serum Albumin 
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CAA Casaminoacids 
CE Crude Extract 
Cmr  Chloramphenicol resistance 
dH2O Deionized water 
DNA Deoxyribonucleic acid 
DNase DNA nuclease 
dNTP desoxyribonucleoside- triphosphate 
DTT Dithiothreitol 
EDTA N, N, N’, N’‐ ethylenediaminetetraacetic acid 
Emr Erithromycin resistance 
FDA Food and Drug Administration 
Fig. figure 
FT Flowthrough 
Fwd forward  
IPTG Isopropyl thiogalactopyranoside 
Kmr Kanamycin Resistance 
LAB Lactic Acid Bacteria 
LB Luria Bertani 
Max maximum 
MWM Molecular Weight Marker 
NAD Nicotinamide Adenine Dinucleotide (oxidized) 
NADH Reduced Nicotinamide Adenine Dinucleotide 
Ni2+-NTA nickel-nitrilotriacetic acid 
NICE Nisin Control Expression System 
NIH National Institute of Health 
Nis Nisin 
NTP ribonucleoside triphosphate 
ODx Optical density, measured at the wavelength λ = x nm 
P promoter 
PBS Phosphate buffer saline 
PCR Polymerase Chain Raction 
pH Power of hydrogen 
rbs Ribosome Binding Site 
rpm Revolutions per minute 
Rv Reverse 
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SDS sodium dodecyl sulfate 
SDS‐PAGE polyacrylamide gel electrophoresis with SDS 
Sn Supernatant  
Spp Species 
TEMED N,N,N’,N’- tetramethylethyldiamine 
Tris tris(hydroxymethyl)amino- methane 
WT wild type 
X-Gal 5-bromo-4-chloro- indolylgalactopyranoside 
Units 
A Ampere 
bp base pairs 
Da Dalton 
g gram 
h hour 
Lt. liter 
m meter 
M molar 
min minute 
Mol mol 
V volt 
ºC degree Celsius 
Prefixes 
K kilo 
m milli 
µ micro 
n nano 
Nucleosides 
A adenine 
C cytosine 
G guanine 
T thymine 
U uracil 
Amino acids nomenclature 
A Ala 
C Cys 
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D Asp 
E Glu 
F Phe 
G Gly 
H His 
I Ile 
K Lys 
L Leu 
M Met 
N Asn 
P Pro 
Q Gln 
R Arg 
S Ser 
T Thr 
V Val 
W Trp 
Y Tyr 
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